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Despite having been initially described more than fifty
years ago, sclerotherapy of oe~ophageal varices has only
relati vely recently beOt>iJl.Eit r('yarded as one of the primary
modalities both to corrtz-..11 1;1Heding oesophageeLl varices and
to prevent recurrent bleedin~. Sclerotherapy, however, ts
associated with numerous complications and its exact
mechanism of action, particularly that pertaining to its
effect on haemostasis, has to date been poorly
documented. One of the problems of comparing the various
tr:tals has been the diversi·ty of both the technique and the
type and concentration of the sclerosants used~
This' thesis .1nv~stiqlated the effects of Sodium Tetradecyl
Sulphate (S.T.D.); a sclerosant, on haemostasis~
Haemostatic function was determined in relation to the
effect of varying concentrations of S.'I.D. on platelet
function, the coagulation pathvay and endothelium.
Platelets, which play an integral role in the initiation of
thromb~s formation, were shown to be completely lysed by
concentrations or S.T.D. likely to be found within varices
injected with standard dosage S.T.D. HO~'ever, on dilution,
a potent and altogether unexpected activation of platelets
was documented by platelet aggregometry. Th\~ aggregation
pattern comprised both primary and secondary waVeS and was
similar to that seen following platelet aggregati~n induced
by physiological agonists, such as adrenaline and ADP.
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In further in vitro studies, involving time sequence phase
contrast light microscopy, designed to simulate the
gradient of dilution occurring in varices as the distance
frcm. the injection site increases, a similar p~ttern of
local high dose lysis, with distal low dose aggregation was
exhibited with S.T.D.
effect of S.T.D. on the endothelium. This model showed
S.T.D. was shown to destroy functional coagulation
paramete~s of the intrinsic and extrinsic pathways at
dosages which are used clinically. At dilute dosages
these parameters were not altered. There was, however, a
selective reduction in Protein C, which is a physiological
anticoagulant. This suggested that a hypercoagulable
state occurs, not at the site of injection but rather
further downstream. As hypercoagulable states are
notoriously difficult; 'co document I thromboelastography was
perfo~med to try and demonstrate tne presence of
hypeccoaglllabili ty • Thromboelastography did provide
further evidence that at low dosages hypercoagulation
occurred which was distinct from the marked hypocoagulation
which res~lted trom addition of relatively high dosages of
S.T.D.
An umbilical vein model was developed to investigate the
extensive denudement of endothelium with exposure of
subendothelium which still contained von Willebrand
factor. The extent of the damage induced by standard
dosage S.T.D. was extensive, but could be limited and
vii
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co~trolled by Idiluting S.T.D. tenf~ld.
All the above evidence suggested that the dilute S.T.D.
would be not only e.s effect.! ve as undllute sclerosant at
causing endothelial damageat the site of injection, but it
would also. be more thrombogenic as it would activate
platelets and cav.se a hypercoagulable sta.te. Ina pilot
st.udy, tenfold d.L~utedS.T.D. was shownto be as effective
as 3·%S.T.D. in controlling varic~s which are acutely
bleedinq. T~re was a lower complication rate and to date
there have been no.failures with this sclerosant.
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pathophysiology to liver disease. Sixty years later,
1.1.1 History
The Egyptians were the first to document an
association between liver disease and ascites in the
Papyrus Eb@r.s (Bryan, 1931). Tbe first report in the
literature of a "'~talvariceal bleed was in 1240
(Power).. Although he docUlll6ntedruptura of v&rices of
tht~oesophagus I he failed to connect the
an autopsy series of Preble (1900) sholNedthe
inter-relation~hip between variceal bleeding and liver
disease. In 1906, twO' French workers ware the first to
use the term Portal Hypertension, after realising that
cirrhosis of the liver was connected to an in'creased
portal venous pressure (Gilbert, 1906).
1.1.2 AetiQlogy
The most important aetioloqical causes of portal
hypertension in southern Africa include the following
categories:
1 .1. 2•1 Prehepatic - PriUi;inuspidal
Portal vein thrombosis which is usually a result
of sepsis in the neonatal period is an important
cause of portal hypertension especially in
children (Sherlock, 1989).
1 .1•2 •2 IntrahepatiQ - PresinusoiQa.l
SChistosomiasis is worldwide one of the ~oat
common causes of portal hypertension (Hem..tf9rSOn
et aI, 1986,. In Southern Africa, particularly
along the east.ern coast, it is responsible for a
large nUlllberof casas of portal hypertension in
rural communities (Donnely et aI, 1984). The
parasite causes fibrosis of the terminal portal
venous radicles (so called pipe stem fibrosis)
but leaves hepatic function and architecture
essentially intact (H~nderson et aI, 1986).
Liver function in these patients is usually
completely llormal. Other causes of
intrahepatic presinusoidal block are congenital
hepatic fibrosis and early primary biliary
cirrhosis (Sherlock, 1989).
1.1.2.3 Intrahepatic - Sinusoidal.
In southern Africa, the most co:mmon cause of
portal hypert~"1sion amongst the White popUlation
group is cirrhosis (Kew et aI, 1984).
Cirrhosis is derived fro.''!the Greek word
"kirrhos", which means orange-yellow
discolouration. Liver cirrhosis is defined by
the World Health Organization as a diffuse
process characterised by fibrosis and the
conversion of normal architecture into
structurally abnormal nodules.
--- ----- --- ------ --- ----- ---
4Anthony et al (1977), who were responsible for
the definition, felt that cirrhosis is a chronic
progressive condition and that re~ession or
reversabilH:y was a rare event and subject to
doUbt. Recent experimental data however
suggests that macronodular cirrhosis might well
be reversible (Ishii at aI, 1990).
The current histological criteria for making a
diagnosis of ,._""rrhosisof the liver are hepatic
parenchymal necrosisl fibrosis due to activE}
formation of connective tissue and nodular
regeneration of liver cells (Anthony et aI,
1977).
The.most frequent cause of liver cirrhosis
~!.itongstthe White population of Southern Africa
is alcohol (Kew et aI, 1984). Alcohol rE>lated
liver cir'•.:hosis is becoming more prevalent in
the urban Black population (Isaacson, 1978;
Asvat at al, 1981). Another important cause of
liver cirrhoSis in Blacks, particularly in rural
areas, is macronodular cirrhosis probably post
viral in nature (Asvat et alA' .lQS1).
Iron overload is also an important cause and is
often a contributory factor in many of these
patients (Isaacson, 1978).
in SQlJ.thernAfrica (de Miranda, 1988).
the Human Science Research Council survey on
South African drinking problems showed the
following finding'S on alcohol consumption:
White Population' Male 91% Female 76%
Coloured population Male 60% Female 28%
Black population Male 54% Female 22%
Indian Population Male 45% Female 4~
In the Republic of South Africa liquor sale's for
the year ending March, 1987, were:
spirits (including imported) 83 million litres
Wine (including fortified) 3AG million litres
Beer 1500 million litres
The Institut~ for Race Relations estimates that
at that time the total population of South
Africa was approximately 35 million people.
This then equates to an annual consUll'lp1;:iortof
2 ~<4Iitres of spirits I 8.9 Iitres of wine and
42.9 J.itres of beer per capita.
include children.
These figures
eWorldwide it has been found that a constant:
percentage of people who use alcohol will becollle
,. dependent. This figure is 6 to 8% and would
increase. Thersfore the number of patients
...
appear to he constant despite varieG
environmental conditions (de Miranda, 1988) •
So as.the race groups, other than Whites who
would appear to have reached a saturation point,
increase their alcohol intake, the number of
alcohol dependent diseases will continue to
with alcohol induced cirrhosis will also
increase.
The relatively small study which was performed
at Baragwanath Hospital and pres~ntp.d later in
this thesis confirmed that alcohol was the most
cOlll1lloncause of bleeding oesophageal varices in
patients who presented at that hospital.
;1..1.3Portal Hypertension - De:{initiQn
Portal hypertension is defined by Hobbs as a portal
blood pressure of greater than 15 cm H20 and is
resultant upon an increase of either the volume of
portal blood flowing to the liver or an increased
resistance to the portal flow (Hobbs 1986). The
normal portal vein pressure ls defined at 5-10 m.m Hg
(Henderson and Warren, 1986). Therefore any elevation
of the above would fulfil the criteria of a diagnosis
of portal hypertension.
7The pressure may be measured directly by mean~ of
transhepatic portography, umbilical vein
catheterisation or splano- portography. 'llbe pressure
may also be measured indirectly by retrograde
catheterisation of the hepatic vein and by m~a3uring
Wedged and free hepatic venous pressure.
The indirect method (L, e. th~ wedged minufJ the free
pr.-.,ssures)Would appear to approximate the direct
pressure accurat~ly enough for it to be used routinely
as it is less invasive than the direct method.
Direct portal venous measurements in patients with
portal hypertension are ~isually elevated in the region
Df 15-40 IDlll Hg and indirect measurements arfl 10-30 mm
Hg.
Hepatic vein wedge pressure is not recollllllandedfor
assessing prE'sipusoidal portal hypertension as it will
be normal in such cases. In patients without
disease, hepatic vein wedge pressure is ma1:gina,lly
lower than portal pressu.re. Patients who have
intral:.epaticshunting due to alcoholic cir.rhosis Have
hepatic wedge pressures which approximate port~l
pressures (Hoefs at aI, 1990). However, Valla at al
showed in 19B4 that after administration of
propraholol, hepatic wedge pressure was not an
accurate indicator and that direct portal venous
pressure measurement was the techn1.que of choice in
~ ~,L__., .._) _
assessing the response to the administration of aqents
which alter splanchnic circulation.
or the terminal hepatic venules. The current theory
1.L4
and Groszmann, 1990)
Portal hypertension is due to an increase in portal
preJSisure.
Pressure is defin&d by Ohm's law as
P .... kAQxR
where J? is thG change +n pressure, Q is th$ flow, R is
the reRistanc9, and k is the constant.
i/
PoisQuill~r,S l~w states that
R ... k8nL/ 1:'4
where R is resistance, k is the constant, n ielthe
coefficient of velocity, L is the length of ~he vessel
and r is the radius. From Poiseuille's law it is
obvious that r (the radius) plays a most impr 'ant
role in the human body. Resistance is one of the
only variables in the biological systeM, as all the
other factors remain relativ€ly constant.
The liver is the main source of resistance to portal
blood flow, and is unable to cOl.'ltrolthis flow. The
actual site of the resistance in the liver is thought
to be either the small portal veins, hepatic sinusoids
for the cause of the rai~lEtdpressure is thought to b41
due to deposition of fibrc)us tissue around the
at aI, 1990). A separate theory is that the
terminal hepatic venule and adjacent ainu.oids (Mahl
1982). This lat.ter "heory might explain why f in some
hepatooyte enla.rges wilEIn damaged (Blend.:iJ.at &1,
cas_., precirrhotic portal hypertension, consequent
upon a.lcoholic hepatitis improves with. ablItineHce.
All the above theories suggest that portal
hypertension is due to an increased re.istanc61.
HowfIIlveJ:t,J, wit, the development of portal hypertensi.on,
portasystemic shuntin4 occurs and ma.y divert iTtlOstof
the blood from the portal system to the syst~nio
Bystem (Vorobioff et aI, 1983). Despite the
shunting I portal hypertension persists ~ Vorobioff et
9.1 (1983) found that there is ~ relative increase in
splanchnic blood flow and while it does not initiate
portal hypertension, it plays a role in maintaining
it.
These findings are in keeping with those of santi
(1883) who described a group of patients with
splenomegaly, anaemia and leukopenia and postulated
'I..hatthe pathophysiology of tll-eirportal hypertension
was related to increa$eu splenic arterial blood flow1
i.e. he described an increased forward flow was
causing the portal hypertension (Mahl at aI, 1990).
COhn.t al (J..912) felt. tha~1 the col1at(l¢als were the
,I
Clauseof the hyperdyn&mio tJirculaticm. Sikuler
(1!i)16) sh.OWed that the deqree 'Of; ~unting did not
cQrrelate well with the flow. The precise cause ot
tl:Ui'l hype:rdyna.: "! oirculation has not been fully
eluoidated although qlucaqon, bile acids and an
expanded plasma volume have all been incriminat.ed
(Mflhl at aI, J.990). Increased splanchnic flow has
recently been attribUtf.!ldto elevat$d lavels of
vasodilators in the circulation as well as diminished
sensitivity of the splanchnic vasculature to
endogenous vasoconstric..tora (EC'Jtllausarst aI, 1991).
Si.vak et al (1990) maintain that the .prevalence of
.oesophage&l varices in patients with din-hosis is
difficUlt to dstermine. However,. it ha.., b&en .hown
that approximately 60% of patients with portal
hype.rtf.!lnsionhave varices if one us~s autopsy s&ries
(Olson, 1972).
al (1968) documented varices in 40-50% of patients
with cirrhosis. Lebree et al (1980), in a series of
100 patients with histologically documented ..1looholie
liver cirrhosis, demonstrated varicell in 84 patients
using a combination of x-ray examination and
endoscopic assessment.
I•
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The portaeystamic shunting occurs at many sites
(MoIndoe, 1928). These include the coronary and
short gastric veins, the azygous veins, the
intercostal veins, the paraumbilical plexus, the
retroperitoneal veins, the haemorrhoiadal veins and,
most importantly, from a clinical point of view, the
oesophegeal veins.
1.1.3 Anatomy of the Portal vspous System (Meysrs,
1986)
The superior mesenteric vein, which drains the
intestinal bea, is joined by the splenic vein behind
the neck of the pancreas to form tha portal vein. The
inferior mesenteric v$in drains into th$ svlenic vein
a few centimgtr'9s proximal to where the splenic vein
enters ~~e superior mesenteric, although this is
variable. Ano·ther vein of importance is the left
gastric vein (ooronary) whic!halso ei.'1tersin the
region of the confluence although once again its
position is variable.
The port~l vein then runs for approximately 6 to 8 em
and lies posterior to both the common bile duct as
well as the hepatic artery. It lies in the fr~e edge
of the lesser omentarm, On arriving at the liver it
.t"anchesinto left and right branches. The left
lJranchsupplies the left Lobe , cB'ldate and quadrate
lobes. The right branch sUt)plies only the right
lobe.
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'Fhavenous blOt.')d from t...~ portal system mixes wi 1;h
arterial blood from the,\:hepatic arterial branches only
at sinusoidal level. The portal venous blood is
responsible for two-thirds of the oxygen r:equirement
of the hepatoeyte.
1.1.6 The Anatomy of the veins ot: the OepOPAAg'\lB
Ilhe first oomprehensive study of the venous anatomy of
ti,. oesopha<,JUswas publ~shed in 1951 by H. Butler. He
studied 21 foetuses, 17 cadavers and 2 fresh
specim.;n~~ He used India ink injections on the
foetuses and Neopreone on the fresh specimens" ais
Subl:.equMt cla$l!!Iificati~:mhas stood the test of
time. The mO$t recent study by Kitano et al (19$6),
.has ~,laborat.ed on Butler' IS original work and the
:findinqs are of clinical relevance, particularly to
sclerotherapy and its effeot on the oesophageal
varices. Kitano studied t~n fresh human cadavers,
five of whom had known portal hypertension with
oesophageal varioes due to alcoholio cirrhosis.
Because no reference is made to therapy in the last
group of patients, one asmumes that these patients did
not undergo sclerotherapy.
-- ------- ----.---~---------.---~.~~---_._- -....-.-.
The normal OQSophaqus has 4 distinct layers of vein
(Kit&no et al, 1986):
Intra-epithelial channels
Superficial venous plexus
Deep intrinsic veins
Adventitial veins
The intra-epithelial channels are made up of fine
vessels which "lie inside the epithelium and are
actually the veins which drain the capillary network.
These veins drain at right angles to the superficial
venous plexuso This plexus has free oommunication
with its gastrio equivalant. The following vein is
the deep intrinsic vein. There are usually three to
five of these and they are often inter-connected to
each CttherI as well as to the superficial venous
plexus. They a1'-:0 form direct connections with their
gastric counterpart.
The adventitial veins are connected by perforating
veins to the de~p intrinsic plexue. The perforating
veins are found most often at the area adjacent to tl'e
oesophago--gastric junctions. The adventitial veins
are numerous and are found in the peri-oesophageal
region.
1.1.6.1 The Anatomy ~t QesQ~hageal Varic@s
(Kitano et al, 1986)
In patients with portal hypertension all o~ the
above veins are significantly dilated.
The ltl't)st _rked would appear to be the three to
fiv. deep intrinsio venous ohann.lsQ They do
»=«;
!( not ~pp.ar t.o have marked oommunioation witll
J/
,')eao)'lother and eommunicate less frequentl.y with
the superficial venous plexus.
The superficial venous plexus is also dilated
and has marked OOJ!l1l'll."Wlic.i.'don with the
intra-epithelial channels.
'rileadventitial veins are also dilatetllland
perforatinv veins.
veins at the oesophaqo-gastric junetion'TAOuld
app&ar to be more lonqitudinal in th•••
patients. The deep intrinsic veIns $om.tius
are so large that they ~isplace the superficial
venous pleKU$ and li~ just below the
~e appearanoe of a dil.ted
superficial venous plexus immediately on top of
a dilated deep intrinsic vein results in the
clinical appearance of the so called varioes
upon varices.
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1. 2 THE CAUSE OF BLEEDING VARICES
The presence of varices dOGS not necessarily result in
haematemesis. Several factors are thought to play a role
(Mahl et aI, 1990). These are overlying mucosal damage;
size, degree and protrusion of the varices1 portal pressure:
and finally actual variceal pressure.
When one considers these independently I the mucosal damage
theory has bean widely propounded. The erosive theory was
first suggested by Waagensteen (1945) who showed in an
experimental animal model that erosion and ulceration
occurred more frequently in response to histamine when the
splenia or portal vein was occluded. However by 1961
Liebowitz had reviewed all the available literature at that
stage and felt that the mucosal damage was overestimated and
playsd a minimal role in causing rupture of vEl;.:ices. He
also suggested that the oesophagi tis and ulceration were a
result of venous congestion rather than the effect of acid
on tho mucosa. Orloff at al (1963) biopsied oesophageal
mUcosa overlying varices at the time of transthoracic
variceal ligation for bleeding varices and fpund
histological evidence of mucosal damage in only 1 out of 20
patients on whom he operated. Eckhardt et al (1979) showed
that the incidence of oesophageal reflux is not increased in
"'\stients,which would support the notion that oesophagitis
seems to play little, if any role, in preciJIJi't;~'tingthe
haemorrrhaqe , The above ::"15 confirmed in the study by
MacDougall et al (1982), who showed in a double blind study
that cimetidine was no different from placebo in
16
preventiq1'1 of var'iceal haemorrhage. 'rhis.was despite a
rQlati.ve1.:~high dosage of cimetidine, viz. 1.2 grllllll$
;. >'
J ~daily. (l'be authors also showed no difference in
oel!oph;!iqealfunction in patients with varices (both
cirrhotic and noncirrhotic) and healthy control subjects.
any role in initiating rupture of varices. The above
Sherlock (1990) feels that reflux oesophagitis has little if
obviously does not hold for patients who have had
sclerotherapy. Some of these patients have marked problems
with oesophageal motility, Which is discussed later, and
reflux oesophagitis might certainly playa role in bleedirtg
which occure \in these patients.
The 'seCond factor w'hich could play a role is the size of the
varices and the degree of the protrusion.
Laplace's law
According to
T = kPr
(T = Tension, k ..,constant, P ;;:Pressure, r == radius), one
would expect that the varix which has a large radius would
be much lUore likely to rupture than a similar varix with a
smaller diameter. This hypothesis has been borne out by
Palmer and Brick (1956) who showed that out of 3.8patients
who were actively bleeding, 78% had varices greater than 6
mm, BEtker (1959) performed a longitudinal study and his
find-in<:;rscorroborated those of Palmer in that the incidence
of bleE~ding was doubled in patients with large diameter
var.i.cea ,
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Large varioes also protrude into the lUlU.illI'lof th.
oesophagus .. This results in less SUPPOll't from surrounding
tissue. Polio at: al, (1986) bave I,hown that the surrounding
tissua itself is an important facto,r in that when a vnsel
is surround.ed by tissue, its radius is smaller at a qiv~m
pressure and. therefore less likely to rupture.
The next factor to consider is portal pressure. The
varices are iii. direct result of an increase in portal
pr~ssure. one would therefore expect tha't the risk of
bleedinq from these varices would be proportional to the
pressure. However I the correlation betwelan the absolute
amount of portal hypertemdon present and the risk vI:
bleeding illScontroversial in the literature.
~damsons et al (1917) showed that recurrent or prolonged
bleeding in patients with higher pressures occurred mor0
often than in a similar group of non-bleeding patients with
portal hypertension who had a lower pressure. Surcharth
(1980) showed that the portal pressure, measured
transhepatically, was higher in patients who had bled within
the previous 90 days. However, there have been numerous
studies which have f~iled to show this correlation, e.g.
Smith"'Lalng et al (1980) investigated 64 patients with
variceal haemorrhage who had portal pressures from 11 to 45
rom Hg (mean 30.2) and found no correlation between portal
pressure and the number or size of bleeding r;'::'>isodes.
J
They also
, ,
Tbsre w~ )0 oorrelation betltlQGn the ~.al p:tr_~ure and the
collateral circulationr
the previous discrepancies in the literature, it would
appear that t'he degree of portal hypertension is a poor
predictor of size or amount of \.Tariceal haemorrhage. In a
more recent study; Vinel et a1 (1986) have shownthat long
term survivors had lower portal pressures than patients who
A larqe well
performed study by Garcia-Tafto et al (1985) revealed that
a pressure Of gr~ter than 12m:m Hg is usually present before
-;~0
bleeding OCCurs. Tb'$Y~~ned 93 patients with liver
oirrhosis and found that the hepatic vein pressure gradient
W!\$ ,less tba.n l~ Hg in the 49 patients who 4iid not bleed.
RndosoopicmeasurEU1lelltc;>f .acrtual variceal pressu.re has also
been evaluated and pressures greater than 13, mmHq have lba.n
associated. with a higher incidenc.~eof bleadinq (Hoofs at. al,
1990).
~..9S00p,ic evaluation of the varices has been used as a
pred.iar.or of impending hae:morrb.aqQ(Beppu at 801, 1981).
The Japanese Res.arab study for portal hypertension has
developed a classification for recordinq endoscopic findings
(see Figurfl1.1).,'1 .. 'Sivak at al (1990) feel that the mEtre
presence of any red marking is associated with a rj,skof
bleeding.
I'. ..
thermal dilution principle. They investigated 10 pntients
Azygous vein blood flow has been measured in patients with
portal hypertension. The reason is that blood flowing from
the portal system in portal hypertension drains via
oollaterals into the a3ygous.,system and correlates with
gastro-oesophaqeal blood flow (Hoefs, 1990).
Bosch and Grossman in 1984 described the technique uj,ing a
with alooholic cirrhosis, and showed that the flow in
patients was significantly higher in those patients whQ bad
,not undergone decompressive surgery and that a high flow
rate was also associated with bleeding.
t •I
1. Red Colour signs
(a) Red wale markings (Grade 1-3)
(b) Cherry red spots (Grade 1-3)
(c) Haematocystic spots
(d) Diffuse redness
2. Fundamental coj.our
(a) White
(b) Blue
3. Form
(a) Small straight var'Loes
(b) Enlarged, tortuous, occupy less tnan one-third of
the Lumen
(c) Largest, coil-shaped, occupy more than (.:<3-third
of the lumen
4. Location
(a) Lower third
(b) Middle third below tr<llchealbifurcation
(c) Upper third above tracheal b:lfu:rcation.
5. Adjunctive Finding
(a) Erosion prese~t
FI.;URE 1.1
Gelleral Rules for Recording Endoscopic Findings on
oesopnageal Varices according to the Japanese Research
Society for Portal Hypertension
~.,.,--~-------
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1.3 THE HISTORY OF SCLEROTHERAPY
The first descr'tption of sclerotherapy of oesophageal
varices was in 1939 by Clarence Crafoord ana Paul
aniso-poikilocytosis ort '·..ssion. After 2 months the
Frenckner. They described a caL6 of a 16 year old girl
who presented at the Sab'batsbergs Hospital with "great
vumitings of blood". The history of the patient wap. non
cOJ"tributory. Clinical examination revealed a Jc;lrgeliver
at that stage. Th;a patient was t't'eatedwith i'cQagulen"
and a blood transfusion. The patient had
each as thick as the little finger It.. .. . Crafoord thought'·
patient developed a palpable spleen and CJ:f ,o;t'dperformed
a splenectomy in June; 1934. At the time of laparotomy'
the findings were "a number of illmlargadsoft glands along
the upper edge of the pancreas but. otherwise the abdomen
disclosed no pathological changes. The cours~ was free
from complications." However 2 ye~~s iater the patient
again presented with haewatemesis. X-rays 'r~eredone , as.
well as oesophagosc'OPY which was perfor'ahedby F.renckner.
He described "a collection of grape-like varices located
mainly in the posterior and left parts of tt-,e'Oesophagus I
wended their way downwards i~ two cord-like formations,
it..would be of benefit "to produce collapse of the veins
and varices through injections of quinine according to the
same princ.1ples a~id doses approved at the surgical
department for haemorrhoids". Frenckner designed a
s_.:>el:ialnec::!dleto deliver tht 'clerosant via the
oesophagoscope. It was deciued to begin proximally, and
if the procedure was effective, to continue distally •
...
__ .
Two millilitree of quinine-urGtan was injected into aach of
3 varices. They reported that at repeat oes0phagoscopy
the varices were "in a collapsed condition, forming an
undulated, firmer part cf the oesophage::tlwall". The
procedure was repeated on numf'rousoccasions and at the
time of going to press, i.e. 3 years later, the patient had
not had a relapse.
The firat report of sclerothertapy of oesophageal varices
from the unite~ states was from Herman J. Moersch from the
Mayo Clinic in 1941. In his paper be not&s that in 1929
Rowntree, Walters and McIndoe ad~ocated, at • " hos9ital,
ligation of the coronary vein as a possibJ.e It ).....~'l.odf
preventing bleeding from oesophageal varices al'ldin 1933
Walters suggested that it might be advisavle to inject a
sclerosing solution into the vdrices at the time of
ligation of the coronary vein.
In the discussion of the paper, Dr Edwin J. Grace states
that in 1938 he injected 8 ml of sodium morrhuate into th$
coronary vein of a 53 year old male who had "massive
,'"'""
I0
I
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oesophageal haemorrhage second;"lryto liver damage". This
does not predAte Crafoord and Frenckner's work. Moersch
states in his paper that Pemberton (who was not a co-author
of the paper) and he had thought of doing this procedure as
early as 1933, however they thought it prudent to first
demonstrate its safety and efficacy in the experimental
laboratory.
,:~
I·
They attempted to produce oesophageal varices in dogs, but
only managed to produce "enlarged vessels over the thoracic
wall" and were therefore reluctant to attempt this
procedure on a hUman patient. After the report of
Crafoord and Frenckner appeared, Moarsch felt justified to
now attempt tae procedure. The patient was a 30 year old
i t
male with r$current gastrointestinal haemorrhage, due to
cirrhosis of the liver. Dr Walters referred the patient
to Dr Moersch, who performed oesophagoscopy u~der local
anaesthesia and found large varices at the lower third of
the oesophagus which were almost obstructing the lumen.
He inj~cted 0.5 ml of 2.5% sodium morrhuate and states
"much to my surprise, the procedure was accomplished with
practically no bleeding". He repeated the procedure three
more times at four day intervals and injected 1 ml of 2.5%
sodium morrhuate at each procedure. The changes to
varices which he describes is not:eworthy. "The vassels
that had been inj~~ted lost their bluish color and became
yellowish gray.1t
The fir.stproponent of sclerotherapy 1n GreE'c Brit"in waS'
Ronald Macbeth, a clinical lecturer in otolaryngology at
the University of oxford. He first described his
technique and results of nine cases at the Fourth
International Congress of otolaryngology in 1949.
Subsequently he published his experience of 30 cases in
1955 in the British Medical Journal.
The technique which he employed was to give the pat:ient a
gefleral anaesthetic and then he used the largest Negus
oesophagoscope which could be passed, and injected the
varices with a long needle oarrier mounted upon a bayonet
type fitting which locked onto a 10 ml or 20 ml syringe.
The solerosant used was 5% sodium morrhuate and he injected
3 ml to 4 ml into each venepuncture and injected six
varices per session. 1J.·;:~arewe 14 cases with liver
damage which had been shown biochemically, whoae age varied
from 5 to 72 years nnd of note is that 50% w~re dead within
on€:llyear. In contrast, out of the 16 cases without "liv~r
damage", 14 were "alive and well", although the mean follow
up was not stated in this paper.
An interesting point in the paper was that in the follc.w up
of one of these patiemts Macbeth notQ!!-that the patient was
alive at 11 years, which implies that Macbeth must have
started his sclerotherapy as early as 1944. Macbeth
stated that patients could live normal lives. However he
found the varices recurred and insisted that the patients
be exami~ed by oesophaqos~opy once or twice a year
indefil"i.tely. He also advised that a :lydrostatic bag be
placed in the oesophagus post sclerotherapy for 2 hours if
the varices injected were profuse in number or large in
size. Macbeth stated that splenectomy wa3 obligatory as
adjunct therapy as it "makes the veins more readily
cO:ltrollable."
Despite these pioneering efforts, sclerotherapy failed to
become a standard recognised modality of therapy, probahly
for a variety of reasons, one of which was the popularity
of portocaval shunting. As the results of prospective
portocaval shunt trials became available, it was apparent
that these operations had a high morbidity and mortality
and did not greatly improve long term survival (Larson,
1986) •
Johnston and RogarB reported on 117 patients whO had
sclerotherapy with good r.~ults in 1973. In 1975, Bailey
described a modification of the rigid Negus oesophagoscope
which he demonstrated while in Cape Town, and this prompted
TlIilrblancl:uaet a1 to set up the first prospective oontrolled
trial in Auqust, 1975. ~neir initial report in 1979 was
encouraging. However, Ln 1983 they failed to show
improved long term survival. Westaby et al in 1984 did
however show an improvement. These latter authors, as
well as Pacquet's paravariceal methods (1983), can be
considered as the reason for the resurgence of the role of
sclerotherapy.
1.4 SCLEROTHERAPY TECHNIQUE
1.4~1 lDtrayar19 ••1 V' parovaric.al Inj.gtion
Paravariceal injection was firs'cdescribed by Wodak in
1960 in tha Garman literature (Terblanche et aI,
1990) •
Pacquet subsequently reported on a large series of
patients whom he treated usinq paravarioeal injl8Ction
of polidooanol with exc"llent results.
The aim of paravarioeal injection in the acute.rstage
is to compress the varix. 'l~EJ sul:'Jaequcmt
inflammation is thought to help embed the vftrix in the
wall as well as thicken the overlying oesophageal
mucosa.
The technique of intravariceal injection is more
widely praoi:ised. 'l"heoriginal description in 1968
by Blenkinl!llo!"r',~.path~')logistfrom st Mary's Hospital,
laid down the fouil~ati")nfor this technique. PIe
showed that paraven::.:,t\:\injection of scleros·l!mtin a
rat's tail vein l"1.;d no imp!.ct on the flow and that
intravenous irAjection was required.
Although most .tutUea are diviCled into intravariceal
and paravario;aal injections, in my experi.nca, even
,,,henone aims intravariceally, this is often
accompanied by some degree of paravariceal injection
as well. This is confirmed by Rose et al, (198~) who
showed that in their' handa thifiloccurred frequen.i..ly.
GrQP& at al, (1984) used venography during endosoopio
sclerotherapy and found similar results.
Paravarieeal injection, purpos~fully or,:inadvertently,
is associated with a higher local complication rate.
This is 4iSlcusaed in gr6uater detail at a later at,age of
this thesis. Kitano et al (1987) has published a
series where they advocate a combined technique. Most
series that are reported use an intravari(Jeal method
(Sivak et aI, 1990). Ttie technique employed in both
trials in this thesis wa's intravariceal.
1.4.2 Instruments
There are two instruments available, i.e. riqid and
flexible endoscopes. A prospeotive trial oomparing the
two methods has been reported (Bornman et aI, 19S8)~
'!'hey found t.hat the ratE:.'of serious oomplicati~ was
.higher in the rigid endcsoopy group. A disadvantage of
the rigid techl1ique is that general anaesthesia is
required. While some endoscopists miqht feel tbat. this !.'
is advantag-&otlsin that th,Qrisk of aspiration is
reduced, others feel that thi$ is offset by the dan.qers
of anaesthesia in patients with poor liver funotion
(sivak et al 1990). For lbo'thtrials in this thesis,
The use of an oVert,nbe
for oompression is controvElrsial and is diacutiliiledin
Chapter 2. An overtube W8S not used in either of the
clinical trials.
1.5 THE SCLEROSUT
Various sclerosants are available. However, their
mechanism of action is poorly understood (Sivak at aI,
1990) • The sclerosant used in this thesis was Sodium
T,,-,tradeoylSulphate (S.T.D.). The reason for ohoosing
l/this solerosant inoluded the pioneering work by
Blenkinsopp, who showed it to be superior to other
scleromants in a rat model.
The availability of the sclerosant was an important
factor. In south Africa one ot the only other solerosants
which is available ls ethanolamine oleate and althouqh
KleMo at &1 (19B7) and Terblanche et 8.1 (1990) prefer this
scl$rt>sant, Sivak at al (1990) st~;ll racollllMmd the use of
S.T.D·,
A third factor for choosing S.T.D. was its viscosity and
colour. S.T.D. is a clear non-viscous solution as
compared to the yellow viscous ethanolamine oleate. This
facilitated th. us~ of various concentrations where the
patient, the endoscopy assistaJ'ltand the endoscopist were
unawars as to what concentraticm of sclerosant was l~einCJ
\\\\Ethanolamine oleatE~ i.sextremely difficul).tt.o
'~'\
injected.
inject.
preserved with benzyl alcohol 2% m/v. It is a sterile
Therefore if it had been chosen it would not have been
possible for the investigators to be blinded as to the
ooncentretion of the sclerosant.
}i
The final reason for choosing s.T.b. is that S.T.D. is a
single substance rather than a mixture of oils
(ethanolamine oleate) and therefore it would be more
amenable to ~Oditication should this prove necessary.
s.ToO. is ~.rianionic detergent. Its structure is shown in
Figure 1.2. It is supplied as 3% mass per volum. and is
aqueouB solution and is buffered for a pH of 7.6.
, • -... -I' • ~ • ~~
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. '0 FIGURE 1.2 : The chemical structure of
, Sodium Tetradecyl Sulphate.
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1.6 ROLE OF SCLlmOTmmAPY IN COMTROLLnlGTIm ACUTBBLEED
Sclerotherapy has been shown to control varices in 95% of
~'Qisodes (Terblanche et al, 1981) and their findings have
been conf inned by nuaerous workers 0 A problem has been
that various authors use different techniques as well as
sclerosants. Terblanche1s findings were similar to those
of Johnston, who in 1973 had a 93% success rate in stopping
the acut.e bleed.
The rebleed rate would appear to be in the region of 13 -
30%. The high mortality would appear to correlate well
with the degre~ of underlying liver disease, viz. Child C
has a much worse prognosis than Child A (L&rson, 1986).
Larson et al showed in 1986 that patients who underwent
sClerctherapy had a significantly lower transfusion
rQquirement than those who did not.
Sivak at al (1981) reported on 22 patients and showed a
marked decrease in transfusion requirement.&! prior to
initiation of sclerotherapy in theses patients. A study
performed on 52 patients by Cello et a1 (1984) where
patients were randomized to sclerotherapy or shunt surgery
showed that sclerotherapy patients had shorter
hospitalis~tion periods and transfusion requirements than
those patients who had shunt surgery. However,
hospitalisation periods for rebleeding was higher in the
patients who had sclerotherapy.
in 8. stU4y from ta.•. _u·aohusett$ ~r~l liO$p;ktal, von
Ryll Gryska at a1 (1985) used a combination of thrombin,
oephalothin aUld ethanolamine oleate to i>Oleros$ 113
patients with varices. Sclerotherapy was performed for
acute ble.ding varices in the majority of their patients.
Their initial suoaess rate was 95%.
An import¥)lntprospeoti vely randomised trial show("ri a :marked
1\
\.benefit oil,sclerotherapy venus tuponade (Paoquet et aI,
1985) .. In this trial 43 cirrhotic patients wers
ralldomised to either sclerotherapy or Sengstaken-Blakemore
tube for actively bleeding oesophageal varices. Long term
survival, as in most. studies, was related to Child
classification on admission. However, efficacy in
stopping the acute bleed and initia: mortality was
siqnifioantly il'lllProvedin the sclerotherapy group.
DeSipite all the olaimed benefits for the acute bletJd, one
shoul.d be aware that as many as 75% of pati\.:.,,~,ts will have
stopped. bleeding at the ti'JllCa of initial endosoopy prior to
sclerotherapy (Shields, 1991).
1.7 ROLE OF S~y IN COHTROLttDlG ~
VAlUCEAL~B
It appeared logical that if sclerotherapy was ~fficacious in
controlling acutely bleeding oesOpbageal varices, long term
management would obliterate and reduce recurrent
haelltorrhaqe. The first controlled randomised trial of
sclerotherapy by Terblanche (1983) showad that while the
sclerotherapy group had significantly fewer rebleeding
episodes, their overall survival rate at 1 and 5 years was
not ~.1CJt'd.licantlydiffe!.'entfrom the control group.
MacDou~all et al, in 1982 showed a statistically significant
ihlprovelllentin survival at 1 year and of notre is that there
was an increased incidence of death dOle to bl~edinq in the
control group.
The major stU?y by Westaby et al (1985) showed a
~tatistically significant improvement in survival of
patients who had received sclerotherapy. There was also a
decrease in both the total nUlllberof patients who rebled as
well as the number of episodes. This study also showed
improved survival fIN':'each of the Child's grades of
severity. Soderlund at nl (1990), also showed a decreased
risk of rebleeding. Sivak at al (1990), feel that despite
the above studies, recurrent bleeding still occurs in 30-60%
of patients.
The fact that Child's classification plays an important role
~ 'oozne out in numerous stadies (Von 'Ryall Gryska et ali,
1985; Pacquet et al, 1985; Westaby et al, 1985);
In a meta-analysis whiCh examined several controlled
clinioal trials, the results showedan imnrov&~nt in long--r. I ~
tera stirvival attributable to serial sQlerotherapy
(Infante-Rivard et 111, 1989).. The question of lonq term
survival remains contrnversial. The copenhagen study
(1984)"\ \,/h randollized two grc..lps into medical and
) i
sclerotherapy showed nc difference in the long term
su~ival. An impo~tant study by Sauarbruch at aI, (1985)
s~ow&dthat the mortality was directly related to Clii~'s
Cla$sific~t1on.
for Child's C.
.Child'&IA 1 yelf.rsurvival was 100%. vs 3l~%'
))
Not only does Child's clas:sifi\,'":ationplay a role, l1Jut
perhaps. more importantly t1'>l! fact tha:t; pati~. C:bildis
classification is not statio but r.ather dynamic and is based
on th~ underlying hepatic pathology. It has • )(gem.suggested
that sclerotherapy ham bec"i: overutilized at smae eentr.es at
the expens:. ';If other therapeutic modalities including shunt
,.
surgery and pharmacotherapy (Terblmche, 19901 Shieldeh
1991) .. It would appear tb.a"t;:theunderlying hepatic
patholoqy must be the· major l,eterlUinantLn long term
survival of patients whate"rer modality is used •
.., .t 1 ~)- ,, ...
-
1. >.3 ct;~CAcrIOKS O}i"~1iEP.APY
Sclerotherapy has been &ssooiated with numeroua
complications. The following is a review of some· of the
impo~tant oomplications wh~ch have been documented.
1.8.1 R~temic Complications
An important systemic compllcation is the effeot of the
sclerosant on the ~ulmonary ci~culation. One. of the
most common thoracic complications is pleural
effusion. The incidence would appear. to correlate
with the total volume ir.jected and the volume injected
per 8ite but not; with either ....,~1~ type of sclerosant or
the total volwne per session (Edling et ali' 1991
Roentgenographic findings ather than effusions include
deviation of the azyga-oesophageal reflection into the
right hemith(._...t.x~ thickening of the posterior wall of .
the bronchus intermedius, an indistinct periaortic
stripe and subsegmental ateleotaais. The effusion
when aspirated and analysed is normally a sterile
exudate (Edling at aI, 1991). Bacon et al (1985) also
showed radiological evidenoe of pleural ~ffusions in
numerous patients.
There :is ~videnoe that the sclerusant embol Lses to the
lung in numerous ,;..>atients.De Peuy et aI, in 1988
performed a study where they showed eviuencd of
embolization to the lungs at 2 hours in 60% of oases.
Acute respiratory failure was ~ooumented by Monroe et
al (1983).
1_:
I
Vallgren et 81 (1988) performed a study Ol'l(::rj.vensheep
to Jete:"''1I1inet.h l!ef!ect of sclerosing agents. They
tested ethanalamine oleate and S.T.D. and injected them
intravenously. Both agents caused a severe fall in
total respiratory compliemce and arterial oxygen
tension. There was marked trapping of platelets in
~he lungs. They concluded that both sclerosing agents
cause severe lung injury in sheep if gtven in
corresponding doses of 20-50~ of what is normally used
fl1>rsclerotherapy in human patients and postulate that
th. mechanis~ is besod on increased microv8.3cular
permeability. Another interesting paper demonstrat,ed
that .:lclerosantscaused pUlmonary hypertE:msion in sh(/uap
(Hammond at aI, 1985). These worker. found that the
raised pulmonary pressure could be ~ryviated by
pretieatinq the sheep with indomethacin which suggests
that the raised pressure is due to sclerosant-mediated
pro£taqlandin rele~se. Siqurdsson et al (1989)
confirmed the above by demonstrating that aspirin
prevents pulmonary damage in sheep giVen ethanolamine
oleate.
I
t 0
l
Connors et a1 (1986) injected sclerosant containing
Technetium labelled albumin microspheres and
demonstrated that in their ••rjes only 20* of the
injected sclerosant reached the pulmonary
vasculature.o
1'5 , t
They "howed no chanqes in the pulmonary diffusion
capacity using a carbon monoxide technique. EnCloscopy
can caus~ relative hypoxia in nearly half the patients
undergoing the prooedure (Barkin et al, 1989).
at 8.1 (1984), howevsr, demonstrated transient
deterioration in pulmonary function after.
scleroth>erapy.
Korula
The effect of sclerotherapy on cardiovascular
haemodynamica was assessed by i.nvasive monitoring in 8
patients (Bailey-Newton at aI, 1985). They
demonstrated a statistically significant increase in
pulmonary vascu;lar resistP.'lnce,although the elevated
levels were still within normal limits.
other pulmonary complications des~rib.d include
bronchitis (Barsoum at aI, 1982), adult respiratory
distress syndrome due to massive ch~flothorax (Gertsch
et al, 1983) and a fatal right lower lobe collapse
(Barsouxnet 15.1,1982).
~nother interesting systemic complication is
haemorrhage from other sites. Foutch and Sivak (1984)
d~monstrated 3 cases which bled from colcnic 'varices
after andoscopic sclerotherapy. Keane et al (198~)
repor" >~don massl ve bleeding frontrectal varices
~ollowing repeated i.njected sclt:3lrotherapyof
oesophageal varices.
Fry at al (1988) repo:tted on a 78 year old patient:with
haematoohezia which occurred !XUJt sel&rotherapy of
oesophageal varices. They found, at laparotomy, that
it was due to adhesion related varices at the site of a
previous h.yste:t:actomy. They did not eomment on the
sclerosant used for the oesophageal varices.
Distal mites of thrombosis have been reported.
Goodale at al (1982) described superior mesenteric vein
thrombosis in 2 patients. The sclerosant 'Whichthey
used was 5% sodium morrhuate .. In the same year
Barsoum et al, described a ~~tient who develope~ portal
vein thrombosis post sclerotherapy using &thanolamine
oleate. This resulted in recurrent haemorrhage whioh
proved to be fatal. A tragic case of spinal artery
thrombosis which occurred in a 4 year old child a.fter
intravariceal injection of 5% sodium morrhuate was
described by Seidman et al in J.984. This resulted in
subsequent paraplegia. More recently, Ng at al (1988)
described ci case of digital gangrene which oocurred
post sclerotherapy.
Duodenal varices have been described as a complication
after endoscopic sclerotherapy (Eleftheriadis, 1988).
The cause of this complication is obscure. Gastric
varice~ may increase in number and size aftor
sclero'therapy (Eleftheriadis, 1988).
reported that tJ::t$ recurrence of oesophageal varioes wail
not associated with gastric varices.
Congestive gastropathy is a common finding and oo~~
in a severe form in 55% of patients with varioes. It
has also been doc~nted in one trial to occur in 79%
of patients who rec6Iived sclerotherapy (D'Amico at aI,
1990). In their study, they felt that recurrent
bleeding was in some oases due to tha qestropathy.
This is at variance with other studies (Westaby et aI,
1985; Kitano at aI, 1987), where recurrent bleedinq
was associated with recurrence of varices. The
pathoqen~~i$ of portal hypertensive gastropathy is
controversial. Decl:;e.sedmucosal blofJd flow,
congestion and ectasia, decreased p«psinoqen I,
increase serum gastrip...~d inorease mucosal
prostaglandin E2 l(ivel,'Ihave all been inc:r.·iminated
!f
:I(Blackstone, 1991Xi. Chung et al (1988) described a.,
"technique of endoacopic measuremeni: of gastric blood
/-
flow using lase~ Doppler velocimetl~. Although
gastric mucosal '",bloodflow was elevated in patients
if
with portal hypertension, the mucosal flow was not
altered after solerothelapy.
1.8.2 L~l, Cgmplj,g,a,tioM g &G1UQ:1;t2carlgy:
1 ..8" :2.1 o.~g;u.l. Stricturfi
This i. a reasonably commoncomplication
oocu.rrinq e\fter sclerotherapy. Maynes at al,
(1986) compl'1't"eda grollp of patients who developed
strioture POIst S.T.D. injection, with a qroup in
whom this did not occur. They could find no
differences in eith.r the total volwne o:t:'number
ot injections between the two groups,.
onophaqeal dilation was successful in all !\
oases. The use of intentional paravarieeal
injection has a high stricture rate (Kja~rgaard
at al, 1!J8:2) ..
1 • 8. 2 .:2 QfUiQ1)}1ag:ialpertr,,:atit;m
Oesophageal perforation has been reported as a
complication of sclerotherapy (Perino et al,
1987) •
1•8•:2 • 3 ,QesQphag:.alUlceratiQn
The incidence of ulceration would appear to vary
directly with the time interval of endoscopy post
sclerotherapy. sarin at 61.1(1986) show~d th&t
94% of pat:~ents, when they war" endosooped 24
hours after the procel'iura,developed ulceration
after sclerotherapy with absolute alcohol. This
figure dropped to 69% at one week and at 3 weeks
the figure was 12.5%.
1.8.2.4 QfifiliPPAAO:.,J,·¥oj;1lity
Decreased oEuhlophaqeal motility and acid olearance
have been assooiated with solerotherapy, although
the lite~ature is controversial (sivak at aI,
1990).
1.8.2.5 ~
NUmerous patients complain of chest pain post
solf1rotherapy. This pain has been thought to be
due to a ohemical mediastinitis but this remain.
to_b~ proven (Sivak et aI, 1990).
~.i i--
Gebhard et 8.1
(1982), on the basis of barium swallows,
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2" m gYfREMlC IRECTS OF 3li soo:rQK TmADECXt ~
QB COAfiltJW.IIOJi
2 • 1 INTRODl1C't10lf
Although the systemic eff6i~,t;~;of scl~rotherl!ipyon
coagulation have been previc::cislyreported, no trials to
date have I!i$sessedthe systemic effects of S.T.~. on the
co~qulation system and liver function.
~rdner and Brooks in 1982 performed a study on 11 patients
at Emory University Hospital. They injected a combination
of 2 ml of 5% sodium morrhuato followed by 2 ml of an 8 ml
mixtur4l/~-;;e!!~ining1 ml (100 units) of thrombin, 2 ml of
oepbalothin sodium concentration (1 g/5 ul) and 5 ml of 50%
i;roseinto each varix. A balloon for proximal dilation
...... !:'ilI used. At 7 a.m. on the day of s.clerotherapyI the
haematocrit, haemoglobin. platelet count, prothrombin time,
partial thromboplastin time, fibrinogen, fibrin split
products, Factor V and Factor VIII were analysed
(approximately 16 hours after the oompletion of the
procedure). They found no statistical differences in any
of the parameters measured.
They concluded that the sclerosant combination they were
using had no systemic effects and postUlated that the reason
for the lack of ~ystemio effects was that they used an
Qvertube.
I ..
I""
This tube ccnaLs ted of a balloon cuff l.!"'hichwas attached to
the flexible endoscope proximal to the instrument tip and
inflated prior to sclerosant injection and for 1 minute
afterwards. This was performed in an attempt to retard
cephalic spread of the sclerosant.
The problem with this study was the time interval for
testing of clotting parameters. They only tested the
patients approximately 16 hours post sclerotherapy and
would therefore hava missed any significant changes which
would have occurred during this crucial time period. The
time of approximately 16 hours would fail to detect a
transi$nt coagulation defect. One would expect that if a
coaqulopathy such as a diffuse intravascular coagulopathy
(which is what the authors W6re specifically looking for)
was present 16 h01XCS after the injection, then these
patients would have had marked clinically apparent siqn~ of
coagulation disturbances. The authors did not document or
discuss the clinical appearance of their patients post
sclerotherapy. Thei~ techn~lque was int"!:'~.varioealand they
used an overtube.
The use of an overtube is controversial. Grobe et al (1982)
showed the flow of the varices was cephalic in 50% of
patients with or without balloon compression and that in 15%
the flow was as caudal with OI' without compression. In 35%
the sclerosant accumulated locally. whioh suggests either
paravariceal :i.njectionor no flow in the varioes injected.
However, 3 hours later, there was no residual contrast
material in the chest or abdomen suggesting that the latter
was mote likely.
The seIer-omant which was used in this trial was 5% sodium
morrhuate mixed with an equal volume of 60% renograffin. A
'I
total of 10 - 20 ml was injected at each session. The
authors concluded that balloon compression was probably
unnecessary during sclerotherapy.
Bernardi et aI, a year later in 1983, criticized Gardner's
paper because they felt that the time interval was too
lengthy and any transient coaqulopathy would be miss~~.
They evaluated the coagulation profiles in 10 patients with
liver cirrhosis before, 30 minutes after, and 18 hours after
elective injection of oesophageal varices. They injected
5% ethanolamine oleate • only 3 parameters were measured;
the platelet count, Owren's normotest and plasma
fibrinogen. All these parameters were significantly
impaired at 30 minutes. The platelet count; was reduced, as
was fibrinogen and Ow~en's normotest. The authors
suggested platelet consumption and coagulation factors occ~t
shortly after injection sclerotherapy using 5% ethanolamine
olea't<d.
Baele et al in 1984 published an abstract where they
described the effects of injecting 1% polidocanol on the
haemostatic system.
cirrhosis.
They inje:::ted12 patients with liver
They measured the following parameters; the activated
partial thromboplastin time, the prothrombin time, Factors
II, V, VIIi VIII, IX, X, fibrinogen, plasminogen,
antithrombin III and alpha-2 "lntiplasmin and fibirin(ogen)
degradation products. These tests were performed before,
10 and 60 minutes after sclerotherapy in 12 patients.
r.•ney found no significant changes in any of the parameters
tested except for one patient whose fibrinogen degradation
products became positive. They concluded that polidocanol
did not activate the coagulation pathway.
Musso et al in 1987 published a<l.~tter where they ass()ssed
25 patients who wero scleros~Jwith 1% Polidocanol for
oesophageal varices. The following parameters were
measured immediately before, and 10 minutes, 60 minutes, 360
minutes and 24 hours after sclerotherapy, viz. platelet
count, prothrombin time, thrombin-coagulase time,
fibrinogen, fibrin(ogen) degradation products, Factor XII
and plasma prekallikrein levels.
Their results showed a statistically significant drop in
Factor XII ~nd plasm& prekallikrein levels at 10 minutes
which had returned to normal at 60 minutes. The authors
concluded that Polidocanol was able to activate the contact
phase of coagulation which implies that the reason for the
low factor XII is consumption. Kan9 at al in the same year
(1987) publisheJ a trial in the British Journal of Surgery.
They evaluated 20 patients with oesophageal varices.
These patients underwent endoscopic injection sc~erotherapy
with 5 percent ethanolamine oleate.
The followirt<lparameters) were assessed: Acti vated partial
thromboplastin time, the Normotest, pla.sma fibl"'~'!";ogen,
fibrinogen degradation products and complete bll,.:>dcell
count. Fibrinopeptide A and fibrinopeptide B B 15-42 were
also measured. The time interval used for sampling was before
the sclerotherapy, one hour after the sclerotherapy, 1 day, 2
days and 3 days after sclerotherapy.
Their findings showed a statistically significant decrease in
p'~othrombin time at 1 day after sclerotherapy although this
did not appf9ar to be of clinical significance. There was a
significant lQuoocytoses at 1 and 2 days post sclerotherapy
and the plasma fibrinogen had gradually increased at day 3.
They also showed a statistir.:ally significant increase in
plasma fibrinopeptide A and fibrinopeptide B B 15-42 at 1 hour
and 1 day post sclerotherapy. Fibrinopaptide A is f~rmed
after being liberated from fibrinogen b'j the action·~'f.
thrombin and fibrinopeptide B .s 15-42 is liherated by plasmin.
These tests therefore were accurate in assessing and
confirming a transient activation of coagulation and
fibrinolysis after sclerother.apy. The authors howav~r do note
that this might be a secondary phenomenon that they are
mp.asuring due to the inflammatory responsive rather than a
direct action of the ethanolamine oleate. An alternate
explanation might be that the fibrinopeptides are released
from thrombus which has formed on the ethanolamine oleate
induced damaged en.d.othelium.
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The aim of t.ltletrial was to Jetermine the systemic effects.
of the scl.l!U:osant,sodiwn tetradeayl sulphate (S..T ..E>.) I with
particular l'~ef&ren~eto the coagulation system ..
time that ~la study was conducted, S.T.D. (3% m/v) was one
of 'the solerosants in routine usage at Baragwanath \\
Hospital. SClerotherapy was not used as a primary modality
for controllinq tb. acute bleed in patients wi~ O$sophageal
varices.' It was used as a treatment for prevention of
rebleeQ.inq i~ patit.ants who ha.dpresented with. bleeding at
admission or who had Ii history of a prior oesophageal
PatiQnt~ who presented with an acute
'vario~~l bl~ed were treated in the first instance with a
Sen,gstaken"'lBlakemore tube. SClerotherapy was ,pnly performed
one week after thG incident in line with polil!cyat
Baragwanatb Hospital at the time. The follow up of patients
'Wasand remains extr~ly poor at BarCtgwanath Hospital, so
the study was confined to the acute effects of the
schl!rosant ..
•
Fifteen adult patients with portal h~n;ertellsion from
Baragwanath Hospital were included :in the trial. All
patiant~ qave infonted consent and the trial was 14pprovedby
the HumanEthics Comnittee of t~E University of the
Witwa'tersralld. The ml!<:&nage of the patients wa ~ years
(rang~ 30-69 years).
patients.
There were 12 male and 3 female
Thfl only eribarion for inclusion in 'the study was any
patient whopresented. with oeso:ph_"')Jealvarices whohad a
history of a prior variceeLlcc_J:)leed.
,/">
All fi~t.een platients had liver biopsies to obtain
histological E,vidence of the aetiology of ".;:heircirrhosis ..
Of these, 13 pllti&nts had, alccholiq, live:"",cirrhosis, 1 had
schir.::;tosomiasis·ann in 1 patient t.'le cause was undetermined.
Tbe ChilCl.-Pughc.~lassificatlion of the patients was as follows
9 of the patieats werE!Chi.Ld/a A, 4 we:ta Child"s B, and 1
was Group C.
The pat.Lents were all sedated wi't:h5mgof midazolam.
,
have bee~ rasponsibJ.e for the bleed., The patients then had
/i ::'/ ' -"-: \'_, .:
A1.1: ~\~.\\filntll had a full uppar gastrointestinal endoscopy
!j:
perfoni~ed using a forward viewinlJ Olympus flexible
Iigastroe,:\Copeto document any concurrent pathology which might
\",
one or mo~~ val.:icElIIinject&d. The injecti?n was aimed
intravariceally a1though i.8 pl:obable that some of the
sclerosan~ was probably injected paravariceally.
An overshaath. was not used. The agent us~d was
ilSol.HUlft, tetradeoyl sulphate J m/v, preserved with
benzyl alcohol 2% m/,'. The ag~nt was supplied by MPS
Laboratories (?ty) Limited. The amount of sclerosant
injected vz;.riedfrom 6 to 12 mls, with l'.L mean volume of 8.6
mls inj'.:ltcted.
ldl patients had oJ ood d.l:awnill1lllerliatalyprior to
sclerotherapy, immediately after sclerotherapy, ~nd
30 minutes, 60 minutes and 24 hours post sclerotherapy.
This was p$rformed to ensure that any transient
abnormalities were not l1\\issed•
These specimens were submitted for analysis of the following
parameter!!:
prothrombin timer partial thrombopla~tin time,
fibrinogen, flbrin(ogen) degradation products (F.D.P.),
F'ectorVIII, full blood counts and liver function
tl3sts.
--------------- ---------------
'rh$ m.atbodology employed in the prothrOllbin time, partial
thro1Ul:;x;)plastin1:.i•• , fibrin (ogen) degradation products, and
factor VIII iU.JUI.Y. is identical to the methods deseri~ in
the seotion on the in vitro trials. The full blood counts
were verfor.mad on a Coulter S Plus Analyser and the liver
function tfist. were assayed on a Instrument Laboratory 503
Abbot 100 machine
2 *4. J. i:tA:tilj:..i.ga
~he .tati~tical analysis was done by the Institute for
Biostatistics of the South African Medical Research
Council.
The many-one tests, ia...oolllpar..Lngt.'1epre-solerotl':..rapy
value. i't dividually to all ti~a post-solerotherapy
valu.1! I Wftre performed by employing Wl.lcoxanI" iJ.9Tied
rank test. usdnq thiftBon"".lrroni 4~'~ustm1tn;;for m'-'..t-eiple
com.parifSQHs.
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2.5 RESULTS
2•5•1 ~l.tui.?J&.l:
All tile tJ!l '~:teut.b;9xperiencQd retrosternal chemt pain
imm.diately af~er sclerotherapy. All the patients
were hospitelized overnight for observation.
the patients complained of mild dyspnoea post
TWo of
sclerotherapy. None of the patients had a
haamatemesis during this period. There were no other
document\i:dcompl.ications. Follow up on these patients
is not available.
2.5.2 Labgratory:
The white cell count was significantly decreased at 60
minutes (p=O.0115), and significantly increased 24
hours post sclerotherapy (p=0_024) [Figure 2.1].
There was a statistically significant decrease in
fibrinogen from 2.92 gil to 2.68 gil 60 minutes after
sclerotherapy as compared to before (pdO.0355) [Figure
2.2]. In three patients this was associated with a
mild elevation of the fibrin(ogen) degradation
products. There was a trendJ although not
statistically significant, for the prothrombin index
to decrease at 60 minutes after sclerotherapy [Figurp
2.3].
The remaining parameters of the coagulation profile,
viz. Factor VIII levels and the activated partial
thromboplastin time were not significantly altered.
--~ -------
The haemoqlobin, mean cell volume and haematccrit and
platelet counts did not show any gtatistically
significant alterations. The platelet count bhowed a
trend to decrease at 30 minutes post sclerothexapy.
Howaver, it was not statistically significant.
The liver function teats, which included total
,
protein, direct bilirubin, total bilirubin, albwnln.,
91obuljn, alanine transaminase, aspartate
transaminase, gamma glutamyl transaminase and alkaline
phosphatase were all unchanged.
FIGURE 2.1
The in vivo effect of intravariceal injection of S.T.0.
on the white cell count. (Mean ± SEM)
At 60 min p=O..0115 as compared to Pre-'.
At 24 hr p=O.024 as compared to Pre-.
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FIGURE 2.2
The in vivo effect of intra variceal injection of S.T.D.
on fibrinogen levels. (Mean ± SEM)
At 60 min p=0.035 as compared to Pre- ..
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FIGURE 2.3
"he in vivo effect of intravariceal injection of S~T.D..
on the Prothrombin Index.
directly or whether they were consumed. The in vitro work
2.6 DISCUSSION
In th,,,present study 3% m/v S.T.D. was demonstrated to have
a transient systemic effect on coagulation. There was a
statistically significant decrease in the level of
fibr1nogen. While this did not result in an acute bleeding
diathesis one would not have expected this to occur as the
fib:":,,inogenconcent:.,"ationdid not drop below a level which
would result in a bleed. The same argument holds true for
the trend for the prothrombin index to decrease. The
question is whether the S:.T.D4 destroyed these factors
presented later suggests that at the volume ,:!nd
concentrations injected, the former is unlikely.
The transient drop in the white cell count ~hich was
followed by a leucocytoses is interesting.
Leucocytes ha.ve been shown to playa role in thrombosis.
Belch (1985) in a review article states that the leucocyte
has the ability to damage endothelial cells by means of free
radicals. The endothelial cells then produce less
prostacyclin and the breakdown of endothelium der~ved
relaxing factor is increased (McCord, 1985). Furthermore
neutrophils interact with platelets and stimUlate
aggregation (Canoso at aI, 1974).
The converse is also true, i.e. that platelets can stimUlate
leucocyte activation (MacLouf et al, 1982). The drop in
the leucocyte count was probably due to margination and
sequestration.
This was follow·ed by a rebound leucocytoses which occurs as
a result ot b~ll release from the aarro~.
endothelial damage (Stroncek et aI, 1985). In a larg~
The above phenomena are analogous to the events which OCCUl·
post endotoxin ad'l!.inistration;itohuman subjects «('70ldeI
1990) •. other reasons for the rebounfi leucocytoses include
a transient bacterae:mia which sclerotherapy can induce, and
pyrQxia which .LS thought to be caused by the c11emica1
phlebitis or the acute inflammatory response (Schuman at
ai , 1987).
The site of the ~equestration of white cells which occurred
Sclerotherapy .£S a W~ll
documented cause of acut~ adult respiratory distress
syndrome; the basis of which is postulated to be
proportion of pa11iientsthere is rapid flow of sclerosant
from the varices to the pulmonary circulation (Grobe Gt al,
1982) • This would also explain the transient fall in
fibrinogen levels, as well a~ the elevated fibrin(ogen)
,
degradation products which was found in three pat:I':entm.
The findings of this study t..howedthat sclerotherapy with
S.T.D. did have systemic effects on the coagulation system
and suggested that modifying the dose might be a useful
adjunct in limiting the above effect.
'\II
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3. PUW,ITS
3 • 1 IIf'l'RODUC'l'IOIf
The in vitro effect of sclerosants on platelet function has
not been adequ&tely studied. Stroncek et al (1985)
demoJl'!tratedthat scl~l:'osantscause haemolysis and that
this haemolysate could induce platelets to aggregate. These
workers suggested that the aggregation was due to the red
cel~ membrane, which is a documented agonist capable of
causing platelet aggregation.. Yamaga et al (1989) showed
in an in vivo trial that ethanolamine oleate depressed
platelet aggregation as evidenced by a decreased response
to ADP for 1 weE~ after sclerotherapy.
The .motion of platelets has been revi~~ed extensively in
recent years (Roth, 19911 Bloom, 1990; GinSberg et aI,
1988). The following is a selective review of platelet
function, which, although not comprehensive, is relevant to
the understandinq ofcthe mechanism of action of S.T.D. with
particular reference to platelet aggregation.
3•1.1 Platelet£? and their Functt:<>n- A Review
Bizzoz8f\,oshowed in 1882 that platelets accumulate at
injury sites in small vessels and thus establi~;.:.·t'idhe
crucial role that platelets play in forming ;:.g~
haemostatic plug. Wright in 1906 described the origin
of platelets. He discovered that they are produced
by the megakaryocyte.
00
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Platelets circulate in a resting phase and their
i \
i'survival is estimated to be approximately 8 tl.)12 days
(Heyne at aI, 1980).
3.1.1.1 Platelet Structure
one of the :mechanisms which enables them to
perform their function is their trilaminar
platelet membrane. This membrane does not
appear to be''.i.nherentlydi,fferent from other
cell membranes on initial analysis. However
freeze fracture analysis has shown that the
platelet membrane is in fact different from
oth~r cells in that it is turned inside out
(Zucker-Franklin D, 1990). Platel~t membranes
have numerous glycoprotein receptors which are
summa:t', '~edin Table 3.1.
Platelets cont.ain organelles, including
mitochondria but are anucleic. The organellea
include the alpha granules and ~~e dense bodies.
Alpha granules contain B thromboglobulin,
fibrinogen, thrombospondin, fibronectin,
platelet derived growth factor, platelet factor
4, and V0n Willebrand factor (Wencel-Drake at
al, 1985), while dense bodies corrcaIn sarotor"in
and probably ADP. The density of the granule
would appear to be proportional to th«t amount of
serotonin present (Tranzer et al, 1966).
TABLB 3.1
,~------------~--~--------~"..~~
.,
II.
PLATELET MEMBRANE
GLYCOPROTEIN
Ia
Ib
Ic
IIa
lIb
IlIa
IV
V
FUNCTION
Collagen receptor
vWF receptor
Fibronectin receptor
complexes with -]a and IIo
vWF receptor
Fibronectin receptor
Vitronectin receptor
Fibrinogen receptor
Thrombospondin receptor
Thrombin receptor
plat..eletsencoanter a defect in the vessel wall,
it will change its shape, adhere and spread on
Small vesicles contain lysosomal enzymes, viz.
acid' phosphatase I .B glucoronida.&e, cathepsin and
arylsulfatase (Bentfield-Barker et aI, ~982).
Platelets contain a canalicular membrane sY$tem
which is one of the mechanisms responsible for
exocytosis of the granules. After the
platelets have been stimulated by an agonist,
the\\jranules coalesce in the centre of the
plate~at togethe.r.with canalicular cisternae
leaks which occur i:no:sideblood vessels. These
(Zucker''''Frar.:klin,1970) ..
3..1 w 1. 2 Adhesion interactiQDS between cell, ,~'!l5l
the vessel Wall
Cell adhesior,~'are re~ponsible for sealinq off
adhesions require surveillance which is specific
as well as selective and occur as a result of
cell~adhesive molfi!cules,alf;O known as
anchorins .. These bond a site on one cell ~p a
q
}/
site on another cell or solid phase.
It iA estimated in lUan that 1 trillion platelets
survey 1 000 square meters. Should the
: "the surface and seal the ~~ak by initiating a
platelet plug. Pethica (~961) demonstrated
various processes of intercellular adhesion.
distanoe of qreat.er tharr'10 AngeltrOlllfJ. This
'l'be initial ~roc•• s involve. membrana
protrusions on '.\ smooth lBurf&OG whiab reduoed
elaotro8tatic rftp't.1.1sionand thereby promotlis
For example, a pseudopod protruding
from a pla~let is probably able to pftnetrate
the electrostatic force. on the opposite
surface. Another procc.s inv{'llvee the presence
of polyvalent i()O., e.g. calciWll, which :further
reduce the electrostatic neqati ve foro.e. A
final mechanism which he propos.~ is the
,\
J:lIrnel'1oeof large lriOlecule,) which can bridge III
prooe.s is utilised in platftlets, in that
platelets contain and can bind fibrinogen whioh
i. 75 Angatro:ms long and./60 AnqS't.'t'omewide and
/{
can therefore s~n a 1~1~. area and overoome
hydrostatio as well asJelectricllll charc;es ..
d
\\
For platelets to be functional they require not
only cellular adhtlsive molecules but aJ.so
intercellular a6hasive molecul ••. The cellular
adhesi ve molecules may operate ir.:dep_ndently in
sOlIlecases or with the help of an intc;:cellular
adhesive molecule.
An example of this is the gl~'coprotein lIb/IlIa
complex, an inteqrin (Gin,aberg,1988) I which has
the abi~ity to bind one platelet to another
directly. However it ce-.also bind to
fibrinoqan which then binds to the glycoprotein
lIb/IlIa oom.plex on another platelet. I:;;, this
instance the fibrinogen is ~n intercellular
adhesive molecule (Gogst<" et aI, 1982).
A third group of molecules act as substrate
adhesive molecules. These substrate adhesive
molecules are present in the subendothelium, an
example of which is von Willebrand Factor.
Platelets have specific receptors for the von
Willebrand factor and this provides an anchor
f)r the adhesive process to be stabilized.
All the intercellular adhesive mol~cul~s are
produced in the alpha granule of th~ platelet.
The identical intercellular adhesive mOlecules
are produqed in the end9thelial cells and
ditlltributeci·inthe ablwnenal surface" thereby
providing two "sticky" ends which will meet if
the endothelium is damaged and ~e platelet is
activated.
From an evolutionary point of view it is
interasting to note that almost all adhssive
p,t"oteinscontain or biud the R-G-D tripeptide
sequence (arginine-glycine-aspartic eci".)
(Pierschbacher 6t al, ~9a4). It would appear
that this particular sequence was crucial in the
evolution of unicellular to multicellular
organisms. In this regard it is of interest
that the unicellular s?"~im.mould Dichtyostelium
discQideum acquires a R-G-D conta1ning lectin
When its food supply is exhamsted. This th6n
enables it to aggregate to other c$lls and
survive (Springer et al, 1984). R-G-D
~equen~es are essential for haemostasis and
platelet function. However R-G-D sequences
have acquired specificity and are not
necessarily interChangeable, e..9'. platelet
aggregation does not oocur in afibrinoqenaemia
(Inoeman at al, 19(6) and this defect is not
correoted by addition of fi:t.roneotin. The
speoificity of R-G-D is thought ~o be determined
by the amino acid seque~ce within the rest of
'f
Ii'
the molecules as even a:l, ~light change in
sequencing will oause major conformational
cbanges (Berzofs7~y, 1985).
3.1.1.3 Fibrinpgen binaing to flAtelets
Platelets from patients with congenital
afibrinogenaemia are insensitive to ADP (Inceman
et &1, 19(6). 'rheplatelet function can be
restoroadby adding fibrinogen.
------- '------ --
SOllUP.et a1 (1965) showed that washed normal
platelets failed to aggregate when eithar ADP or
fibrinogen a10na are added. The fraotion of
fibrinogen which is responsible has been
determined by Niewiarowski et a.1 (1977) to be
the carboxy-terminal portions of the A-alpha
ohain and the gamma chain. It has been shown
by Marquerie et a1 (1982) that 45 000 to 50 000
fibrinoqan molecules can be bound per platelGlt
in the presence of oa1cium.
3.1.1.4 ~e Fibrinogen Reg§p,tQr and AD~
RaceptQ;t:'
This receptor would appear to reside in tha
lIb-IlIa complex. Two classes of binding sites
ha:vebeen described by Kornacki et 8.1 (1981).
'.T'hGy are h rh and low aff.inity receptors.
3.1.1.5 Platelet-SurfAce Inter8Lation
sixma et a1, (1977) have pEIlrformedmorphologioal
stUdies of the haemosta.tic plug and shown that
after injury bleeding begins immediately.
Witilin seconds the initial response is platelet
adherence to the edgs of the severed vessels.
This re$ulta in the formation of a lOOSe plug.
After several minutes bleeding is halted by the
plug becoming more consolidated.
separately in this thesis. The endothelium has
The plug consists almost entirely of densely
pacr,.edplatelets which have no remaining
granular context.
3.1.1.6 Endothelium and Plataletl
;~
The role of the endothelium is reviewerl
the ability to act as either a pro- or anti-
coagulantQ Most stUdies on the role of
endothelium hav~ been performed by damaging the
endothelium and exposing the subendothelial
layer (Kinlough-Rathbone et aI, 1983) ..
3.1.1.7 Subendotfielium and Platelets
Tranzer (1967) has shown that gaps between the
endothelium and defects in the endothelium are
promptly plugged by platelets.
Platelets adhere to either the basement membrane
or otzler connecti ve tissue alemellts. Stememan
et al (1972) performed experiments on primates
using a balloon catheter to denude endothelium.
Baumgartner (1973) used a similar technique on
rabbits and showed that within 1 minute
platelets were already deposited on the
surface. Although these platelets had
morphological alterations as evidenced by
pseudopodia, they still had most of their
granules.
artGrial flow conditions. In contrast I mural
Within 20 minutes the platelets had form&d a
oontinuous layer. This was under normal
thrombi, peak at 10 minut~s 4nd disappear within
40 minutes. No fibrin is detected in either.
case. Plat.leta which are attached to the
I!
alpha 9ranu~\\.sand 5-HT st.:>rageorqanelle s,
subendothelial surfac4i seorets most of theil"
Platelets spread rapidly on the subendothelium
as compared to artificial surfaoes (Baumgartner
et :.:.l19'6). It is though.t tha.t spread
platelets release granular material which
promote adhesion (Weiss at. al 1986).
3.1.1.8 Elatel~t Aggregation
Platelet aq<jreqation is defineci by colman (1c)S7)
as that. procst.'sby whioh platelets interact wi t.h
one another to form a haemosta.tic plug-. The
process bQgins with adhesion of the platelet to
subendothelial tisl!lIaeconl!llequentupon
endothelial damage. Pseudopod formation of the
platelet occurs as a results of collagen induced
change.
The platelet u':so changes from a discoid shape
to a spheroid shape, during which time it
secretes its dense and alpha-granule contents.
the latent fibrinogen receptor. This action of
The activated platelet forms a sita for the
inac..tivatedplatelet to collide against and
platelet aggreqat$s fOrlil. Fibrinogen :binding is
the crucial step for bridging from platelet to
platelet aDd consequent aggregation.
Fibrinogen binds to the lIb-IlIa glycoprotein
complex (Holmsen .t aI, 1979). Patients with
Glansman's Thrombasthenia lack this complex and
tllereforecannot aqqreqate their platelets.
For fibrinogen binding to occur the platelet
Eust first be exposed to a chemical substance
which will cause a latent receptor to be
expressed on th~ oell surfaoe. Examples of
these substanoe:) imolude thrombin, adrenaline,
collagen and oertain prostaglandins. ADP is
also an agonist and it is felt by most authors
ttl:atADP is the oentral mediating substanoe
through which all the agonists work to expose
ADP may be separate from the action of ADP which
causeS changes inside tha platelet relating to
decreasing cyclic AMP.
The aggregation is divided into 2 phases. The
first involves exposing the fibrinogen reoeptor
in rasponse to an agonist. All the agqnists,
other than !ldrenaline,cause a structural change
as evidenced by a shape change.
The second phase involves the binding cf
fibrinogen to platelets. This bindinq is
initially reversible but later irreversible,
The binding leads to aggregation.
3.1.1.9 A HOWll of Plettelet Aggregat.ion
The primary focus is a transmembrane protein
which is the ADP or AT!> binding site. 'l'heADP
binding site when activated is thought to cause
a spatial reorientation Of lIb and/or IlIa. This
reorientation in the pres~nce of ~~lcium ions
allows the lIb-IlIa complex to now be activated
and therefore to act as the fibrinogen
receptor. Adrenaline, collagen, prostaglandin
and thrombin all require ADP binding to tbe
lIb-IlIa receptor molecule, although their mode
of action would appear to be mediated by binding
to their own respect.ive receptors which are
probably not latent.
3.1.1.10 The Principle of AggrsgOlllfttt:y
Born (1962) described a method. of evaluation
platelet function by usinq a platelet
aqqregollleter* The basic prinoiple is that
platelets in suspension are relatively opa~le*
However, as they aggregate they cause a
reduction in the total nUlllberof free particles
in suspension and therefore the density
decreases.
-_-_._---- -.-~-
This ohanqa in optical density is measured with
the platelet agqregometer.
~
I
recognises two phases I viz., a primary
aggregation wave and a secondary aqgregation
wave. The prisary wave is present usually only
at low conoentrations of a~onist and is
reversible, the secondary wave is felt to be
irreversible '1dis associated with seoretion of
the granular contents of the platelet.
3.1.1.11 Platelet pysfunctiQn in I:1vex cirrhQsis
Thomas at al published a trial in 1967 where
they showed abnormal platelet aggregation in
response to ADP in patients with liver
cirrhosis. However, the teohnique which they
used was a direct visual observation performed
with a magnifying glass, hardly adequate
teohnology by todays ~tandards.
A large well performed study, whioh is often
cited, using standard dual channel aggreqometry,
found that in the presence of a normal platelet
oount the platelet aggregation response to ADP,
adrenaline, and collagen was normal (stein and
Harker, 1982). On the other hand, Desai et al
(1989) showed a deorease in ADP induced
aggregometry due to abnormal high density
lipoprotein parti·cles.
"~""~"~='~ll!i~""' __ '"."__ """"" ~~~"_'lI'i( ~
, • I
1Georg'eand shattil (1991) feel "it re:l\\ainsto be
proVed that platelet dysfunction ditle
specifically to liver disease ia a clinically
important problem.1I Accordingly, the question of
liver dysfunction in liver oirrhosis remains
controversial.
-------~-.------ ----_._--_ ..
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3.2 AIM
The aim of tt~is study was to evaluats the in vitro effect
of S.T.n. on platelet aggregation.
3.3 METHODOLOGY
3•3.1 I..ltelsrt Aggregation
Venous blood w~s collected from four healthy
volunteers. The blooo.was drawn with a 21 gauge
butterfly needle and added to tubes in to rat.io of 1
part 3.8% trisodium citrate, whiCh was freshly made
up I to 9 parts venous blood. The aggregation tests
were parformed in duplicate.
To determine whether platelet aggregation in patients
with liver cirrhosis differs in response to ADP'and
STD, blood was taken from three patients (Mr E.N.; Mr
P.M. and Mr L.M.) who all had liver cirrhosis
(Child"s :8)
The tubes were then centrifuged in a Beckman M~del TJ5
centrifuge at 130 g for 10 minutes. The platelet rich
plasma was removed with a Gilson pipe~te using a
plastic tip. The remaining sample Wt·\.s • •an
centrifuged for a further 10 minutes ~~ 1700 g. The
platelet poor plasma was removed with a Gilson
pipette. A platelet count was performed on the
platelet rich plasma using a H*l Technicon Auto
Analyser.
The platelet count was then adjusted to a50 x 1091
by addition of platelet poor plasma and 450
mior(illitres of the plasma with the adjusted platelet
count was. used. This plasma was pipetted into a
siliconised glass tube followed by the agonist.
The following agonists were prepared (Table 3.a):
i) ADP from British Drug House which contains
adenosine -5'- diphosphoric acid trilithium
salt waft madeup to a stock ooncentration
3.5..mg/ml~
ii) Collagen was obtained. from HormonChamie
MUnchen, GMBa and was diluted 1:10 with SKF
Ho:t1llBuffer (Prod No 1050().
iii) Adrenaline was madeup from May a:nd Baker
inj,ection ampoules containing Adren,aline
Tartrate equivalent to 1:1000 m/v
adrenaline. These were diluted 1:10 with
normal saline.
i v) Ristocetin Sulphate was obtained from.Ii.'
LunbeckA/S, Copenhagen. Onehundred
milligrams was dissolved in 6.6 ml of
(normal saline.
vi) Arachidonic Acid was madeup to a stock
concentration of 10 mmol/J..
TABLE 3.2
AGONIST
RilStocetin 50 ul 1.5 mg/llU
ADP 50 ul 5 ugjml
10 uq/lUl50 ul
Arachi~~onioAcid 10 ul
Collagen 10 ul
===.=-_=_ ..~....====='_~"",a·_ .......z .r=r=-·=·-==
1 mmol/l
:2 ug/lUl
with a phase contrast system. The shutter speed was
The Payton dual channel aggregation module W&s allowed
to wanD. 1,11;> for 20 :minutes.
\",
Specific glass tubes and
magnetic stirrers for the aggregometer were
,I'; ( siliconised with Repelcote for 30 minutes and r:tnsed 5
times with distilh ..d watex and dried~
The Chart paper was set at 20 lDlU/lninand the
sensi tivity a.t 50 mV for both channels. The
temperature was set at 37·C and the stirbar at 11
r.p.m. Channel 1 was set at 0.5 em to 5.5 em while
Channel 2 was set at 4.5 em to 9.5 em
3.3.2. @aSShContrast Time ~egyen¢e Light Microscopy
Platelets were obtained from 't;hr""ehealthy volunteers
using the same method as de~cribed under platelet
aggregation. One millili tre of the plasma contziining
t":"~adjusted platelet C""Quntwas placed on a glass
I
slide and a cover was placed over the plasma. one
hundred microlitres of S.T.D. was added -to the side of
the cover slip so that it tlould diffuse under the
cover slip. Photographs were taken at 30 Dacond
intervals at the centre of tb.e slide. The
photographs were taken using a Reichert tTnivar
Microscope. A magnification of 400 times was used
1/30 second. 64 ~~~ daylight fil~ was used,
A field with aggregates containing more than 20
platelets was considered a positive response (Heyns et
aI, 1979)_
3.4 RESULTS
3.4.1 Plltelet Aggr<lgAti.Qn.
Examples of the platelet aggregation are chown in
Figures 3.1 - 3.10. These were all duplicated.
Thera was a normal response to ADP, adienalinel
ristocetin, and collagen. The ristocetin and ADP
showed single waves without lag phases. The
adrenaline showed a primary first wave of a9gr~gaticn
in the first 2 waves. A second '>JlaV61occurred in the
next 4 minutes with 100% light transmiasion. The
collagen showed a lag phase for 1 minute, followed by
a single wave of aggregation in tile next 2 minutes
wi~h 9~% aggregation.
3.4.1,1 SQd;Lum..h~
Addition of less then 25 ul of S.T..D. failed to
elicit a response. However, the 25 ul
S.T.D. (figure 3.5) showed a primary wave
response over 2 minutes with 50% light
transmission. A s.condary w~ve response
occurred which was completed after a further 4
minutes and 40 seconds with 90% light
transmission. Thirty five microlitres of
S.T.D. (figure 3.6) caused a single wave of
,.
aggregation without a lag phase over a 1 minute
45 second time interval. Addition of 50 ul
caused an almost identical reaction
{figure 3.7), however thare was now evidence of
disaggregation.
This is shown by the tracinq returning to the
baseline. Addition of 100 ul of $..'1'.0.oa,WJed
I:
aggregation followed by rapid disaggre9ation
(f.igure3.8). H1.yilerconcentrationz caused 100%
l.ighttx-ansmission (figures 3.9 and 3.10).
These could b. confuaed with platelet
aggreqation, however in thes~ cases there was no
visible platelet aq~~egate which is indi~fttive
of platplet lysis. In all the other cases (viz.
,\fi9ilres3.1 to 3.7) an agqregate was visible at
the end of the experiment. The patients with
liver cirrhosis platelet aggregation, in
response to ADi?and S.'1.\. D., were the same as the
healthy volunteers
Platelet aggregation is regarded as essentially
a qualitative test rather than a quantitative
test. A response of more than 50% was defined
as an adequata response. As platelet responses
to S.T.D. in both the healthy volunteers and the
pati~nts with liver cirrhosis were gre~ter than
50% in all cases, quantitative statistical
analysis was deemed unneceF~ary (Heyns, personal
communication).
3.4..2 P1l.a1P1iCQ1lt.,rastLigbt MiQrP$QQP~
Initially normal platelets werQ visualised .l figure
3.11). As the ~oncentration of the sclero.ant
increased, the platelets aggregated and this is
depicted in figure 3.12. However I w::tenthe &lllOuntof
sclero~ar.t at the site exceeded a certain level all
the platelets were lysed (figure 3.13). These tests
were repeated once for every healthy volunteer. The
identj,cal reault. Were obtained.
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Figure 3.1
A tracing of a typical normal platelet
aggregation response to addition of the
agonist ADP.
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Figure 3.2
A tracing of a normal platelet aggregation
as a result of addition of Adrenaline.
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0"
RISTOCETIN
1.6mg/ml
100"
Tlme(20mm/min)
Figure 3.3
A platelet aggregation tracing showing the
normal response to addition of rlstocetln.
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Figure 3.4
A normal platelet aggregation tl'lf'Jng
following addltlon of eol,lagren.
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FigureS.5
A tracing of a plata'iet ag!greg,atton occuring
following addition of 25,.,1of S.T.D.
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Figure 3.6
The platetet aggregation tracing which
occured after addition (,..,135J.l1of S.T.D.
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Figure 3.7
The platelet aggregation tracing after
addition of 50,.,1 of S.T.D.
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Figure 3.8
The ,Qlateletaggregation tracing following
addition of 100 IJIof S.T.D.
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Figure 3.9
The platelet aggregatic.ln tracing after
addition of 150 JJI01 8.1",D.
Fiyure 3.10 .
The p!atelet aggregation tracing after
additfJn of 200 fJl of S.T.D.
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FIGiURE 3.11 : Phase c-:...trast microscopy of
platelet rich plasma sl.. ,wing normal platelets.
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FIGURE3.12 : Phase contrast microscopy at
30 seconds after addition of S.T.O.
Note the visible aggregation.
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FIGURE 3.1e : Phase contrast microscopy
two minutes post addition of S.T.DII
Complete platelet lysis has occurred,
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3.5 DISCUSSION
As previously disoussed, platelets play an essential role
in haemostasis. The first event that ocours with a breach
in th~ ~asoular system is the formation of a oellular plug
which is made up entirely of platelets (Zuoker 1949).
These platelets maintain their inteqritY' and secrete their
qranular contents. Stripping of the endothelium and
exposure of underlying oollagen was demonstrated in the
umbilioal vein model (whioh is discussed in the chapter on
endothelium) and platelets are known to adhere to oollagen
via a collagen reoep'tor (platelet glyooprotein Ia) which
participatelllwith platelet glycoprotein Xla (Kunick.iet aI,
1988). This occurs at low shear raten, higher shear ratlts
require von Willebrand factor (Baumgartnex' et aI, 1980).
Platelet aggregation was assessed in vitro. In platelet
aggregation the platelets stlck specificall~' to eaoh
other. It requires prior platelet stimUlatIon as well 58
active metabolism (Sannet 6ft aI, 1990). The agoni8ts
tested revealed normal aggr~gation patterns and the
significance of these aggregations.
3.5.1 AD£ (Figure 3.1)
ADP elioited a single wave of aggregation :i.nboth the
healthy volunteers and.the patients with liver
cix'r.hosis. It is thought that ADP is one o,fthe
primary platelet activators in that it is released
from damaged tissue and red bloOd CQlls (Gaarder at
a l , 1961).
The capacity to secret.~ these dense granules is
nyclooxygenase dependent t:.ndis therefore inhibited by
aspirin and anti-inflan~atory drugs (Charo at aI,
1977) • ADP activation is postulated to be mediated
via a receptor on the platelet surface although this
has yet to be positively identified (Jefferson .t aI,
1988).
3.5.2 Mrenaline (Figuro 3.2)
Adrenaline elicited a classical primary "first wave"
aggregation, which is not; associated with secretion,
followed by a secondary wave where secretion occurs.
Th'$,primary wave is reverl!liblewhereas the secondary
wave is not. The mech~nism of action of adrenaline
is to bind to alpha-2 adr,me:r:gicreceptors on the
platelet (Newman et aI, 1978). The receptor action
is mediated via guanine nuc'leotide-binding protein,
Gi, which inhibits a~enylab; cyclase (Kim et aI,
1987) •
3.5.3 Bistoo@tin (Figure 3.3)
Ristocetin aggregation showed a single wave without a
lag phase. Ristccetin is an antibi.ptic. It was
found to aggregate llormal platelets but not to
aggregate platelets of patients with von Willebrand's>
disease (Howard & Firkin, 1971). Coller (1983) has
sho'li.'nthat positively charged ristocetin binds to
platelets whi.oh altars the charge on the surface thus
enabling vWF to bind to its recaptor.
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3.5.4 CollAgen (Figure 3.4)
Collagen induced single wave aggregation after an
initial lag phase. This is a classical response
which collagen elioits. Collagen also elicits
adhesion which was not tested for. The mechanism for
adhesion differs in that it cen be caused by both
monomeric and fibrillar collagen (Brass et aI,
1974) • The reason for tne lag phase is that after
the fibrillar collagen binds to the platelet, the
platlSllet..b}"'nthksizesthromboxane and ADi? which are
released and act 8~ agot1i~ts (Charo at aI, 1977).
:3 • .5 • .5 SQ.Cl.ium T~traaec~r._~uJ,phate
AdditioD of eX't:rem&ly~~c;.ll volumes (L, a. 10 ul., !,15 ul
ami 20 ul) failed to elicit a rtlu~.pons~. The retsponse
that 25 ul, 35 ul end 50 ul was ~hicited would. appear
to be of extreme impa rta.nce. A1th~ugh stroncek et
al,(1985} showed that sclerotherapy induced red blo~d
lysis and the lysate has the capacity to induce
platelet aggregation, it has not been shown previously
that S.T.D. can induce platelets directly to
This finding is dOSQ dependsnt. The
meohanism by wh:lch it induces aggregation is unknown.
S.T.D. acts as ~n anionic detergent and is used to
alter charges of proteins for electr~phoresis.
possible that S.T.D. WOUld act in a similar way and
directly alter the chan9!~on the meltibraneof the
platelet, thus facilitating aggregation. An
It j.s
a1tern ate exp.l.anat.Lonwould be that S.T.D. daiiic:t~d
platelets and lyses them. They then release their
contents which include agonists contained in their
granules (which has been discussed earlier). The
remaining platelets are thus able to form Ii r,dngle
wave of aggregation. Should the concentration exceed
a criti~al point, the S.T.D. interferes with
subsequent aggregation and this would explain the
disaggreqation which occurs slowly when 50 ul of
S.T~D. is added and rapidly when 100 ul of S.T.D. Is
added.
The higher volumes, i.e. 150 ul and 200 ul, caused an
increase in optical density, which is the finding
which occurs post aggregation. However, no clot was
visible and it would have appeared that the platelets
had all been lysed. This finding was confirmed on
the time phase contrast light microscopy which showed
that aggregation did occur at a specific local
concentration. However when the local concentration
exceeded a specific point lysis occurred.
setting aside the controversy as to platelet
dysfunction in 1iver cirrhosis I in this study low dO"..e
S.T.D. was as ef:tecti'Ve in inducing platelet
aggregation in rllatelets from cirrhotic: patients as it
was with normal platelets. Similarly patterns of
platelet lYSlis induced by high dose S.T.D. were
unaffected by the presence of cirrhosis.
!n conclusion, S.T.D. has hetm shown to cause platelet
aggregation at specific low doses. From a r~ematological
POi9t of viewp this in itself might prove to be an
imU°rtant finding, as non phy:aiological aqonists such as
ristocetin (which is discussed earlier), have in the past
proved to be important tools :Inelucidating platelet
function. In the clinical si1:uation the aggregation would
occur at a site which 1s distal to the injection, i.e.
downstream,. where dilutibn has.occurred. At the site of
injection initially platelets are destroyed. However,
platelets would also be activated at the sit.'t$of injection
when it has rrililutedto a sp$eific oritical conO$lltratio~.
CHAPTER 4
4. CQAGtlLATlON
4.1 INTRODUCTION'
The in vitro effect of sclerosants on the coagulation
pathway have not been fully elucidated (Sivak et aI,
1990). In 1967, Fegan in relatively crude experiments,
found that Sodium Tetr.adecyl Sulphate caused a
hypocoagulable state. In 1985 Stroncek at ~l, confirmed
that SodiUm Tetradecyl Sulphate in high concentrations
caused the activated partial thromboplastin time, the
prothrombin time and the thrombin time of plasma to be
prolonged beyond assay limit times. In 1987 Kang at al
Showed that the reoalcification time of plasma is prolonged
on addition of ethanolamine oleate, another sclerosant, and
this prolongation was felt to be primarily due to
ethanolamine. In vitro studies of the sclerosant in
concentrations used clinically demonstrated that fibrinogen
was direotly dama.ged by the sclerosants (Jacobson et aI,
1984). That study was aimed to evaluate the advisability
of the practice of addition of thrombin to the solution
prior to sclerotherapy. In view of the relative paucity of
available information, the effects of Sodium Tetradecyl
Sulphate on in vitro coagulation are evaluated in this
thesis. A detailE~d review of coagulation is beyond the
scope of this theEis. However, the following is a brief
review of the coagulation pathw~y with particular emphasis
on the functions of the factors 'studied.
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4.2 COAGULATImt OVERVIEW
4. 2 .1 The Evolution of the COAgulation systg
Coagulation in the human is a complex network of
interrelated chemical reactions~ These reactions
ensure that coagulation (i.e. transforming blood from
a sol to a gel) occurs only at specific sites and also
enables thie prooess to be reversed when required.
Molecular evolution would requ;'re that this complex
system evolved from a simple system. The most common
mechanism by which this occurs is duplication o~ genes
whose "offspl;ingfl have divergent function. This
would explain an increase in the number of steps in
the ooagulation pathway (Patty at aI, 1990).
In the invertebrate horse shoe crab, coagulation has a
dual role in that it immobilizes invading bacteria.
Human coagulation probably evolved from a similar
meChanism. The evidence for the above is the close
homology that Prothrombin, Factor VII, IX and X share
with each other and with haptoglobin and c1r and
c1s, sU9gesting that a common anoes ....ral protein
Which was part of a general defence system diverged
after gene duplication and this led to speciali2ation
of the clotting mechanism (Brenner, 1988). An
j,mportant event in the evolution of the ooagulation
system was the aoquisition of a calcium binding domain
which made the coagulation dependent on calcium ions
and phospholipid surfaces. This enabled the
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coagulation cascade to be localized to the site o·f
endothelial damage (Mann at aI, 1988).
4•2. 2 The coagulation GaSQA<.ia
The classic cascade pathway is a two dimensional
r.epresentation of current unders'tfllldingof the
coagulation pathway. The factors involved ar,.. not
only involved in coagulation but also in fibrinolysis
as well as in initiating the inflammatory response.
The oascade has positive feedback as well as negative
feedback control mechanisms.
The initiation of the intrinsic pathway is due to
oontact activation. This has pa~ticular relevance as
it is likely that sclerotherapy would activate this
area of the pathway.
4.2.2.1 Faat9. Xll
Factor XII would appear to be the first protein
involved in the cascade process. Landerman at
al (1962) described the lack of "permeability
factor" i.e. Factor XII as a cause of
hereditary angioneurotic oedema. Factor XII
can bQ activated by enzymatic cleavage of a
protease or by a negatively charged surface.
The major activator is thought ,tobe the
subendothelial vascular basement membrane,
however collagen as well as a variety of the
components of the basement membrane do not
lU2
initiate coagulation in normal plasma and the
role of the b'lsement .embrane remains therefore
controversial. The precise mechanisa by which
negati~ely charged surfaces cause Factor XII
activation is unknown. Factor XII is activatsd
by proteases which cleave it to produce smaller
molecules which are active. The major
inhibitors of Factor XII are C1 inhibitor (the
first component ot the oomplement casoade),
antithrombin III, as well as tissue plasminogen
activator inhibitor. One major substrate of
Factor Xlla is prekallikrein (Fletch~r
Factor.). Seventy-five percent of Fletcher
Factor which circulatee is bound to high
molecular Weight kininogen (HMWK) (Scott,
1980). Activation involves limited proteolysie
and conversion of prekallikrein to kallikrein
can be accomplished by eithsr XlIa or XlIf
(Hageman Factor Fragnuant) (Wuapper et aI,
1972). The two major inhibitors of kallikrein
are ~lpha-2 macroglobulin and C1 inhibitor (van
der Graaf, 1983). It has been postulated by van
der Gr~af at al (1983) that Hw.MK proteots
kallikrein :t:rolnC1 inhibitor as e:tt! functional
site .ofC1 inhibitor has been localized to the
light chain of kallikrein which is the same area
where HMWK binds. Kallikrein a~tivates Factor
XII via a positive feedback /t'oop. A diagram of
this pathway is represented in Figure 4.1e
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FIGURE4.1: A simplified diagram of the contact
phase of the coagulation pathway. Note the
positive feedback system of amplification of
Factor Xlla which activates PrekalUkreln. The
negative feedback ls shown where Factor Xla
• inactivates High Molecular Weight Kininogen which
then no longer inhibits C1 ~nhibitor. This
anows C1 li1hibitor to inactivate Kallikrein
and turn off the sys~em"
Factor XII _l ~ Factor XUa
Factor XI
A paradox of Factor XII has been to explain a
lac~ of bleeding problems which occur
clinically. AltLough Factor XII deficiency
leads to a prolonged P~T, these patients tend
to suffer from a thrombotic tendency rather
than a bleeding problem.. ,K.;,ttnoffet al, (1.968)
have shown tha't these pathmts have an
increased incidence of myocardial infarction,
the basis of which iu postulated to be the
result of diminished fibria,i~lysis.
4.~,,2.2 Factor XI
Another major substrate of Factor Xlla is
.f"actorXI ''''':asmaT}:)romboplastin Antecedant).
Factor XI is a gamma globulin two chain
homodimer (Bouma, 1977)" Factol::'XI consists
of two almost identical molecules held together
by disulphide bonds. Activation occurs after
limited digestion by Factor Xlla (Bouma,
1977). It would appear that kallikrein is not
necessary for the reaction but that HMWK is.
The only other ~ctivator of Factor XI is
trypsin ThE.I major inhibitor of Factor XI i6
alpha-l antitrypsin. >rhe action of kallikrein
on XI and XII is an example of amplificatio17' or
p013jtive feedback. Facl..~rXlla, which also
resul ts from cleavage of kallikrein a11("':18reo):,e
kallikrein to be Eict~.vated. An example of
negative feedback 1. that Factor XI act. ~n
HMWK which then is ina~tivated and this allows
Cl inhibitor to inactivat. kallikre.:Ln.
4.2.2.3 lAQtor IX
The action of Factor Xla i. to activate F.ctor
IX. Factor I~ was first described by Biggs et
a1, (1932) tfhodescribed a patient' with
haamophilia and normal Factor VItI levels and
called th1 disease Christmas d~,~_a.e. It baa
aubsequ.,ntly a180 been c",J.led haemophilia B.
Factor IX is a vitamin K-d.penden~ factor,
containing unique gamma glutamyl carboxyl acid
re.idue. at the N terminal end of tn. molecule
which undergo •• post-ribosomal modification by
vitamin K so that calcium binding at the
oarboxyl group can occur. Factor IX is similar
in IIIItr1.lctureto Factor X and Protein C, lehioh
ia discua.ed later. Factor IX ill I'A sin9'le
chain glycoprotein oontaining ~pproximately 20%
carbohydrate. Its moleCUlar weight is
approximately 55/000~ Due to it. homology to
\~,
L,
the other Vitaruin K d.pend~r.t factors, Katayama
at &1 (1979) have propose6 that all vitamin K
dependent factors have evolved from a oommon
ancestor.
Faotor XI aotivates Factor IX in the presenoe
of calcium. '!'his is achieved by cles,..ntqe of
two internal peptide bonds. Factor IX can
also be activated by Factor VIr and tissue
factor. This represents a bypass mechanism
and its precise role in vivo h~a not yet been
determined. Factor IX can ~e aotivated by
Russell'. viper venom. FSI}:::torIXu is
inhibited by antithrombin wh.ich is greatly
enhanced in the presence of hl:..parin. !'h is
also inhibited by hirudin which is present in
the saliva of leeches (Hirsh, 1991). F~tor
IX il~';:synthesized in the liver and, in the
pr.slln(!eof activated Factor VI:):I,calr:ium, and
phospholipid, activates Factor X.
4.2.2.4 Foetor VIII
Faotor VIII was first described by Addis in
1911. Factor VIIlo is separate from von
Willebrand Factor (vWF) although they cirCUlate
in the plasma as a complex. Factor 'VIIlo is
a product of an X-~'omosome linked qene, while
VWF is a product of a qene on chromosome 12•
•
Using SDS-page analysis, multiple bands of
Faotor 'TIIIhave been ident.1.fied,the majority
in the region of 79,000 to SO,O(lO. The DNA
sequenoe has beHn determined u well as the
protein's 2;51 amino acid sequenoe (Vehar,
1984)~ It is interesting that there is
homology of the Factor VIlla domain with Factor
V as well as caeruloplasmin. Factor VIII'fij(
action is that of a true Cofactor, as
previously stated, and accelerates the cleavage
of Factor X to Factor Xa caused by Factor IX.
Factor VllIc activity is lost after thrombin
activation but the precise mechanism is not yet
understood.
4.2.2.5 Factor X
Factor X is also a serine protease whose
structure is very similar to ~actor IX~ Factor
X has a molecular weight of 55,OOOe It alao
has gamma carboxyglutamic acid residues Which
can bind calcium ions after carboxylation by
vitamin K. Activation of Fa.ctor X involves
cleavage and loss of the so called activation
peptide. Factor IXa alon.ll3can activate Factor
x in the presence of phospholipid, albeit
slowly. Factor VIII however cannot do this
and is therefore a true cofactor (Hultin at aI,
1978)• Factor X is also activated by
Russell's viper venom as well as trypSin.
4,,2.2.6 Factor VII
Faotor VII i.s synthesised in the livt"!r. It is
a single chain gll'coprotein Which requires
Vitamin K for gamma carboxylation. It is
1:08
converted to .~~dloti va form ~ tissue
",::':'_,,~> ,I," -'<,,_
------::::::._, // ",,~-
tbroanboplastLl, thrcnnfi1.i:'l:;:, ~~ctor xiri,:;~pdxa,
-~_// .... ,::.:_:::
Th~ activation is due to oleavage of a peptide
bond which results in 2 ohains forming, viz. a
light and a heavy chain, which are joined by a
disulphide bond. This factor shows close
homology with the other vitamin "K deptmdent
factors. Factor VII appears to activate small
amounts of Factor X. Factor Xa bas t.heability
to amplify the Factor VII. Factor X can
therafore be activated by both the intrinsic
and thQ extrinsic pathways.
4.2.2.1 Faotor V
Faotor V is a large polypeptide molecu14il.
Immuno-electrophoresis show~ that this protein
is a gamma globulin (Greenquist at aI, 1915).
Thrombin inoreases Faotor V aotivity which in
turn accelerates the conversion of prothrombin
to thrombin 2'78000 times (Nesheim (ittaI,
1979.) Protein C inhibits Factor V by
cleaving it (disoussed later). Factor V is
found in platel~ts and is associatwd with the
alpha granules (Ittyerah et aI, 1981) and
Factor Xa binding to platelets requires releasa
of this Factor V or plasma Factor V. Factor V
is also associated with andothelisl oells and
is thought to play the sam~ role as it does
with platelets. It is thought that injured
end;Qt:helial oellSJ exp:r:ess Factor V on their
aurfaos.
4.2.2.8 faqtox IX
The nut commonB'btp is the ,activation of
Factor II (Prothrombin) to Factor IIa
(Thrombin). As praviously described Fa~tor Va
and Factor Xa as well as calcium are important
and tbe phosp'tlolipidsurfaoe helps to 10qaliE9
the 8ite ot thrombin fo.~t:.ion.
Prot.h;t,'OOlibin,w t.h a molecular weight of 71.600,
is synthesised in the liver a..,d then secreted
into the blood. prothrombin is a glyooprotein
whioh Mil <JtI.ll'llIla oarboxyqlu·::.amioaoid residues
and is 'thus a vit!Unin K dependent factor. It
also oontains a reqions which are called.
krinqle struotures. carboxylation by vitamin
K oocurs on i::h:elumenal side of 'fAle'railiqh
en~oplasmio reticulum (Carlisle at aI, 1980).
Thrombin is formed wh6m prothrombin is oleaved
both at the internal arginine- th:reonine
peptide bond Which is after krinqle 2, as well
as at an arginin& i;,oleucine bond looated at
the end of the light chain.
111
The natural ~ubstrates for thrombin are
fibri~ogen, which will be discussed in detail
later, and Factor XIII. Thrombin has a
positive feedback on Factors V and V~ ~~
previQusly discussed and also activates
Protein c.
4.2.2.9 fibringggn
The fibrinogen molecule is a dimer consisting
of two sets of three palrs of.polypeptide
chains, viz. A alpha, B beta and gamma
(Doolittle, 1984). Single copies of thase
genes are found on chromosome 4 and are closely
linked, supporting the concept of a common
ancestral origin which has duplicated and
diverg6d. Thf principal proteolytic enzyme ~
fibrinogen is thrombin which hydrolyses
arginine glycine bonds on the A alpha and B
beta chains and releases fibrinopeptides A and
B respectively (Hurlet-Jensen, et aI, 1982).
This e~poses binding sites on the E domain of
the fibrin monomer which bind to D domains on
nearby gamma chains of different fibrin
molecules producing the "DE staggered
cont.act;", D domains also bind to other 0
•
domains longitudinally, the so called DD long
contacts and Ubus form fibrin polymers. A
simplified diagram 'illustrating the above is
shown in Figure 4.2
FIBRINOGEN MOLECULE
~~
rnO'~~~\._EEJ b"oocOQOQOl~ 0
FIGURE 4.2 : A simplified schematic
representation of the fibrinoge.n molecule
J • and its .conversion to fibrin.L"S,<
•
1'\Fibrin polymers are the t~inal step in '(
oontTtertinqa liquid sol to a gel state. The
fibrin polyme1ts intarconneot and form the
lattice for t:('Ul t.h.rolul1in. Throl'ltbirtalso
converts Factl.':::rXIII from its inactive state to
active Factor XIII. Factor XII:a links the
side chains of lysine and glutamine residues by
isopeptide bo~.ds and this strengthens the clot
mechanically as well as making it more
resistant to fibrinolysis.
4.2.2.10 Antithrombin II!
'I,'
The ma jor linhibitor of thrombin is anti thrombin
,I
III. Antithrombin is III protein with a
moleoular weight of 58,000. It contains an
Qnzyme binding region as wElillas heparin
binding sites. Proohownik et aI, described
the human gene for anti thrombin in 1983. It
is Hi kilobases in size. An interesting
feature is that alternate splicing of primary
transcripts may take place E'I:t tWOl sites within
the first intron. The result: iii ai'ther native
antithrombin or a truncated product which
remains within the cell. The function of th.
latter remains unknown. The mechanism of
action of thrombin inhibitIon by antithrombin
III is a mechanism by whi,ch complex formation
occurs by means of an arginine serine
interaction. (Rosenberg et aI, 1973).
This reaction is qrsatly acoelerated by the
presenoe of heparin. The above authors also
demonstrated that antithrombin inhibits Factors
Ilea, Xa, XI. and xrra, Thrombin is also inhibited
by heparin cofactor II. This protein .is more
specific for thrombin inhibition and also requires
heparin as a cofactor.
4.4.2.11 hparin
Reparin is a glycosaminoglycan with a molecular
weight which varies from 3,000 to 100,000.
Synthesis involves formation of carbohydrate
prot.t!)inconnecting sequence followed by polymer
oJaain~sembly of the muoopolysaccharide. Heparin
oonsists of alternating residues of urania aoid and
gluoosamine. The meohanism of aotion would appear
to be that Domain 1 of the heparin moleoule binds
to a disorete reg-ionof antithrombin III Which
rssults in a oonformational change. This
acoelerates factor xa inhibition. Domains 1 and :2
of the heparin moleoule bind to separate areas of
the antithrombin molecule wbich induces a different
conformational change which inhibits thrombin,
factor IXa and factor Xla. Domain 3 of the
heparin molecule aids in thrombin inhibition.
Heparin alL> has multiple other roles and thG-.ge
include a role in angioge~asis, lipoprotein lipase
~otivity and alteration in platelet aggreqation
(O'Brien et al, 1969).
4,,2..2.12 lf~@in ..~ (owen, 1~$7)
This protein is a vitamin K dependent zymogen,
activated by thrombin, whioh raoves &.
tetradecapeptide. Its action is extremely
important as unlike the other vitamin K
dependent factors its :mechanism of action is
inhibition of coagulation, rather than
activation of coagulation. Several families
with protein C deficiency who have recurrent
thro.mbot:i.oepisodes have been identified. The
control mechanisms of protein activation a~
oomplex. While free thrombin can activate
Protein c, this activation is greatly enhanoed
by thrombin first binding! to 1:hrombomodulin~
The latter is a protein produced by endothelial
cells. Therefore intact functional
endothelium (whioh would exist in vivo
downstream from the sit. of injury) binds the
thrombin which has been produoed at the aite of
injury. This tl1·Ml activates Protein C which
inactivates Faotor V and Factor VIII. The
cofactors for this reaction are thrombq~odulin
1.":::- ..,_~._ -;:::;
and Protein S. Protein S is a vitamin K
dependent factor. Protein C also aotivatel!!l
plasminogen activator which then initiates
fibrinolysis.
••
4.2.2.13 Coagulation factor a.Qnormalities in
c.hx:Qnicliver giseafjls.
Declining hepatic function due to chronic liver
disease is associated with a decrease in plasma
levels of all the factors of the coagulation
pathway, with the exception of factor VIII.
Tne basis of the observed deficiency is is due
mainly to decreased. synthesiS (Joist, 1981;). The
vitamin K dependant factor reduction norm~!illy
correlates with the extent of the hepat~,c disease.
Factor IX, however, is u..c;uallyonly mild~.y reduced
(Lechner et aI, 1979). Factor V is often markedly
reduced and is considered to be a more accurate
predictor of hepatocellular damage (Joist, 1987).
Factor VIII levels are usually elevated ':'npatients
with chronic liver disease (Maisonneuve et aI,
1977). Fibrinogen levels vary from normal to
elevated or tiley may be decreased (Lechner et aI,
1977). Dysfibrinogenemia is common in patients
with liver cirrhosis (Soria et aI, 1980), and is
usually the basis for the explanation of the
prolongation in the thromUin time which is
frequently observed in patients with relatively
normal fibrinogen levels. Disseminated
inLravascular coagulation I particularly the low
grade fo.pns, is often also associated with liver
cirrhosis (Verstraete ..aI, 1974).
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4. 3 METHODOLOGY
All tests were performed on seven healthy volunteers.
\\
4.3.1 ~@in C determinations
The principle of the Protein C assay is that the
protein c in the sample is activ~ted by a specific
component of the snake venom Agkistrodon contortrix.
Simultaneou$ly the intrinsic system is activated by
adding a cephalin surface activator and Protein C
deficient plasma which contains all the other clotting
factors in excess. The prolongation of the activated
partial thromboplastin time will increase
PI'oportionately to the amount of activated Proteiri C
/
\
as the latter inactivates Factor Va and Factor VIIIa.
Protein C was determined with the Behrinq~t, using
the following technique:
'.. ,;
The plasma was separated .bymixing 1 part TriSOdium
citrate solution with 9 part$ venous blood.
ce~~rifuged for 10 minutes at 1 700 9 and the
supernatant was stored at -Jooe if the test was not
It was
done immediat~ly. Samples that had been frozen
were thawed at 37°C for 10 minutes and assayed
within 2 hours. The patient's samples wer.e
prediluted with 1 part pat.ient's sample to 9 parts
of Dwrens Buffer (pH 7.35). These predilutions were
used within 10 minutes. The assay procedure was
performed by pipetting the follOWing reagents intD a
~I el •.
test tUbe, which had been pre-warmed to 37°C ~
0.1 m1 of the 1:10 dilution of the patient's sampl~,
0.1 m1 Protein C deficient plasma (which consists of
citr~ted human plasma with a Protein C concentration
of less than 1%), 0.1 ml Protein C Activator (which
Ls extracted from the venom of th~ Agkistrodon
contort1:ix), 0~1 .1 Neothromtin (whic....'is a PTT
reagent ~~nsistin9 of ellagic acid and vegetable
ph\?spholipids)
~e above were all mi~ed and incubated for 4 minutes
at 37·C in a waterbath. The ord.er of pipetting was
kept constant. 0.1 ml of Calcium chloride solution
at 37 C was then added. A stop IN'8tchwas used to
determine the coagulation time.
A reference curve was drawn up on log/log graph paper
and used to read off the reBul ts, as a percelltage of
the normal. Samples having results outside the range
of the reference curve were retested using different
predilutions. normal reference range Was
considered to be 70 - 140% •
• 4.3.2 Factor V AS~
The principle of all the factor assays is that the
sample is added to plasma which is deficient in the
specific factor which is being assayed. The amount
of factor present in the sample will proportL,mately
shorten either the partial thromboplast~ ..n time or the
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prothrombin time. The specitlc factor deficient
plasma contains all the remaining co.aCjUlation factors.
Factor V activity was assayed using the following
methodology:
Dilutions of normal and the patient's plasma were
prapa!"ed. 1:5 was made up ulling 0.1 .1 ,plasma and
0.4 ml buffer 1 1:10 I...sing0.1 m1 plasma t~nd 0.9 ml
buffer; 1: 50 using 0.1 ml of a 1: 10 dil ut,ion of
plasma and 0.4 ml buffer; 1:100 using 0.1 ml of a
1:10 dilution of plasma and 0.9 ml buffer. The
buffer used was l:)wrens Buffe.t'(pH 7.35). Only one
,set of dilutions was madl.~at a time and they were
not allowed to st~and lon~rer than 30 minutes, as
Facto.!:'V is V9l"Y labile.
The following' were pipetted in sequence intc) a
ciotting tube:
t;..1ml of Factor V defic:i(tntplasm 1 0.1 ml
dilution of normal/patie11t:'s plasma: 0.1 m1
phenolised brain; 0.1 ml calcium chloride
(0.025M). A stopwatch was started and the times
were recorded. The times obtained were plotted on
log/log graph paper using the following
parameters~ 1:5 == 200%; 1:10 = 100%: 1L20 ==
50%; 1:50 == 20%; 3.:100 == 10%.. The results were
always extrapolated from the 100% line and were
determil'ledas a percentage of normal.
L- . ~------ ..-
1.19 '
\1
4.3.4 ;emctgr VIII AllAY
4.3.3 Factor VII AaIAY
Factor VII acsay wal id~:nti~~~"'1J:o t:ba Faator V assay I
. '\':
;\owever F'actor VII defici~'lt p\~a$:ma is used. instead of
'II,
Fact~r V deficient plasma. :j\\
\',
'\
The following were pipatted in sequ.nC8 into
I
I
The dilutions of norrual and patiedt'. plasma in buffer
were made up exactly the same as in the Faotor V
a clottillg tube:
0,1 ml F:;" 1lrVI:tI deficient plasma; 0.' ml
dj.lutio.t'1,;.0.1 ml aPTT reagent containing cephmlin,
0.1.ml
oa~ciu:m chloride (0.025M) was then addad and a
'~topwatoh was sltaX'tedand the clotting times
recorded. The reDults were graphed on logllog
paper.
4~3.5 FActor IX Q~
Factor IX assay was dona in the identical way tIP the
Factor VIII, using IX deficient plasma.
4.3.6 EBctor XI assiY
Factor XI assay was done in tha identical way to tha
Factor VIII, using Factor XI deficient plasma. However
the incubation time was increased from 3 to 10 minutey
because Factor XI is a contact activator.
4 •3 •7 EllQt.pt' XlI assay
Factor XII assay was done in the it'lentioalway to the
Factor XI, using Factor XII deficient plasma.
4.3*& lactor X M,ay
Dilutions of normal and patie.nt's pl..ueu were prepared
illtha sa.e way as the Factor V assay except that
Factor V deficient plasma '.aa substituted. witb Factor
X defi':'~~Qntplasma.~
4.3.9 Fibrinpgen Assay
Fibrinogen was assayed by the method aocording to
Ellis and stransky. 0•.5 lit! of plana was added to
5.5 ml of barbitone butfer. Three millilitres was
transferred to the test cuvette and ~he remainder was
used as a blank. Fifty microlitres Qf caloittltl
chloride/thrombin solution was added 'Cothe teat
cuvette and inverted gently 6 times. The optical
dEmsit.y of the test was read aqainst thQ·· blank at 470
nm after 20 minutes.
4.3.10 The Kaolin Actiyated Partial ThrombQglaatin
~m
The Kaolin Activated Partial Thromboplastin Time
measures the intrinsic pathway and the common pathway
via contact ac'...ivation. The test consists of adding
the following reagents in the following seqt'lenoaa
0.1 ml of normal or patient's plasma; 0.1 ml aPTT
reagent containing C"ephalin (supplied by Lennon
Diagnustics) • The mixture was ino.:} iQ.t~dat 370 C
for 3 minutes. 0.1 ml calcium chlori'ie {O.025M)
was then added and the clotting time was recorded.
These tasts were all performed in d<"plicate.. Normal
range for our laboratory is 27 - 41 seconds.
4.3.11 :J,'h@ Prothrombin Ratio/International Hormaliud
Ratio
The Prothrombin ratio measw:es the extrinsic and
common pathway using tissue (brain) thromboplastin as
the activator. The test consistB of adding the
following reagents in th\. following sequence:
0.1 ml or normal or patient's plasma: 0.1 m:i
phenolised human brain.
at 37°C for 60 seconds.
The mixture was incubated
0.1 ml calcium chloride
(
(O.025M) was then added and the clotting time was
recorded. These tests were performed in duplicate.
The prothrombin ...atio was then calculated as the
ratio between the patient's time in seconds divided
by the normal time in seconds raised to the power of
the Inte:::nationalSensitivity Index (lSI). Tbe
normal range for our laboratory is less than 1.25.
The prothrombin time is measured in seconds and by
dividing the result of the test plasma by the control
plasma the ratio is obtainsd. A major problem has
been that variouu thromboplastins have different
sensitivities. This has had serious,.clinical
implications for patients on coumadin oral
anticoagulant therapy as dosage is depandepj: on the
prothrombin ratio. In order to standardize'
prothrombin ratio worldwide, reference thromboplastin
from the WHO Reference P:r.eparationswas obtained.
The International sensitivity Index (lSI) was obtained
ay comparing the reference thro~oplastin with the
test thromboplastin using standard arithmetical
techniques (Dacia, 1991). The International
Normalised Ratio is obtained by raising the ratio of
the sample tested to the power of 14~elSI.
4.3.12 fibrin/Fibrinogen Degradation FrQducts
This teat was done using the Thrombo-Wellcotest Latex
suspension HA08 kit. The principle of the test is
that antisera are raised to highly purified
preparations of human fibrinogen fragments D and E.
After solid phase absorption to remove antibodies to
all other serum proteins, the specific antibody
globulins are extracted an-iUBeldto coat by adsorption
a suspension of latex particles in a glycine saline
buffer. The sensitivity of the latex reagent is
adjusted so that in the presence of FDP conoentrations
of 2 ug/ml or greater the latex particles clump
together giving macroscopic agglutination.
was performed in the following manner:
All samples were taken into bottles containing an
The test
inhibitor of proteolytic enzyme activlty (soya bean
f.:roDl calls and fibrin before prfiPlrinv "t•• t
ciilutions ..
a. 'two rinqs on the slide were similarly .. rke~D
1:5 antS. 1:20 dilutions of the serum ~lQ W4>re
prepared using glycine saline buffer pH 9.2 in tubes
1 and 2 respectively_ Using the same pipette for
both dilutions I 1 drop from test tube 2 was
trfJUl:Sferred to positien 2 on the slide and similarly
1 drop ft" test tube 1 to posi tien 1.. The latQX
suapenslon was thoroughly mixed. by rapidly inverting-
~ bottle 3 times I alia J. drop of the su&pansionw.s
thel'l added to eaeh-,of the 2 positions.. The
mix...ur_ were then stirred in turn and t.1le s.licte Wa$
roalted 1:::.0 and fro for 2 minutes while looking: f()r
macroscopic agqlutination.
The slides were interpreted as pesitive if
ag'glutinatien took place'~ A pesitive resUlt in
positien 1 indicated that FOP I S were present in the
or:tginal serum at a concentration in excesS. of 10
ug/ml ,.mile agglutination in position 2 indicated
tne origina;;" concentratien to haw been qreater than
~O ug/l1l1.
ResearCh Council. The analysia was performed with.
4.•3.13 atat.istios
Statigtieal analysis was perfo~ by ..'t11At Institute
for Biostatistics of the SOuth African Medical
the appropriat\i analysis of variance at the 0.05 !.1:!vel
of "iqnificanoa with the help of Tukeyls Studentiz~
Range (Keppel at aI, 1980).
4 • 3 .14 Q1.l,al:tty CQutrgl
The laboratory where the tests were performed is a
reference laboratory for ooagulation studies.
Prothrombin times and aotivated partial thromboplastin
times were assayed in duplicat.e and the s.veraqe times
reoorded. If there wam a discrepancy of more than 4
seconds, the test was repeated. The referenoe llulsays
were obtained fr~m normal pooled plasma from 15 normal
people~ 'l,Ihianormal pooled plasma was prepared
daily. The standard: :t'$,ferenoecurves for factor
assays and Protein C were obtained from commercial
lyophilf;~ed plasma which has a reference value for.all
coagulation factors. This was ohecked against normal
pooled plasma. Reproducibility of all kits was
assayed prior to using the kit. This was performed
on normal plasma and assayed ten times. The
coefficient of variation was less than 2.
L_ ~, =_~ '~_'
Internal quality cohtrol is performed PlOnthly in our
laJ.:)eratory and the laboratory also parti cipatu in
international external quality oontrols, vi~. the
Quality Control of Australian Pathology and the World
Health Organisation International External QUality
Asseamant Scheme in Blood Coagulation. The results of
'/
thes,",internati~nal quality controls, during the
period of this investiqation, were consistently within
the acceptable ranqe.
87%, 150 ul ~O 83% and 200 ul to 75%. Factor X lev&ls
After the plas:rnahad been separa.t0d there was notable evidence
of Qr()$S haemolysis which was dose depwldent (rigllre 4.3}l'
The reaul ts of the lev61s of factQrS present .ft$r addition of
different amount.s of ~.~.D. are all expressed a.sa parcentaqe
of the control.
4.4.1 Factor XII (Figure 4.4)
\;
The Factor XII hlvels were not affected '!-.~!J to 150 ul of
Addition of 200
,
ul resulte¢ in a further drop to 72% while 350 ul
resulted in a reduction to 53%.
4.4.2 haw;" XI. (Figure 4.5)
!rAe .Factor XI levels did not significantly drop BJfter
addition of up to 100 ul of S.T..D. One hundred and
:fifty microlitres of S.T.D. oaused a r-aduction to 88% and
200 ul to 80%. Three hundred and fifty microlitres
ca.used a further reduotion to 52%.
4.4.3 FaqtQt.X (Figure 4.6)
Factor X levels remained above 90% with addition of up to
50 ul. One hundred microlitres caused a reduction to
were markedl\\"reduced to 19% after addition of 350 ul of
S.T.D.
l!dditio.nof up to 100 ul of S.•T.D ..
4.4 ..4 lewtQX::..IX (Figure 4.7)
Factor IX levels were also all greater theI:.n gO' with
S.T.D., viz. 150 ul, 200 ul and 350 ul, rosulted in drops
to ~~%, 70% and 42% respectively~
4.4.5 Fijctgr VIII (Figure 4.B)
Factor VIII levels remained at 90% or hiqber with up to
100 ul of S.T.D. One hundred and fifty miorolitres of
S.T.D. resulted in a drop to 74%, 100 ul of SeT.D.
dropped the Fa(..,"tor VIII levels to 59% and 350 ul of
SoT.D. dropped. the Factor VIII levels to 43%.
4.4.6 ~ (Figuro 4.9)
Factor VII levels showed a gradual decrease fl."O!l1l 95%
after addition of 10 ul of S~T.D., q4t after 25 ul of
S.T.D~, 92% aft.er 35 ul of S.T.D., 90% after 50 ul of
S.T.D., 85% after 100 ul of S.T.D .., 80% after 150 ul of
S.T.D., 67% after of 200 ul of S.T.D. and 29% after
addition of ~50 ul of S.T.D.
til.an90%. Two hundred microlitres of S.ToD. caused the
4.4.7 FaCCj:QX' Y (Figure 4.10)
Factor V was resistant to addition of low doses Q' S.T.D.
\
in that at GP to 150 ul of S.T.D. the levelS were qz~ater
level to drop to 53% and 350 ul caused a further drop to
22%.
+~... . '\ . r:. . . - : ~. .. ~. . j ~
4.4.8 Fagto.. Il..
\
~r.G 4.11)
Faetor II levels rema.inttdgreater than 90% with up to 100
ul of S..T.D. One hundred and fifty miorolitres of
S.T.D. resulted in a drop to 88t, 200 ul of S.T.D ..caused
a decrease to 74% and 350 ul to 38%.
4.4.9 Fibrinogen (Figure 4.12)
Fibrinoqen levels remained greater than 90% wittl 25 ul of
S.T.D. Thirty five lIlicrolitres caused a drop to 89%, at
50 ul it remained at 89% and ~J ;100 ul it dropped to
.'·1
84%. ,one hundred and fifty miorolitres, 200 ul and 350
ul of S.T.D. resulted in a reduoti~~ to 79%, 64% and 38%.
4.4.10 Protein C (Figure 4.13)
,.
prptein C proved to be the m06t sensitive indicator in
Ii
thJ~.10 ul of S.T ..D. dropped the level to 90%. TWenty
five microlitres of S.T.D. dropped the Protein C level to
73% of the oontrol. This was statistioally
signifioantly lower than any of the other factors tested
at this level of addition of S.T~D. (p = 0.00(1). The
level at 35 ul was 75% and at 50 ul of S.T.D. was 72%.
The level at 100 ul of S.T.D. remained oonstant at 72%.
One hundred and fifty microlitres of S.T.D. caused a
reduction to 71% At 200 ul of S.T.D. the Protein C
le",el fell to 61% and at 350 ul the level o.ropped to 30%.
ue.,' ,-
4.4.11 Partial ThrombOPlastinTi_ (~igure 4..14)
The partial thromboplastin time re:mained e$;"~tially
unollang:ed until tie addition of 100 ul of 8.'1' ..D.. There-
after there was a marked increase in the time. Addition
of 350 ul of S..T ..D.. reaul ted in a time of greater than
120 seconds.
" .. 4, ..12 ~@lIOOGiQMllo;rJlAli.ed _:t,iQ -·[.1&2 (:ri~" .15 )
!till :om remained below 1.JCcon aMition of up 'to- 190 u.l
caus-edthe :um to increase 'to 1.25 I 200 111 to 1 ..($3 and
300 ul resulted in t.l:ls ID being prolon<le.d_to 6.6...
\1
. j
I
I
I
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FIGURE 4.3 : A photograph Illustrating
haemolysis after addition of increasing
volumes of S.T.D.
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FIGURE 4.4
The in vitro effect of S.T.D. on Factor XII
{Mean ± SEM}
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FIGURE 4,5
,
The in v~i;ro effect of S.T.D.. on Factor XI
(Mean ± SEM)
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FIGURE 4.6
The in vitro effect of SeT~D. on Factor X
(Mean ± SEM)
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FIGURE 4.7
The in vitro effect of S.T.D. on Factor IX
(Meara ± SEM)
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FIGURE 4,,7
The in vitro effect of S.T.D. on Factor IX
(Mean ± SEM)
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FIGURE 4.8
The in vitro effect of S.TD. on Factor VOl
(Mean ± SE~,J
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FIGURE 4.9
The in vitro effect of S.T"O. on Factor VII
(Mean ± SEM)
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FIGURE 4.10
The in vitro effect of S.TD. on Factor V
(Mean ± SEM)
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FIGURE 4.11
The in vitro effect of S.T.D. on Factor II
(Mean ± SEM)
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FIGURE 4.12
The in vitro effect of S.T.D. on Fibrinogen
(Mean ± SEM)
110
,--- 100-0.... 90.......
r::
0 800
..... 70
0
~
60-
0
50
Z 40-w 30
I-
0 20a:
0... 10
o -
o
141
50 100 150 200 250 300 350
S.T.O" (#.d)
FIGURE 4.13 (a)
The in vitro effect of S.T.0. on Protein C
Note the reduction in Protein C levels
at low dosages of S.T.D.
(Mean ± SEM)
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FIGURE 4..13 (b)
The level of Protein C at 25pl was signicantly less (p < 0.001)
than the normalised levels of each of the other factors
which were also not significantly different from each other
(Mean ± SEM)
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FIGURE 4.14
The in vitro effect of S..T.D. on the
Partial Thromboplastin Time. Note the
hypocoagulable state which occurs after
addition of high dosagfJs of S.TD ..
(Mean ± SEM)
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FIGURE 4.15
The in vitro effect of S.T.0" on
the International Normalized Ratio
(Mean ± SEM)
originally surprising (Fegan, 1967). This f indlnq has now
••, 5 DIBCllSSIOlil
Tbe find.inq of a hypocoagulable effect of sclerosant8 was
been shown to be due to a decrease in acti vi ty in all of the
factors of the pathway which were tasted. The findinq of
hatmlOlysis, whioh. most sclerosants cause (stroncek, 1985), was
confirmed in this study. The olinical sit.uation whioh is
ourrently practised involves injection of approximately 1 :a1
of 3% S.T.D. into an oesophageal varix. Addition of 350 ul
to 5 11.1of blood results in a total incoagulable state.
Therefore it is safe to assume that a similar state would
occur in t..."tJ:'y varix oontaining less than 14" 29 ll':lof blood ..
As S.T ..D~ dilutes either by diffusion, or by a flow effect, a
lower concentration will occur both at the site of injection
and, depending on the direction and speed of the flOW, t!his
lower oClllcentz'ationwill also occur at a site d~.stat1:tfrom the
original injection sitae
This low concentration would not affect any of the other
factors tested other than ~;ctein c. As previously discussed
in the introduction, a depletion .inprotein c is associated
with a hypercoagulable state. This selective Protein C
inhibition is a possible mechanism by which thrombosis occurs
both at the site of injection as well as at distant sites ..
of S.T.D. resulps in a hypoooa~lable state.
The rQason that the effects were not compared with blood.
obtained from cirrhotic patients i$ that While accepting that
patients with oesophageal varioesl'/lue to alcoholio liver
cirrhosis might have co 1ulation abnormalities, those who
"
ii
bleed from their varices have these coagulation abnormalities
correoted, by the administration of fr£sh frOzen pla$llll whioh
cont\~in all t~ "':..elevantfactors. Coagulat,i.on factors erG
thus normalis$cl'.
4.6 COBCLUSIOlf
Addition of more tt1lan 200 ul to 5 lItlof wholo citretad blood
less than tha~ used clinically, suggesting that during
injection of varices a looal hypoco~gulable state OGours.
However, at lower volumes, i.e. 25 ul, the result is selective
depletion of Protain C with a probable hypercaagulable
state. These findings S\ q'ested that there wb.i> scop.e for
considerable improvement in the dosage af S.T.D. injected; into
oesophageal varices.
Iv
'I),
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4.7 THR01.mDELASTOGRAPHY
The thromboelaatogram was originally developed by Hartcrt in
Heidelberg, who first published his preliminary results in
1948. Subsequently a large amount of literature has appeared
expounding the use and benefits of the thromboelastogram as a
global test of the coagulum. The predominant portion of the
literature has been of European nature and at present there ls
a relative paucity of literature, fr.-omthe English-speaking
haematoloqy communities. Despite this lack of enthusiasm,
thromboelastograpt] would appear to be one of the very faw
methods of de·tecting a functional hypercoagulable state (Franz
at aI, 1981) and the effect of Sodium Tetrartecyl sulp;nate was
evaluated using this tachnique.
4.7.1 Mfjchanism ot wwn
Tha thromboelastogram is an optical system designed to
giva a ccrrcfnuous recordirJg of coagulation of blood or
plasma. 'rbeprintout is termed the thromboelastogram.
Tbe thromboelast~graph Is designed with tl1ree cylindrical
cuvettes of 18/8 chromium nickel steel are maJ.ntained at
37°C. An example of the instrument is shown in Itigure
4&16.
(
Each cavett. containing the blood or plasma sample is
connected to a moving device by which it is rotated hack
and forth over an angle of 4 degrees 45 mim.:'i...esaround! a
vertical axis. A piston composed of the same material
is lowered by means of a to~sion wire into the cuvAtte,
leaving a space of 1 romfor the sample between the piston
148
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I. AdjUlt.blG feet to IeVilI B. ClrCullr IIIVt11Ito thoW when
the Ini!trument the inltrument II IeVilI
2. Plexlglan cOllllr to proteot 9. Il!umlnated POWER a-NItoh (green)
the ma.urlng units to tum the In.trument on
3. Two ouvtttitl to 11010the 10. Ilum1n911!d <lH...RT .wltoh (yellow)
blood .. mple. to tum t.". olllr! c:ifIvIt on
4. MARKER button to apply tlme- II. Oil paPl for clampan"':;, the
marking pulse. for the :aft manuring unltl
~ channel
<:
5. Zero POSITION oontrol for the 12 Zero POSITION oonl1ol for the
111ftItylua right Itylua
6, Knobs to lower and lo'Jk the 13. C/I.'ldrlcal pistons
pistons
7. Plexlgla$ll cover to proteot
14. MARKEn button to apply tim"
the reoortl6r unit
marking pulse. for the right
chennel
FIGURE 4.16 The Thromboelastograph
and the ouvette. A mirror attached to th& torsion wire
refleots the liqht fl~m a slit lamp as It direct visual
read out.
While the sampls' is fluid, the pistc. i.smotionless. As
soon as fibrin strandfs form betwe.,n the ouvette and the
piston, oscillations occur which are proportionate to the
rate of fibrin formation as well as to the elasticjty of
the coagulum.
One osoillation requires 9 seoonds for a full cycle (i.jl$t.
3.5 seconds for each 4 degree 45 minute turn in either
direction and 1 second delay at end position).. ThEil
light source will reflect the oscillation so that it can
be graphically racordQd (Franz at al 1981).
4.7~2 Intergretation Qt ~hrQmboelastQgram
(Base line - Figure 4.17)
The reaction time (r time) is a measurement from the
starting point on the ohart to that point where the
amplitude of the oscillation bas reached 1 Mm. This
re~ording is equivalent to the coagulation time or rather
the reoaloification time.
4.7.2.1 TOft r-tim§
The r-time has been considered by Marohal at
al,(1961) to be the rate of thromboplastin
generation. It will, therefore, be influenoed by
haamophilia A or heparin therapy. The .quivalent
changes in either generation of plasma
thromboplastin or by factors of the first stage of
the intrinsio pathway, i.e. factor XII, XI, IX and
VIII. A lenqthening of the r time will represent
an inherent defeot in one of the above, •• g.
in the test vibe is a recalcifioation time.
4.7.2.2 ~. ~-time
The k-tin~ is measured from the end of the r-time
to a point 'where the amplitude measures 20 '\1ll1\.
The k-time is indicative of th~ rapidity of the
fibrin bu.I,,ld-upor the spaed with which a clot of a
certain solidity is developed (Franz fiat aI, 1981).
The k-time is referred to by Marchal as the
\
thrombin constant which is unaffected by the
factors of the prothrombin complex but responsiVE!!
to intrinsic plasma and platelet functions.
Prothrombin depressing agents in ~~erapeutic doses
have little effect on the k-time. prolongation of
the k-time is found in deficiencies of the
intrinsic factors, circulating anticoagulants and
platelet disorders either quantitatively or
qualitatively.
Reduction in th~ k-tlme is associlliltedwith a
hypercoagulable atate (franz et al., 1981) ..
clot. The elastici t.y ot tbe olot i. a· f·tlll\Ilt.!on
of platelet function, fibrin Md all the taator.
relatinq to tne fibrinolytic pathway.
The ma is converted to elasticity unit. (ma) by the
following formula:
The ma reaches a peak and then recedes. This is
11:.. lOt! ma _
100 - ma
thouqht to be ,~ function of clot softeninq rather
than fibrinolysis and is :£\'apresentedby a "spindle
shaped" decline .:l.n ma,
One would thGreforQ expect that any reduotion in
platelet function or oount would result in a
decrease in mao Other well documented causes of Ii
decrease in rna are oirculatinq antiooagulants,
deX".::.rantherapy and <1.ecreasEidfibrinoqen level ••
In hyperfibr1nolytio states one finds a normal rna
which is rapidly degraded.
and 0.06 ul of 1.29% CaCl2 was adaed. special care was
4.8 ~LOGY
The lIlethodologyused "''afJ, that desoribed bY Frans !at .1\ . . .,
\ i(1981). Four and a ~~lf aillilitres of venoWi blo~ was
withdraw into a 5ilicon1s.<1 vacutaina:t" tUbe oont.inuinq 0,,5 ul
of 3.6% sodium.citrat(~. The various volumes of b~ were now
To recalcify the blood, a 1..29% isotonic caC12
solution waS used. A disposable tip pipette wa. used to
pipette 0.3 ul of eitrated blood into the proheated cuvette
taken to avoid foaming" The piston wail lowered into the
cuvette, the /Speeiman oovered with liquid paraffin and the
recording started. The tests were performed in duplicate
fram blood obtained from 3 healthy volunteers.
n
!il ,'I
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4.9 RESULTS
Examples of the actual thromboelastograms are shown in Figures
4.~7 - 4.23~ Of note is the shortening of the r-time and
k-time with addition of between 25 ul of S.T.D~ and 30 ul.
Addition of larger amounts qaused both the r- 6tnd k-time to
prolong 0 Fifty microlitres of S.T.D. resulted in failure to
clot. These results were reproducible.
FIGURE 4.17
T.E.G.
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ma=45
: A tracing of a normal
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FIGURE 4.18 : A tracing of a T.E.G. after
addition of 25 ul of S.T.D. Note the
shortening of the r time and k time.
The rna is decreased.
Ma=21
FIGURE 4.19 : A tracing of a T.E.Gi. after
addition of 30 ul of S.T.0" The r time
is further shortened.
r = 12,5
Ma= 10
FIGURE 4.20 : A tracing of a T.E.G.. after
addition of 35 ul of S.T.D. The r time
.s now increased and the rna is further
decreased.
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FIGURE 4.21 : A tracing of a T.E.G. after
addition of 40 ul of SliTrD. The findings
are relatively unchanged.
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FIGURE 4.22 : A tracing of a T.E~G. after
addition of 45 ul of SIIT.fJ. The r time
is now markedly increased and the ma is
further decreased.
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FIGURE 4.23 : A tracing of a T.E.G. after
addition of 50 ul of S.T.D. The blood
is incoagulable.
...... ~. jII,;it ~ ,l'l<'~ t, ~".~.
'. , •• '! '.... ., .'. '..
4. 10 DISCUSb.!OK
Ahyperoo8.<]lllablestate is diffic'.llt to define in terms of
laboratory parameters. Thromboelastoqrams 1118:( be one of the
few methods tv demonstrate the presence of a hypercoaqulable
state (caprini et aI, 1976). The findings ot the
thromboelastogram study are in keeping with 'the previous in
vi tro work, al t,hough it has not been proven that the
TEG-defined hypercoagulability was the result of selective
Protein C inhibition spec.'ifically.
Addition of small amounts of S.T*D.. resu~.ted in a
hypercoagulable state, as evidenc:ed by the reduction in both
the r- and the k-tim8. The 'lltramge appearance of the sliqht
spindle shapQ of the maximal amplitude ltlight be attributed to
softening of the coagulum (J.I'rar.zet 8.1, 1981). On addition
o1~larger volumes of S.T"D., a hypocOC:lgt;llablEIIstat.e oocurred,
which was in 'keeping with decreased levElls of clotting
f~llctors.
In conclusion, the thromboelastogram provides additional
evidence that 8. l1~ypercoagulablestate occurs on add!tion of
S"T.D. in small Volumes. Ls.rger volumes caus« a severe
hypocoagulable state.
1&1
CHAPTER 5
",
m
5.1 INTRODUCTION
The previous two chapt~rs haye evaluated the effect of
S.T.D. on platelet function and coagulation factors. The
cell that orchestrates thrombosis is th~ endothelial cell
and the effect of S.T.D. on endothelium was studied.
The following review ie.intended to higblight SOlUenew
discoveries of endothelial function so that the importance
of not only deetructlon but also inJUry to the endothelium
is appreciated.
5.1.1 Qy&rviQw
The endothelial cell plays a crucial role in
determining coagulation status. Its importance has
only recently been highlighted by the discovery of the
nuasrous subst.ances which it produces I some of which
are procoagulant, while other$ are antiooagulant.
These substancQS are also subject -tovectorial
secretion Ii. e. 1UIllens.llyor ablumenally • The
surface area which they occupy in an averag~ adult
male is greater than 1,000 m2 (Jaffe, 1987). The
control of endothelial proliferation is very tight and
while haemopoietic cell turnover for example is 5
days, endothelial turnover is measured in years
(Folkman, 1987). Physiological angiogenesis occurs
mainly in females during menstruation and placental
development.
Anqioqenesis at other times, and particularly in adult
males is however generally pathological.
5 •1.2 Anaj;.omy
The endothelial cell is unique in that it lines a
conduit for the blood and is the first line of cells
which separate the rest of the ,.ody from the b1oo~.
The cell has a lumenal surface which under normal
conditions is antithrombogenic, an ab1umen~1 surface
where it s\~ronqly adheres t.othe suber.dothe1ia1 tissue
and a third cohesive surfdce where it binds to
adjoining endothelial cells by means of cell
junctions.
5.1.3 fhYliology
The ~ndothelium plays an important role in transport
from the intravascular to the extravascular
compartment. It is more permeable to maoromolecules,
watar and water soluble molacu1es than other tissue.
The mechanism of the above is thought to be due to
"pores" in the cell a~ well as vesicles. Another
mechanism is postulated to be due to the cohesive cell
junctions between adjoining endothelial cells opening
up_
&.1.4 MStabolic FynctiQnm
The endothelial cell h~s numerous functions, one of
which is secretion of connective tissue oomponents on
its ablumenal surface.
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!fbis enables i.tto adhere to this surface ".
Bndothelial cells have reoeptors on their surface fot'
the proteins and it is thought that the.e interactions
between reoeptors and these self-mad.e proteins is
vital in maintaining the cell's adhesion to the
underlying subcellular matrix.
The endothelial cells respond to damage by producing
vasoconstriction which aids in thQ proc2tJR of
haemofltasis. This is accompli.hed by ~~romboxan. A2,
~ prostaglandin which although found mainly in
platelets, is also produced by ~.l\e "''''e end.othelium.
Another meob.5.l1ismof 'V'asoconstrictionis as a result
of adrenaline which is rainsea in reS};:Ol~.eto
u
stress. Reoently at peptide was dQ~I':;ribooby
Yanagisawa at al (1988) whioh has the ability to
produce prolonged vasooonstriction._ 'rl'lisprotein,
whioh is a short peptide, is released by the
endothelial cell after exposure to thrombin and
adrenaline and has been named endothelin.
The cells secrete basement membrane which differs from
other collagens in that it hall a high t3- and 4-
hydroxyproline content. The basement membrane is a
thrombogenic surfao·e which is exposed by remJ.>va.lof
thg overlying endothelial oell. Endothelial oells
also possess the ability to remodel the basement
membrane via collagel'la.seu(Kalebic, 1~183).
Ii
,
q
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Endothelial 0$11$ which have been ~l~ur.e ,~ human
U'Iltbilicalveins secret.. type IV prooollag-en, a. well
as lam.ininr f ibronectin and. tlu:ombospondin...
lIndotbalial 0.11s in eul t.ur. have beg $b;OWn to,
eecret$ type V collaqen int.o their underlying-
extracellular matrix (Sage, 1982). Type V collagen
has been shown tc inhibi.t endothelial cell growth.
Tne endothelial oells produce von Will.brand Faotor
(V\U') wllicm.i. stored. in tn. endothelial o.lls u
and ablumsnally where it is stored in t.he
subtm.d.otbelial tissue.. This enhance. the
~ambOqenioity of this area should tt.4 endothelial
cell be remov6'd (Bloom, 1973). Prepro von Willeb3'.and
factor, which is th$ translat.i.ona1 product., underqou
dimerisat.ion and further modification before it
underqoes final a~$exnbly into multilllers (Ruqgeri,
19B7) .. The VWF mult.imers are huqe and. supply
multiple binding' sit.u for platelets ..
The vWF factor in oiroulation can bind t.o the
~ndoth.1ial cells via two receptors, viz. glycoprotein
Ib and the vitronectin rec9ptor. This was shown by
Aech Qt a1 (1988) in endothelial cells which had been
cultured from human umbilical veins.
pm
The platelets cont.aina receptor for vWP' and this is
thought to be the mechanism by which platelets adhere
to the subendotheliwa. Patients with vWP disease
have decreased platelet binding to tilesub~ndothelium
which is corrected by the exogenous addition of vWF.
The endothelial cell, when stimulated or damaged, will
act as a procoagulant. Tissue factor activity, which
is normally not found on endothelial cells, is
markedly increased after exposure of the endothelial
oells to thrombin and especially to platelets (Johnsen
et aI, 1983). Factor V has been shown to be produced
in endothelial cells as well as to bind to endothelial
cells (Maruyama, 1984). Another mechanism by which
endothelial cells localize the coagulation cascade is
to bind Factors IX and X and they also activate Factor
XII. Endothelial cells appear to bind stimulated
platelets only. unstimulated platelets ao not adhere
to endothelial cells even when the endothelial cell
prostacyclin production is completgly halted (Booyse,
1975). This would appear to ba therefore an inherent
property of tha endothelial cell membrane. stimulated
platelets do bind to the endothelial cell when
prostacyclin production is inhibj,ted.
unstimulated endothelial cells are inherently
nonthrombogenic and secrete fibrinolytic agents.
Prostacyclin is a non thrombogenic eicosanoid which
the endothelial cell produces.
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It is a prostaglandin synthesised from araohiuonio
acid and is secreted by 'the endothelial cell after the
cell has been stimulated. stimulation is effected
by numerOllS agonists which includ(~ thrombin, high
density lipoprotein, histamine, changes in shear
stress (Grabowski, 1985), activated neutrophile and
bradykinin (Bennett et aI, 1990). It ~ould appear
that endothelial cells are not homogeneous in their
ability to synthesize prostacyclin, for example
endothelial cells from human foreskin capillaries
synthesize other prostaglandins (Charo, 1984).
prostacyclin is a potant vasodilator as well as an
inhibitor of platelet aggregation (Bennett et aI,
1990). It is Clinically unstable wi'th a T ~ of 2-3
minutes and is degraded to 6-keto-PG Fl alpha. The
mechanism of a.ctivation which is induced is related to
a rise in c-AMP. Prostacyclin also plays a role in
cytoprotection, ennanced fibrinolysis and cholesterol
metabolism (Bennett et al, 1990). Removal of
endothelium stops the production of all prostacyclin
from exogenous ar~~h':4onic acid. Bovine aortic
endothelium cells whi,ch are. bovine have been shown to
produce bursts of prostacyclin in response to sh~ar
stress levels (Moncada, 1987)v A diet rich ,in fish
oils of the N-3 class results in prostaoyclin 13
being formed instead of the normal prostacyclin
I2• The former is Tt'lorepotent in torms of its
vasodilator and anti- platelet activity.
Endothelial oells also possess the ability to modify
platelet funCtion by their oapaoity to metaColi2e ADP
and ATP to adenosine and a4enosine monophosphate which
inhibit platelet aqqreqation. In.contrast when
damaged they release ATP which results in platelet
aggregation (Pearson, 1979). Antithrombin III is a
plasma prote.in whose aotion is to inactivate
thrombin. This action is greatly accelerated by
endothelial cells which hav~ the ability to bind
heparin to tb$ir surface (Jaffe, 1987).
Protein c is activat&(1 by thrombin which is bound to
ThrolUbol1\odulinis an unusually
acidic protein with a pH of 2.5 and is found on
endothelial cell surfaces. The mechanism of action
would ~~~r to be a complicated relationship betwecan
Factor Va and thrombomodulirt. Depending on absolute
e )lative concentrations of these two C('.i~ctors,
\
i~;coteinC activation can be either enhanced or
inhibited. In ~.·>presence of a low concentration of·
Factor Va, protein C activation is aooelerate<:!land
recirculated back to the source of thrombin thereby
dampening the signal. However in the presence of
Factor Va in high concentrations, thrombomodulin will
be depressed. and coagulation will be aocelerated. (Sete
Fig 5.1)
Prateln C -----. Proteift Oa
Low concentretlon
Factor Va
THROMBIN-THROMBOMODULIN COMPLEX
I
I
...,Igh oonoentration
ractor Va
,
Thrombomodulln
Figure 5.1
A simplified diagram showing that
thrombin Is Inactivated by compie xing
with thrombomodulin where there is
a low concentration of Factor Va.
This complex results in Protein C
activation. However, In the presence
of a high concentration of Faotor Va,
thrombomodulin is depressed aSlowing
thrombin to remain activated and
accelerate thrombosis.
factor (PDGF)~blumenally. PDGPbinds to receptors
Bn®tbelial ~ells h~ve been shown to seCrete
plasminogen aat! vater in responn to t.b.rombin(van,;
a:insburqh, 19{i35) and therefore are also inti:mately
involved in t4e fibrinolytic pa:thway. E.n40t.llie11al
cells secreta III growth factor I en40thelial cell
derived qrowth factor (ECDGF),which is very sill\.ilar
to platelet derived growth (PDGIP).
The endothelial cell produces endothelial derived
relaxing factor. This substance bAs b$9n recently
id4ntified. as nitrio oxide (NO) (Palmer, 1987).
Endothelial darived relaxing: faotor has been shown to
produce v(lulQdilatationand inbibi tlil platelet
a.g'gt'&gationas well as platelet adllQaion to
endothelial cells (MaoDonald, 1988).
Endothelial cal1$ produoe platelet activatinq faotor
(PAP') in response to numerous aqonists whioh includ~
thrombin and vasopressin (Molntyrei 1985)"
Endothelial cells secrete platslet derived growth
on fibroblasts and sraooth muscle cells and is
mitogenic fo~ these cells (Ross, 1986).
5.2.1 Endothelial Vein Model
Umbilical cords were obtained immsdiately after the
liJecondstaqe of deli very. All cords were from
patients Who did not have fo·etal distress, and the
cords were trimmed to remove damage caused by
clamps. The umbilical vein was cannulated with a No
23 Jelco oatheter and ttle vein was then perfused for 2
minutes with normal ~nline at a constant pressure (20
tam Hg) to emulate variceal pressure. The
experimentation on the umbilical cords was performed
at 25 c. The flow rate was standardised at 100m1~(in.
The sclerosant was injected freehand usin9 a 2ml
syrint)G in the same manner applied in the clinioal.
situation.
COrd lengths varied from 120m to 200m. :gefore the
experiments using the sclerosant were performed.,
saline was used al3 a oontrol in seven oords to
document that no endothelial damage occurred. one
millilitre of the sclerosant (5.T.D.) was inj~cted.
The concentrations injected were 3% m/v (undiluted),
1/10 dilution and 1/100 dilu~~on. The veins were then
reperfused with normal saline for 5 minutes. ~e
S.T.D. perfusions were performed on three separate
cords. This was repeated for each dilution used.
To det.entine whe-C;perbinding of the f..._,.lerosanto
blood WOUld alter the effect on the 1:10 dilution of
STD, the fatxperiment',,:;asrepeated uain9 whole blood as
the perfusant. The cords were then sectioned ~t 1 om
intervals and then fixed in glutaraldehyde and
submitted for light a~ ~th scanning and !tra~smission
electron microscopY'.. Tiie light microscopy specimens
were also subjected to Factor VIII staining.
5.~,1.1 Transmi§s ion,EleqtroD MicrQsqQ~
one millimetre blocks of tissue were placed in
glutaraldehyde fixative~ The tissue was -,.Lxed
overnight (24 hourS)i and rinsed for 1Q minutes in
Millonigs phosphate buffer. The ti .~':l.e was
postfixed in lltosmium tetroxide for 1 hour and
then rinsed for 10 minutes.
The tisSllGwas rin~J ...\with 50% alcohol and then
left.for 10 minutes in 50% aloohol. This process
was repeated using 75% alcohol, followed by 100%
alcohol $ It was then left fo~ a further 20
minutes in 100% alcohol, following which it ~~~
rinsed with propylene oxide and then left for 20
minutes in propylene oxide. It was then placed
for 10 minutes in 50% resin/propylene oxide
followed by a further 10 minutes in 75% resin/
propylene OXide, followed by 100% resin for 10
minutes ..
resin.
It was then re-imbeddad in fresh 100%
1'14
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100 ....C in an "",en. The';tissue was cut in thick
sactions (1 micron) and stained with aaur~ IX.
i~:!:"eato ~ eXalllinedwas selected by 'Widng
light microscopy. Thin sectioIlS (90 nm) ware
then cut and W$re picked up on copper grid6. The
grids were stained with saturated Alranyl acet>!l'.t9
and lead citrate. The specimens were viewed on
the transmission electron microscope - Hitachi
H-600.
i) Glutaraldahydft fixati ve was made up by adding
90 .1 BufffJr and 10 m1 40% formaldehyde. Thref'
m.l of this mixturQ was discarded and 3 m.l of 25%
EM grade glu'b-1raldehyde W~l':!. ~dded.
ii) Millopigs Pllosphate Butfer" was made up by
,
adding 1000 m.l water I 18.8 9 s(pdium dihydroc;en
:.\
phosphate and 4 I 2 g sodium hY<ii~oxide.
\
!3.2.1.2 i,.yanning.Electt"ODMicrOSCOJ2Y
One millimetre blocks of tissue were fixed in 33%
glutaraldehyde fixative for 24 hours.
then rinsed in Millonigs phosphate buffer for 10
minutes, post fixed in 1. osmium tetroxide for 1
hour and rinsed again for 10 minutes. The tissue
was rinsed with 50% alcohol and then left far 10
\
i
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Ldnut~s in 50% alcohol. This was repea ...:aa using
75% alcohol, and then 100% alcohol.
The specimens were then left to stand for a
further 20 minutes in 100% alcohol. The tissue
was then criticall~l point dried. The tissue was
attachea to stubs for thISscanning electron
microsbopy with a thin layer of colloi~~l
qraphit,e. The stubs W'l!lrethen coated in thE!
sputter coatero The s!')ecimenswer~ viewed em the
scanni.ng electron lDicros1oope.
5.2.1.3 ImmWlQperoxidO&lu'ta:Lning of umbil:Lcr.t.l
~t:Wl
The sections were cut trans\1ers&ly 3-4 um and
placed in a 50uC incubator oVernight. The slides
were brought to water, viz. xylene for 20 minutes,
followed by absolute alcohol ~\nd then ractified
spirits. The slides were thel"iplaced in 0 .1%
trypsin in ,.lhosphatebuffered saline (prewarmed)
for 15 minutes at 37uC to unmask the antigenic
sites. The &lides were well wa~h~d in tap wat~r
to stop the reaction. Endogenou~1 peroxidase was
blocked with 3% hydrogen peroxide ~.nmethanol for
30 minutes. The ~/lideswere than wtlshed 3 times
in phosphaze buffered saline and wel:'I~ placed in an
incubating chamber. Wllebackground ,,,tainwas
blocked with 10% normal horse serum for 20
minutes. The slides were ~rained and wiped
around each section and incubated with rabbit
anti-human von Wi~lebrand Factor ~ntibody Which
was dilut~~ 1:100.
1'16
This antibody was supplied by Dakopatts (AOS2).
The slides were incubated at room temperature tor
60 minutes. The s~.idefJwere then rinsed W6l1 in
phosphate buffered saline, drained knd wiped
around the section. The slidea were then
incubated with secondary antibody, which was
anti-rabbit immunoglobulin biQtinylated species
specific whole antibody £rom donkey, for 30
minutes. This secondary antibody was 8l}.pplh~dby
Amersham (RPM 1004) and was diluted 1:200.
The slides were then again washed well with
phosphate buff..r&d saline, drained and wiped
around the section. The slides were then
incubated for 30 minutes in strept~~idin
biotinylated horseradish p&roxidase oomplex
dilution 1:300 (RPM 1501). The .illideswere was:tM&d
well with phosphate buffered salin. and plaoed in
coplin jars. The slides w~re incubated in
peroxidase substrate solution for 5 minutes.
They were then wasbed with running tap wat~r for 5
minutes. The slides were thsn oounterstainsd
with Mayer's haematoxvlin for 3 minutes. Tlto
slides were then blued by placing them in watel:
and dehydrated by placing them in rectified
spirits, followed by absoh~te alcohol and then
xylene. Finally, the slid~s were mounted.
i)fhoepaate suttered Salina
Th' phosphate buffered oline was mad~ up by
li
adding 8 grams of sodium Ohlor.ifc~e,1.15 grams
of disodium hydrogen phospn~te, 0.2 grams of
potassium chloride and 0.2 grams of
potassium dihydrogen orthophosphate to 1
litre 4istilled water. The pH of the solution
was then adjusted to 7.6
·co ii)pergxidalll sybstraj:e Solution
The peroxidase substrate. solution was made up'
by adding 0.1 ml of 3,4,3'4'
tetra-aminobiphenyl hydrochloride, 3.3'
dlaminob&nzldine tetrahydro- chloride (BDB),
100 m1 of phosphate buffered salina, and 0.003%
3 drops hydrogen peroxidase in 100 ml ,Iii.tilled
water. Equal quanti ties were added to~ether
immediately before use.
;
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5 • 3 R"ICSULTB
A 1/100 dilution of S.T.D. caused no d~tectable damage.
Damage was assessed as absence of endot..helialcells. .I A
1/10 dilution limited the axtent of denudeuent to 8 em
downstream in two ~f the cords and 7cm in one of the
cords. The undiluted S~T.D. resulted in complete
destruction of the endothelial layer for the entire length
of the vein.
Figure 5.2 demonstrates the effect of perfusion of normal
saline for 5 minutes and is the control. The endothelium
is intact. This is also shown on scanning electron
microscopy (Figure 5.4.) alldtransmission electron
microscopy (Figure !5. 6 ) • von Willebrand antibod~~(was shown
to bind both to the endothelial cells as well as the
subendothelial tissue (Figure fi. 8)
,...~",
Figure 5.3 demonstrates the effec~ of 1/10 dilution 8.T~D.
at 6 em. The endothelium is oompletely destroyed. All
that remains at the site are ghosts of amorphous
matElria1. This was confirmed on transmission elttctron
micl:osCOPY (Fiig"ure!5. 7). scanning electron microscopy
(Fig~re 5.5) demonstrated the exposure of the underlying
colla'1sn• The remaining subendothelial tissue was Btill
sho~An to bind to Factor VXtI antibody (Figure 5.9).
The findings of the extent of damage were unaltered when
the sali:;:leperfusant was replaced with b)ood, viz 8 CIIl.
~ .. ' ':I' ";.~ "\' •. !< _.'1.. ..
~ '. ;.: • M •
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FIGURE 5.2 : Photomicrograph demonstratinq
normal endothelium lining a human umbilical
vein.
/I G
! FIGURE 5.3 : Photomicrograph demonstratingdestruction of the endothelial layer after
perfusion with S.T.DII The ghosts of the
cells are visible.l
.e
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FIGURE 5.4 : Scanning electron micrograph
demonstrating normal endothelial surface.
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FIGURE 5.5 : Scanning electron micrograph
showing denudement of the endothelial
layer and exposure of collagen in the
subendothelial layer.
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FIGURE 5.6 : Transmission electron micrograph
showing a viable endothelial cell" I:,
normal tight junction is demonstrated.
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FIGURE 5.7 : Transmission electron micrograph
showing cellular debris after perfusion
with S.T.D.
FiGURE 5.8 : A photomicrograph
demonstrating von Wiliebrand
Factor binding to endothelium
and subendothelial tissue.
•
t
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FIGURE 5.9 : A photomicrograph demonstrating
the von WiUebrand Factor still binding to
the subendothelium after the endothelium had
been destroyed by perfuslen with S.T.D.
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5.4 DISCUSSIVIf
A human umbilical vein model was devised. ThIl validity of
the endothelial function of endothelial cells obtained 'from
human umbilical veins has been documented by Jaffe et aI,
(1973). They used a culture system and subsequently most
of the work on the metabolic functions of endothelial. cells
has been documented using this tissue culture technique.
Pegan £It aI, i~ 1965, showed histplogicelly that S.T.D. is
toxic to the, endothelium, while stroncek £It al (1985)
\
confirme~ their findings using cultured endothelial cells.
An in vivo model, the dorl'la.JvE'linof a rat's tail, was used
by Blenkinsopp (1968) This ...\~el .s more physiological
perhaps than cultured endothelial cells, but it is
difficult to quantify the extent of damage produced by
different dosages of sclerosant due to t.he small size and
length of the vein.
is not human.
Another criticism is that the model
In considering important factors applicable to the design
of a suitable model for investigating varices, pressure,
temperature and flow ~ate came to the fore. 1- pressu'1'.:'eof
20 mm Hg was standardised to emulate intravarice(.\.
pressure. The experimentation on the umbilical cords was
performed at 25 C. Apart from convenience, the .ceason fOJ::'
choosing room temperature w~s the fact that the varices of
patients who undergo oesophageal endoscopy are subjected to
flows of both air and ¥ater at room temperature. This is
especially crucial when the endoscopist is evaluating
bleeding varices.
variable. i1Ocormacket al (1983) developed an ultrasonic
probe wp.ioh was able to detecrt a mini:mwtlflow ratQ of 11
i\ \
:ml/min.\ '!'heyware able to show that.:the flow in lit varix
vlltriedwith the position of the patien~ aIle! that it
increased during inspiration and decreali~ with
expiration.
directions,
In some cases there was flow in both
~xt.narmore I general anR.0sthasia and tos~'tiva
pressure ventilation reQulted in a reversal of previous
flow dir&et..'Lon. Giani at al (1990) confirmed the
variability of direction of blood flow in varices.
In view of the wide variation in variceal blood flow
experianced in vivo, no in vitr6 model can faithfully
represent in vivo flow patterns. However I this probleltlis
by no :means unique to the investigation of oesophageal
varices. Indeed it is common to all vitro
experimentation, of whatever nature, that not all the
conditions prevailing in vivo can be reprod.uced.faithfully
in vitro. Daspita this limitativn, there are numerous
exa:r'!lJ;?;lesof illvitro technology having contributed enormous
insight into the in vivo physiol-.'1YWhich it so imperfeotly
represents.
For instance r the di_m§~'.;'\re1~,b~_Qchel1liea1~haracterisation
Ir
,r---- ;,. \\ .
I \,,' , ",and ultiete1y the 'prodti~,~':\onf6r pharmaceutical purposes
of the eighteen recOl1lbih~~thaemopoietic growth fac;tors and
inter10ukins currently avJ;ilnb1e, was entirely dependent on
\~in vitro bioassays, whi~h w~~.e very poor representati vas of
\conditions within the bone ma,row (Moore, 1991).
rsystemst .mp1oyin~ pieces ofFurthermore, organ culture
tiJiSue removed from.the body lindobserved in iso18.tion for
biological r$sponses to various agents, included th&
seminal work of Vane (1911), which CUlminated in a joint
l$e in physiology in 1982.
For tba purposes of this study, flow rate was standardised
at 100 ml/m:ln for the umbilical vllldnmodel. The majority
of blood f1c)wing through gastro-oesophagea1 varic.s
terminates in the azygous vein system (Sherlook, 1990) and
flow rate in the azygous system is therefore thought to
represent a good index of flow through varices (Bosch at
al, 1988). Azygous flow rates in patienf!s with alcoholic
liver cirrholSis who have bled have been measured at
approxi~~tq1y 600 ml/min (Sl1.arlock,1990). Searing in
mind that the paral~el network of varices which ulti~ately
terminate in the azygous vein, it was decided empirically
to standardi~le thQ flow at 100 ml/min. One has to
acknowledge that flow rates of greater than 100 ml/min in
anyone varix WOuld limit endothelial damage.
Howe.verI 91ven the variability whl.ch occurs in variceal
blood f.lowon inspiration and expiration, indeed even to
the point of reversabili ty in some cases, it seems unlikely
that a flow rate of more than 100 JIll/min(1/6 of total
azygous flow would be exceeded in anyone varix for any
length of tiM. Indeed one would expeot that the model
would overestimate rather than underestimate the ehtent of
d&mage.
The perfusant used was normal saline. This was chosen
based on the work of Mazer at al (1986), who showed that
normal saline was the least damaging of irrigating
solutions on th. endoth~lium of small arteries of rats.
In an effort to render +.:hexperiment more physiologiclilll,
the 1/10 dilution experiment W.:lB repeated using bloO""'.as
the perfuaant with identical results.
model is that the umbilical cord ~lao oontains two
S.,!'.D.destroys endotheliume The contribution of the
arteries, so that the endothelium of the arter';.escould bel
t:sed as a control to exclude an excraneoun cause of
endothelial damage. A final advantage is that with the
ourrent opposition to vivisection, this mOdel bypasses t.he
problem of animal experimentation.
The umbilical vein model confirmed that the sclerosant
model has been to document the extent of damage.
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A disadvantage of the model is that it only assesses the
ability of the sclerosant to ~el~1.tdethe vessel of its
endotheliUl1l and despite showing t..t\.!1t lJt:.. Willebrand Faotor
is still present in the suberdoi..hel\.ulI1,the von Willebrand
Factor an'cibody does not assess whether this procoagulant
protein is still functional. D~spite this disadVantage,
one would expect that if remo"'78.lof the cell is the
endpoint, than there must be a gradient where, although the
cell is da:maged, it is still prAsent. This would oocur in
decreasing frequency as the concentration of the sclerosant
decreased or in other words distal from the point of
injection. RemovClI of the endothelium and the subsequent
exposure of the highly thrombogenic subendothelial surface
would undoubtadly lt~d to thrombus formation if enough
procoagulant protein activity as well as funotional
platelets were present. What is noteworthy, is the extent
of damage that the undiluted sclerosant produced. This is
in keeping with the postmortem findings of Evans et al
(1982) who showed damage a"t considerable distances from the
site of injAl.~.ion. The 1/10 dilution of S.T.D. limited
the extent of damage to 8 om which is closer to what is
desired in the clinical situation.
From the introduction, it is noted that the physically
present endothelial cell acts in a highly thrombogenic
manner when damaged and therefore one would expect that the
thrombus fOrlPation wOl.lldpropagate for some distanco distal
to the site where absence of endothelium was noted.
1II>l!..,...... , , •. , .. ' .. .. .... l1li
The findings of previous chapter~ suggested platelet
hyperagqreqability and hyperooagulability f'rolildilute
S.T.D., as opposed to platelet lysis 16....,""', incoaqulability
,\
from standard d~age S.T.D. When considered in relation
to the findings of this ohapter, these features s'I),qqested
that 1/10 diluted S.T.D. should aotually be more
thrombogenic looally than S.T.D. in standard dosage, and
would have the added bonus of limiting ertenslve and
possibly systemic side eff~cts and complications. This
was the impetus to test the hypothesis in the olinioal
situation both for acutely bleeding oesophageal varioes, as
well as for preventing recurrent bleeds.
CHAPTER 6
I
ic..-
!
1M
6 • JB1ITl£CTS OF ~A'lfDl\ID DOSAGE VlWfUS D:tLW:E ;mOltlJI
TIT.RADICYL $1JLPBA!fB QlIJ QEtJOPHAGBAL yAf{tCE$t
A PBOSPEC'fIVJ BANJXJlISEQ PJ;LOT STUDt
6 .1 IlffRODUCTIOlf
Sclerotherapy of oesophageal varices is widely fW";:.ltptedas
a technique of choice to thrombose the acutely blaeding
varix and for long term variceal obliteration (Terblanche
et al , 1990; Sivak et aI, 1990). Various sclerosants al'a
currently available and wculd appear tQ be of major
impol·tanoe in determining the efficacy and complication
rates for the procedure. Tne reason for ohoosing S.T.D.
has been previously discussed.
Blenkinsopp, in :968, using a rat vein model demonstrated
the superi~rity of intravenous injection of 3% sodium
Tetr&dwuyl Sulphate (S.T.D.) as compared with other
agents. Subsequent studies have shown its efficacy is
compa,t"ablewith ethanolamine oleate (Chung et aI, 1988;
u
Kitano at aI, 1988), but ooncern has been expressed as to
the local complications which occur subsequent to S.T.D.
administration (Terblanche at aI, 1990).
Substantial diiutions of S.T.D. were shown in Chapter 5 to
be effective in stripping vascular endothelium yet Wd'1:'e not
associated with incoagulability of blood nor with platelat
lysis (Chapters 3 and 4).
..
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In4QQettilut.e SAT.E). was found to actually ioouoe platelet
aqqr&g'ation and to oontrihute towarcls hyperooagulability of
blood throuqh a ..leotiv$ low dose inhibition of the
physioloqioal antiooa.gulant.protein c.
~-)
suqtJ_ted that treatment with ten fold diluted B.T.D. may
be as effective as, if not lP?re effective than, standard
dosaye t"l;'aatm.nt,yet probably less prone to ulcerat! va
oomplioations and their sequelae.
A pilot stuCty was therefore initiatad·in which patients
with portal hypertension and oesophageal varices were
rfllldQ;mised prospe.ctively into standard dosage versU8 dilute
$..'.t'.1)~ tJzl!Ultmant. amns.
.J ,
6 • 2 METlIODS AND PATIEN'I'S
Fifteen consecutive patients raceiv~ng sclerotherapy at the
Johannesburg Hospital qver a 6 month period wl9re included
in this study. There were 9 patiente in Group A and 6 in
of the patients in Group A pre$ented with anG:roup B. .'1..
acute index bleed while only 3 in Group B had this
problem.. All the remaining patients from both groups were
on chronic Bcle::-otherapy for a pr.eviolsly documented
variceal bleed. None of the patients presented with an
interval bleed.
There were 5 males in Group A vs 4 in Group B. The
aetiology in both groups included Laennec's cirrhosis in 7,
primary biliary cirrhosis ck.. 1, chronic active hepatitis in
3, portal vein thrombosis in 3 and idiopathic in 1. Their
de1:.ailsare presented in Figure 6.1. All patients signed
consent and the project was approved by the Ethics
co~mittee of the University of the Witwatersrand.
The patiEmts were randomised prior to detailed assessment
into rec~~iving dilute sclerosant (Group A), which was a
1/:0:0 dilc\tion of 3% m./v S.T.D. and undiluted I3clerosant, 3%
m/v S.T.D. The endoscopists and patients were blinded as
to the naf!u:c::'eof Group A and Group B. '.rnedilution was
made up by the Pharmacy Department ~f the Johannesburg
Hospi tal. The technique used was injectio:...via a flexible
gastroscoE.e. The varices were injected intravariceally.
Sex (male/female)
Age (years) range
Median
Child-Pugh Classification
A
B
C
Medi.an volume injectad (ml)
bilge vC)lume injected (m.1)
Mean f·ollow up (months)
A§tlQlagy
Alcohol
GROUP A
5/4
36 - 78
49
Goomtt.D
4/2
18 - 69
47.5
!5
.2
2
8.3
5 - 10
7
1
4
1
7.3
4 - 12
6
5 2
PrimaryBiliaryCirrhosis 1
Chronic Active Hepatitis
Portal Vein Thrombosis
1
2
.2
1
Idiopathic 1
FIGURE 6.1 : PATIENT PROFILE.
\
'. J
Deaths
AOJ1P.A
1/9
0/8
WO\lP·.a
1/6
3/6*Rebleed rate (to date)
Efficaoy in s"oppinq
Acute bleed 5/6 3/3
objective endoscopio
improvement of varices
Ulceration rate
8/8 5/E,
1/8 6/6
0/8 4/5stricture
* 2/6 were due to ulceration.
FIGURE 6.:2 '1% EFFICACY AND MORTALITY
" 1
1. J
j
6.3 ~S
Results of tr&atment in the 2 groups are 8u~rig~ in
Figure 6 ..2. There was one death in eaoh of the groups.
The patient from Group A had an acute cardiac arrest 6
hours after sclerotherapy for an acute bleeding vartx.
Because the family refused consent, it was not possible to
assess the efficacy or oomplications in this pat.ient_, The
pati~nt from Group B had an acute variceal bleed which was
treated by varicaal sclerotherapy. She had acute
respiratory failurb ~g well as cardiac arrest during the
procedure and was successfully r.esuscitated.. She rebled 5
u.lceration as well as residual varices. There was almost
days later and underwent repeat sclerotherapy. She
arrested at the initiation of the procedure and died
shortly thereafter. Post :mortem revealed oesophageal
no viable liver tissue., indicating an extremely poor
prognosis. All the patients from Group .i3 developed
ulceration, 2 of whioh resulted in bleeding. These two
patients r~gl!ired transfusions. They both responded well
to sucralfate therapy. Three of the patients from Group B
had evidence of previous stricture formation due to
sclerotherapy.
sclerotherapy.
These strictures worsened after
One of the patients from Group B deve{bped
a stricture which developed afi)er sclerotherapy with
undiluted S.T.D. Both groups of patients showed endoscopic
lmprovement of both variceal number and variceal size after
eacL session.
".:~ .... "" . ." ; . ", ;';'. : '... ,_ '." ~.' .. .,
All patierlts were endoscoped every ~wo weeks and
sclerotherapy was continued until eradic.ation was achieved,
i ,\
and thereafter the patients were followed ~p at four to six
week intervals. The unacceptable hiqh ulceration rate in
Group B necessitated. an early end to the trial ..
_______ ~ ~ ~ __~.m .....~
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6.4 DISCUSSION
Sclerotherapy of oesophageal varices nas been associated
with numerou~ side effects both locally and systemically.
These are discussed in the next chapter.
Diluting the sclerosant has been reported previously. All
these dilutions have however ~en empirical. silpa at ~l
showed in 1982 that ~.T •.i)., when diluted to 1.5%, was as
effective as 5% sodium morrhuate. Using a canina model,
Jensen'at al (1. 1. evaluated various dosages and methods
of administration. Tiley showed ,1.5% S.T.D. to be an
effective scleroscht. They found however no difference in
systemic side effects as compared with 3%. Diluting S.T.D.
to 1% with normal saline has been shown to reduce th~
ulceration and stricture rate without signifif':antly
diminishing efficacy rate (Trudeau et aI, 1983). Further
dilution to 0.75% by McClave et al (1990) succeeded in
re6uc~ny stricture rate although ulceration still occurred
in 53% of pp.tient~. No studies so far have 'Used a
concentration as low as 0.3%. Technically, a dilution of
0.3% means a concentration of 333 fold (= 33.330%).
This very low ooncerrer-aedon, i.e. 0.3%, is critical in that
in vitro work suggested that the hypercoagulable state is
not achieved at Ligh concentrations. In fact, at high
concentrations, a hypocoagulable or incoagulable state
occurred. There was objective evidence of thrombosis
occurring in all the patients who were injected with the
dilute sclerosant.
(1990) •
f;
Solution B caU$ed an unaccepta'l.)le level of uloaratie;n
supporting- the concern expressed. by Terblanohe et &1,
While accepting t.be obvi~...!Slilllitat i ons of a pilot study
viz. the relatively low n~rs and poor matahinq in terms
of the Child-pUghclassification (whic~:was the consequence
of 4:'andom.isationat initial assess"l1t), 'the brevity of
follow-up I' as wail as, inCluding both patients with index
blsedsitoqetb.er with patients on chronic sclerotherapy,
there is evidence to show that the dilute sclero.ant is
su.coess.ful for the tlhort term managementof oesophageal
varioes I and is not aSsociated w:itl'l unacoeptablen
complicatiW&li. ~~·m relative merit of a low dose S.T.D.
induoed hyperooagulable state has been adcfr.essed in the
c:;:.t~er on ooagUlation.
A ld.r(,Jerstudy and longer follow up are required to
dete~~ine Whether this will equate with a low rebleed rate
(i. e. control the varioes) with fewer com:plicatiom'Jin the
long term. However, to date, there have been no failures
in the low dose group and the follow up of som.eof ,'Ch(lulJe
patients nowexceeds one year.
~",,_-~---..,,-------------- ...-------...
CHAPTER 7
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7. GIlIDAL DISCDSBIQ.
While sclerotherapy has regained its place as one of the
modaliti~s of choice in treating oesophageal varices, it
is, as has been previously discussed, not a benign
procedure. Same of the numerous complications Which have
been documented both locally and systemically are
discussed, with particular refer0nce to the two clinical
trials.
7.1 S~STEMIC COMPLICATIONS
One of th9 most ~isturbing systemic complications which
ocourR is the effect of the sclerosant on the pulmonary
circulation (Monroe et al, 1983; Bacon et al, 198.5; Hammond
et al, 19851 De Puey et 21.1,1988). One of the patients 1n
the second trial developed acute adult respiratory dl~t:ress
syndro'llle.The post mortem revealed almost no residual
liver tissue, ~~ioh in itself is an ~xtremely poor
proqnostio indicator. H~~ver, sections of the lung
contain~what appeared to be sclerosant, inciie&tinqthat
the scleroth,~rapywas probably the cause of her acute
~'espiratory failure. The findings of Chapter 2, i.e~ the
in vivo findings of the Clinical trial:::0).1 the effect of
S.T.D. on the coagulation parameters, showed a transient
decrease in tl'.1II3 white oftl!count and fibrinogen levels.
These findings are in keeping with sclero.ant damage ~o the
pulmonary circulation which resulted in the white cells
being sequestrated.
-----------------------------------------------------~----------------
One would expect tha~ the use of a dilute sclerosant will
lower the risk of damage to the pulmonary vasculature and
the lungs themselves.
Haemorrhage from other sites has also been documented as a
systemic co~plication (Foutch and Sivak, 1984; Keane et aI,
1986; Fry et al,1988). In the trial in Chapter 2 the
patients di~ not show a systemic bleeding diathesis.
Diste..lsites of thrombosis have been reported. (BarsQu,n
et aI, 1982; Goodale et al, 1982~ seidman et aI, 1984; Ng
et al, 1988). From a systemic point of view, undiluted
S.T.D. as previously shown in Chapters 3 and 4, causes a
local hypocoagulable state. However, mar~ed endothelial
stripping occurs simultaneously. Depending on the flow,
which can be either prograde or retrograde (Gaiani at aI,
1991) this high concentration will be delivered to either
the pulmonary circulation or th6 rortal venous: system.
Mixing of the sclerosant occurs nartly as a result of the
turbulent flow set up during the injoction procedure and
partly due to inflow of fresh blood. Dilution also occurs
as a function of the distance frOm the site~f
injection. The concentration of the sclel'osant will
therefo~e diminish at the distal sites. At e low
concantration S.T.O. is highly thrombogenic in that not
only does it act.i.vat~platelets directly and selectively
inhibit Protein C, but it also strips the endothelium.
This would help to explain why some patients develop portal
vein thrombosis while others develop respiratory problems.
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The reason why thrombosis 00curs at the sit·e of injection
is that the initial h!qh concentration of S.T.D. will
decr$ase a.nd "fresh" blood will supply the necessary
coagulation factors and platelets, which are required for
thrombus formation. A problem and 4 potential cause for
rebleedinq might be that this sita of thrombUs would also
occur considerl!4b1y downstream from the site of injection.
This could potentially cause an increase in the pressure
upstr~am from the site of thrombosis a.nd precipitate
another bleed. The fact that thrombus does occur at
distal sites of the oesophageal veins was shown in 1982 by
EVans at a1 in post mortEl. studies.
Cardiac oc>mplications have been described af't.:lr
sc1""rotherapy. Sodium mo" '~huate has been implicated in tt..e
deveJ~pment of bradyarrythmia (Perakos at aI, 1984).
However, the patient had previously docu~ented conduction
abnormal~ ties. Acute pericarditis is an u..",\oo::mmon
C()mplication of sclerotherapy and a cause of chest pain
(JKnauer et aI, 1987). Prinz Metal angina which w&s
confirmed electrographically has also belin describ&d after
sclerotherapy with ethanolamine olsate (Charng at aI,
1988). AlttlOtlghone would intuitiv6tly believe that low
dose S.T.D. would reduce incidence of thf!se compliaations,
this has yet to be d- .ermined.
·---------~---.---:--~-----~------
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Bacteraemia is another complication ascribed to
The incidence of bact.rae.ia post
sclerotherapy var4 es greatly fram series to series.
Camara at al (1983) reported an incidonce of 5%. Coben et
al (1983) documented a mucb higher occurrence, 14 episodes
in 11 patients.. Schuman at al (1981) feel that the risk
of sclerotber~py related s~psis is not associatad with
either the amount of the BOlerosant, the difficulty of the
procedl~e or the aetioloqy of the liver disease. Lange at
al (1983) and Sauerbach et al (1985) recoltlltlendantibiotic
pl·ophylaxsi.sfor patients with valvular heart disease.
Schuman et a1 (19S7) question this and feel that larger
stu~~ are rQqUired to SQpport this approach.
neithor of tn'S studi$s in this thesis addressed this
question, it is doubtful whether a low dose sclerosant
wouLd alter th$ incidence of the bacter~emia.
Sclerc:rl:.h-erapywith ethanolamine oleate haS been associated
with acute renal insufficiency (MalincjJet aI, 197.5).
Miyosshi et al (1991), in a red~nt ~tudy, showed that renal
tubular dysfunction aft'"":::!~clerotherapy with ethanolam~ne
oleate could be prevented by prophylactic admini.stration of
haptoglobin. Further research is necessary to determine
whether low dose S.T.D. has any effect on renal tubular
function.
7.2 LOCAL COMPLICATIONS OF SCLEROTHBRAPY
There have beQl numerous ('.asH of local complications of
sclerotherapy with varying incidences of morbidity and.
mortality.
7.2.1 oesQphageAl str~cture
Sor~nson et al (1984) demonstratsd that 59% of
patient~ developed II stricture and/or d~phaqia after
sclerotherapy with polidocanol. As previously stated,
this is a relatively common complication occurring
after sclerotherapy (Haynes et al, 1986). In the
second trial (i.e. Chftpter 6) none of the pationts in
Group A (dilute S ..T.D.) developed oesophageal
strictures t bUt 4 out of the 5 in Group B developed
oesophag,eal strictures requiring subsequent
dilatations. However in 3 of these patients, the
strictures were noted to be already present at the
time of initial entry into the trial. Presu.mably
these strictures were due to previous sclerotherapy
(WhiCh they were known to have had). Althouqh it is
my strong impression, as well as that of the other
endoscopists involved in the trial, that these
strictures worsened d'lring this trial, it ilSdifficult
to assess the influence of the latest s.rie~ of
injections on this prograssion. The absence I
however, of any stricture formation in Group A is
supporti ve of the low complication ra".e sUbsequent
upon the use of dilute sclerosant.
7.2.2 QssQPhageal Perforattgn
Although in Perino's study 6% of patients who recei ved.
sclerotherapy with 3% of S.T.D. developed perforation
(Perino et aI, 1987), fortunately none of the patients
in either of the trials had this complication
documented. One would expect that a lower dosage of
S.T.O. would reduce the inoidence of this potentially
lethal ~~mplication.
7.2.3 Deecmhageol Ulceration
~ incidence of ulceration varies from series to
series and would appear to be influenced by the type
of sclerosant used (sibramanqam et al: 1986).
sanowski at a1 (1983) showed that 57% of patients who
received 1.5% sodium tetradecyl sulphate developed
ulceration. Ayres et al (1982) desoribed three
patients who developed ulceration with ha&matamesis
after infection with sodium morrhuate. Two of thue
patients died. Westaby et al (1984) showed that 80%
of patient.s who received sclerotherapy at weekly
intervals developed uloeration as oompared with 30% of
patients W:lO reoei ved sclerotherapy at three weekly
intervals. The sclerosant used was ethanolamine
oleate.
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Sueralfate is recommended as the treatment of
sclerotherapy related ulceratior~ (Roark, 1984),
althouqh recently somatostatin has also been shown to
be effective (Jenkins, 1991).
In the trial in Chapter 6, 100% of the patie~ts in
Graul> B (undiluted S.T.D.) developed ulcers which were
still present 6 weeks after sclerotherapy. Two of
these ulcers resulted in significant bleeding. These
ulcers responded to sucralfate therapy. Only lout of
8 patients who were injected with 0.3% S.T.D. had
superficial ulceration which was visualised 1 monthr-.
post sclerotherapy. This responded rapidly tel
suaralfate therapy.
1\7.2.4 pbast Pa~n
One hundred percent o~ patients in the first trial
(Chapter 2~. complained of ohest pain. The cause of
this pain is thought to be due to a chtamical
mediastinitis but this remains controversial (Sivak at
al, 1990). The incidence of chest pain was
unfortunately not evaluated in the second trial.
One would expect that if the mechanism is in fact due
to a chemical mediastinitis then low dose
sclerotherapy would reduce the incidence of this
complication. This has still to be confirmed.
~ ~- 1
J,
7.2.5 QeeQphage~l Dysmotility
Manometric and pH mani toring of patients wi tb
sclerotherapy h£s shown decreased pressure and
abnormal contractions (Schuman et aI, 1987). on area
of future research would be to see whether low dose
S.T.D. causes less dysmotility than other agants.
Other local complications 'wnich have "~$n described
include pseudotllmOur (If the oesophaqus (Korula, 1985),
a mucosa.l bridge of the distal oesophagus {Gottfried
#ital, 1985)I, pseudodivertiaula secondary to injection
sclerotb.~apy (Scherl at aI, 198~), and oes,ophageal
monoliasis (sarles et al, 1984). As they are rare a
larqe ser~es will be reqQired to dooument whether low
dot1J.$solerotherapy has any. effect on their incidenoe.
7.7l.6 Ga;rcinpma af the Oesmmamui
Bochna at al (1988) reported a case of squamous cell
car~inoma of the oesophagus. This occurred 8 months
after scl~rotherapy with sodium morrhuate.
.I .:, -.
Due to
the rarity of this complication it is difficult to
prove a causal relationship between sclerotherapy and
caro.inoma•
al.l 1
7.3 COHCLUSIOHS
Sclerotherapy of oesophageal varices is undoubtedly an
extremely useful weapon in the armamentarium for treating
oesophageal varices. Most of ths current methodology
employed is based on empirical ~pproaches.
The object of the thesis was to evaluate the effect of
sodium tetradecyl sulphate on endothelium, the coagulation
pathway ~n~ platelets. The central recurring theme of
thir.>thesis has been the documentation of a thrombogenic
effect of aclerotherapy, occurring at concentrations of
S.T.D. ten fold less than those actually injected,
following currant practice. Thu~, localised endothelial
strippinq, hypercoagulability and platelet aggrega.tion were
all documented following exposure to low ooncentrations of
S.T.D. In contrast, exposure to high concentrations of
S.T.D. led to more widesp't"eadendothelial s'tripping, blood
incoagulability and platelet lysis. These findings
suggest that a low concentration of S.T.D. may be at least
as effective as standard concent~ation S.T.D. in the
\\
management of acute bleeding var}~~)s and possibly more so,
and would h~.ve the added benefit of limiting most of the
associated complications. A clinical pilot study based on
these findings supported this view.
" '''" _', '.,', ,,0, "" ,p-=~,~<~,"<,<-- '" ,-,-,-"- ,
1
1
I
REFERENCES
ADAMSON'S RJ I J3UTT :K, OENN!S I:!R I :KINmABWALA M I MOSKOWITZ H,
GORDON 0, BABICH A. Prognostic significance of portal
pra$sure in patients with bleeding esophageal varices.
Surg Gynecol Obstet 19771 145: 353-356.
ADDIS T. Tbe pathogenesis of hereditary haemophilia.
J Pathol Bact 1911; 15: 427-452.
bovine aortic smooth musclE! cells. J Clin Invest 1988;
ANTHONY PP I ISHAK KG I NAYAK MC I POULSEN HE, SCHEUER PJ,
SOBIN LH. The morphology of cirrhosis definition,
nomenclature and classification. Bulletin of the W.H.O.
1977; 55: 521-524.
ASCH AS, ADELMAN 131 FUJIMOTO M, N'ACHMAN ru:.,.
Id·entification and isolation of a platelet GPlb-like
protein in human umbilical vein endothelial cells and
81: 1600 - 1607.
AYRES SJ I GOFF JS I WARREN GH, SCHAEFFER JW. Esophageal
ASVAT MS I HODKINSON HJ. Cirt'nosis of the liver in
Johannesburg Blacks S A Med J 19U1; 60: 290
ulceraton and bleeding after flexible fiberoptic esophageal
vein sclerosis. Gastroenterology 1982: 83: 131-136.
Pleural effu~ions after endoscopic variceal sclerotherapy
Gastroenterology 1985;8B:1910-1914.
BAELE G, DE VOS M, HUBLE F t ELEWAUT A 1 BARBIER F.
InfluencQ of injection sclerotherapy of oesophageal varices
in liver cirrhosis on the haem.ostatic system. < Haemostasis
1984; 14: A 241.
BAILEY HE, DAWSON JL. Modified oesophagoscope for
injectir.,)oesophageal varices.
341.·
Br Med J 1975; 2: 540~
BAILEY -NEWTON ."iRS, CONNORS Ali', BACON BR. Effect of
'<
endoscopic va.r~,cealsclerotherapy f'rl gas exchange and
hemodynamics in humans.
368-373.
Gastroenterology 1985; 89:
BAKER LA, SMITH C, LIEBERMAN C. A natural history of
esophageal varices. i,Am /J Med 1959; 26: 228-236.
BARKIN JS, KRIEGER a, BLINDER H, BOSCH-BLINDER L, GOLDBERG
RI, PHILLIPS RS. Oxygen desaturation and changes in
breathing pattern in patients undergoing colonscopy and
gastroscopy. Gastrointest Endsoc 1984; 30: 284-288.
i\j
BARSOTJN MS, ABDEL-WAHAB MOORO H, BOLOnS 11'1, RAMS¥' AF 1
RISK-ALLAH MA, ~UD 11'1. The I\'~omplicationsof injection
sclerotherapy of blaet'"ng oesophageal varices. Br J Surg I1982; 69: 79-81.
BAUMG~.RTNER HR, TURITTU V I WEISS HJ. Effect of shea~ rate
BA'fJMGARTNER •..~. The role of blood flow jn.platelet
adh~$iQn, fiorin deposition and formation of. mural
thrombi. Mic:r.'ovasG'>Res 19731 5: 167·'179.
BAUMGA...~TNERHR, MUGGLI, \R, '.rSCHOPPRB, TURITTO VT.
Platelet adhesioii, rel~lise and aggregation in flowing
\\
\\ r-
blood: Effects of surfa6-;1pr{~erties and platelet.
\\ '/...
function. 11'hro:mb Haemost\.1.916· 35: 124-138.
" {; ,
on platelet interaction with subendothelium in citrated and
native blood. J Lab el· Med 19801 95: 108-h;'.H•
. \BELCH JJF. The role of the white blood cell in arterial
disease w Blood coagulation and Fibrinolysis 19;'<0; 1;
183-192.
BENNETT JS, SANFORD SJ. Platelet Function. In:
Hematology, Williams et a!. 4th edit:ion, 1990. McGraw
Hill, New York. P 1233-1242.
BENTFELD-BARKER ~~, BAINTON DF. Identification of primary
lysosomes in human megakaryocytes and platelets. Blood
1982; 59: 472-481.
' _. ---_""""""'_""'!"!'_--"..~...,""""""!"""'!'*-, _ ....... _Q .... , ...., ... '''''''"f!iIIM:~'"''r~...,....,....,_
BEPPU It, INOKUCHI K, KOYANAGI N, NAKAYAMA S, SAnTA H,
KITAKO S. Prediction of v8.ricealhaemorrhage by
esophageal endoscopy.
213-218.
Gastrointest Endosc 1981; 27:
BERNARDI H, PALARETI C, CALETTI G. Transiqmt coagula.ti.on
abnormalities following endoscopic sclerosis of esophageal
varices. Gastrointest Endosc 1983; 29 (4): 326
Bl:RZOlrBKYJA. Intril'1sicand oxtr.insicfactors in protein
antigenic P'trncture. Science 19851 229: 932-940.
BIGGS R, DOUGLAS AS, MACFARLANCE AG. Ch:l:istmasDisease:
A oondition previously mistaken for haemophilia. Br Med J
1932; 2: 1378.
BIZZOZERO J. Ueber einan neuen Formbestandheit des Blutes
und dessen Rolle bei Thrombose und der Blutgerinnung.
Virchows Arch [AJ 1882; 90:261.
BLACKSTONE MO. congestive gastropathy in cirrhosis - how
bad is red? Hepatology 1991; 13: 1000-1003.
BLENDIS LM, ORREGO H, CROSSLEY IR, BLAKE JE, MEDLINE A,
ISRAEL Y. The role of hepatocyte enlargement in hepatic
pressure in cirrhotic and noncirrhotio alcoholic liver
disease. Hepatology 1982; 2: 539-546.
.,---~.......-....-~----~--...-
BLENKINSOPP WK. compar::.sonof tetradecyl sulphate of
sodium with other sclerosants in rats. 8r J Exper Pathol
19681 49: 197-201.
BLENKINSOPP WK. Effect of injected sclerosant (Tetradecyl
Sulphate of Sodium) on rat veins.
386-396.
Angiologica 1968; 5:
BLOOM AL. Physiology of Blood coagulation.
1990, 20 (1): 14-29.
Haemostasis
BLOOM AL, GIDDINGS JC, WILKS CJ. Factor VIII on the
vascular intima: Possible importance in haemostasis and
thrombosis. Nature New Idol 1973 ~ 241: 217-.al~.
BOOYSn PM, BELL St SEDLAK B. Development of an in vitro
vessel \9'allfor studying certain aspects of platelet -
vessel (endothelial interaotions). Artery 1975; 1: 518.
BORN GVR. Aggregation of blood p1.atelete by adenosine
diphosphate and its reversal. Na'ture 19621 194: 927.
BORNMAN PC I KAHN D, TERBLANCHE J, .~ORTHLEY C, SPENCE RA,
KRIGE JJ. Rigid versus i~iberopt.icendoscopic injecti ......!
sclerotherapy. A prospect:ive rEmdomised controlled trial
in patients with bleeding esophageal varices. Ann Burg
1988~ 208: 175-178.
,'~'. . ...
21.9
BOSCH J, GROSZMANN RJ. Measurement of azygous venous
blood flow by a contir:'"Qusthermal dilation technique: An
index of blood flow through gastroe~ophageal collaterals in
cirrhosis. Hepatology 19841 4: 424.
BOSCH J, NAVASA H, KRAVETZ D, PIZCUETA MP. Diagnosis and
evaluation of portal hypertension.
1988: 26: 8-14.
Z Gasteroenterol
BOUMA BN, GRIFFIN JR. Human blood coagulation fac'tor XI.
Purification, properties and mechanism of activation by
activated factor XII. J BioI Chem 1977: 252: 6432-6437.
BOYD WP, GOLDSCHMID S, BRADY PG, SILVER D, MOMEL J, NORD
RJ. Chronic endoscopic '~ariceal sclerotherapYe Am J
Gastroenterol 1985; 80: AB51.
BRASS LF, BENSUSAN HB. The role of collagen quaternary
structure in the platelet: collagen interaction. J Clin
Invest 1974; 54: 1480-148'7.
BRENNER S. The molenular evolution of genes and proteins:
a tale of two serines. Nature 1988; ~34: 528-530.
BROOKS WS, GALAMBOS JT. Endoscopic sclerosis of
esophag~al varices: evaluation of sclerosing agents. Am J
Castroenterol 1982; 77: A681.
The Vein.:s of th. C•• OphtHJUS .. Thorax 19511 6:
BRYAN CPo The Papyrutl Ebers.
1931. P 134-135.
BUR.CEtARTH F f SORENSEN TI, ~..NDERSON B. :tindings in
percutaneous transhepatic porotoqraphy and variceal
bleedinq in clrrhosia$
881-890.
Burg Gynecol ObBtat 19801 150:
276-2!~6.
of the sclerosant lJodiwn morrhuate in dO<;Js.
Obstet 19851 161: 327-331.
surqGyneool
follO'\ring endosoo'Pic in j$ction solerotherapyl' of $sophaqe6t.l.
varices. Arch Intern Med 1983; 143: 1350-1352.
The hemodynamio effects
CANOSO R~, RODVIEN R, seaON K, LEVINE PH.
peroxide and platelet funotion.
CAPRIN! JA I ZUCKERMAN L, eOHEN E f VAGHER JP 1 LIP]? V. The
id$ntif.ioation of acoelerated. coagulabilit.y.
1976, 9: 167-180.
Subcellular location of the oar~la$. and
ensym6s involved in Vit~in K metabolism.
19: 1161-1167.
Biocha 19S0;
SC);$l.·o'tl:'.ullrapyof esophageal varices ..
204-205.
C~st 1988; 93:
CELLO JP, GRENDELL JH, CRASS! RA, TRONKEY DO, COBBBE,
HEILB:RONDC. Endoscopic sclerotherapy versus portacaval
shunt in patients with s~vere cirrhosis and variceal
N Enql J Me4 1984; 311: 1589-1594.
CHARNG MJ Ii. WANG SP, Cl1ANG MS. cozc: ~ary spasm cQmplicating
\\
CliAliWIF, FEINMANRD, DETWIL~ TC. Interrelatic)n.$ Qf
platelet aq(Jregation and secretion. J Clin InvElst 1977;
60: 866...673
CHARa IF, SHAKS, KARASEKMA, DAVISONPM, GOLDSTEIN IM.
Prostaglandin I2 is !'J;Cct a major metabolite of arat,hidonic
acid in cultured Elndothelial cells from human forEuak.in
microvessels. J Clin Invest 1984; 74: 914-919.
CHA.UDHARGA, TATKEH, ,ARANYARC. Endosoopic Scle.t'otllerapy:
the far and near effects. Er J Burg 1990 ~ .77:.963 •
•
injection sclerotherapy of esophageal varices.
19881 ao: A36.
Endoscopy
Randomi.ed controlled
comparison of sodium.tetradeoyl versus ethanoluine for
~ AW, WESTABY D, SILK DBA, DAWSON JL, MAcootl'GALL BRD,
MITCHELL K..1, STRUNIN L, WII.LIAMS R. Prospective controlled
trial of injection solerotherapy in patients with oirrhosis
and recent varioeal haemorrhs.gbl$ Lancet 19801 2: 532-554.
COf!E'N LlBI KORSTD MAI SCHElL EJ. Bacteraemia after
endoscopic injection solerosis. Gastrointest Endosc
19831 198-200.
Hepatic blood flow
alooholio liver disease measured by an indicator dilution
'b3chnique. Am J Ked 1972; 53: 704-714.
COLLER BS. Biochemioal and electrostatic oonsideration in
primary platelet aggregation.
693-708.
Ann NY Acad Sci 1983: 416:
COLLER as I FOLTS JD I SCUDDER LE I SMITH SR.
Antithrombotio effect of a monoclonal antibody to the
platelet glycoprotein tlb/llla receptor in an experimental
animal model. Blood 19861 68: 783 786.
.~C""·~""'''_.__ ''''''_'''''I'''I'.\fJU'''''W" '''''''''' _'' ---.......,.-........"--.....,_.,.,,.,.......~_
A working model of platelet a99regation. In:COLMAN' RW.
Haemostasis and Thrombosis, Colman et al: 2nd edition,
19874 J.B. Lippincott, Philadelphia: p601.
CONN HO, BINDER H, BRODOFF M. Fibreoptic and conventional
esopbagoscopy in the diagnosis of esophageal varices.
Gastroenterology 19671 52: 810-818.
Copenhagen esophageal varices sclerotherapy project.
Sclerotherapy after first variceal haemorrhage in
cirrhosis. A Randomis~ Mult:icenter Trial. N Engl J Med
19841 311: 1594-1600.
CRA:,fOORD C, FRENKNER P. New surgical treatment of
varilPose veins of the oesophagus.
ii
if
27: \~22-429.
Acta otolaryngol 1939;
D'AJ.!{ICOG, MONTALBANO L, TRAINA H, PISA R, MENOSSI H, SPANO
C, PAGLIATO L. Natural history of congestive gastropathy
Gastroenterology 1990; 99: 1558-1564.in cirrhosis.
DACIE JV, LEWIS SM. IN: practical aaematology, Dacie and
Lewis: 7th edition,1991. Churhill Livingstone, Edinburgh.
p338-389
DE MIRANDA S. Alcoholism: The incidence, treatment
and rehabilitation - The South African perspective.
Rehabilitation in S.A. 1988; 83-87
". . . \ . i. \ !, . • • . . 1. 1 \" ~ •• >'"
ECKHAUSER FE, RAPER SE, MULHOLLAND )iN I KNOL JA. Current
DE PlttlY BG, l:UCHARDS WO, MILLIKAN WJ, Scintigraphic
detection of pulmonary emholi:lation of esophageal variceal
sclerosant. Endoscopy 1988; 20: 91-94.
UESAI It, BAGGET C, BELLAMY MF1 MISTRY P, BURROUGHS AK, OWEN
JS. Inhibi tion of platelet aq,~egation by abnormal high
density lipoprotein particles in plasma from patients with
hepatic cirrhosis. Lancet 1989; 693-695.
OOUF..LY FA, APPLETON CC, BEGG GW, SCHUTTE CHJ
3ilharzill transmission in Nl;ltal'sestuaries anc'\lagoons:
fact ol fiction. SA Journal of Science 1984; 80: 455-460.
DOOLl'i''fLE RF. Fibrinogen and fibrin.
1984; 53: 195-229.
Ann Rev Biochem
Gastroesophageal reflux and
bleeding esophageal varioes. Gastroenterology 19791 76:
concepts in the pathophysiology and treatment of portal
hypertension and variceal haemorrhage. Gastroenterol Jpn
1991: 26(3): 1-8.
EDLING JE, BACON BR. Pleuropulmonary complications of
variceal sclerotherapy. Chest 19911 99: 1252-1257.
ELEFTHERIADIS Eo Duodenal varices aft~r sclerotherapy for
esophageal varices. Am J Gastroenterol 1988; 83:
439=441.
EVANS DM, JONES DB, CLEARY BK I SMITH PM. Oesophageal
varices treated by sclerotherapy: a histopathological
study. Gut 1982; 23: 615-620.
FEGAl'fG. In~ Varicose veins - compression Sclerotherapy;
Fegan, first edition 1967. William Heinemann Medical Books
Ltd. p68-69.
FOLKMAN J. Angiogenesis 0 In: Thrombosis and Haemostasis1
Verstr.aete et aI, 1987. Leuven University Press, Belgium
p583-591.
FO~'CH PG, SIVAK MV Jr. Col~nic variceal hemorrhage after
endoscopic injection sclerosis of esophaqeal varices: A
report of three cases.
756-760.
Am J Gastroenterol 1984; 79:
FRANZ Re, COETZEE WJ. The thrOmboelastographic diagnosis
of haemostatic defects. Surgery Annual 1981; 13:75-107.
FRY RD, FISCHER KC I SUSMAN N I SHATZ BA I HULBERT B.
Adhesion-related variceal hemorrhage following sclerosis of
esophageal varices. Arch Sl.!rg1988; 123: 94-95.
adhesiveness of hUlllanblood platelets.
531-532 ..
Nature 19611 192:
GA.ARDER A, JONSmJ J, ~ S, ~ A, O~1lUnl PA ..
Adenosine diphospha'i:.ein red cells as e. factor in the
GAlAN! S, BOLONDI L, LX BASSI 8, ZIRONI G, SIRINGO S,
&~ L. Prevalenoe of spontaneous hepatofugal portal
flow in liver cirrhosis. Clinical and endoscopic
correlation in 228 patients.. Gastroenterology 19911 100:
l.60-167.
GARCIA-TSAO G I GROSZMAN RJ, FISHER SL I CONK HO, ATrERBURY
CE, GLICKMAN M. Portal pressure I presence of
gastroesophageal varices and variceal bleeding.
Hepatology 1985; !5: 419-424 ..
GEORGE IN, S3ATTIL SJ.
Med 1991; 324: 1671.
Platelet function. New En9l J
GARDNER EC, BROOKS WS~ Absence of disseminated
intra.vaacular coagulation with endoscopic sclerosis of
esophageal varices. Ga.strointest Enaosc 1982~ 28: 66-69 ..
GEBHARD RL, ANSEL JH, SILVIS SE. Origin of pain during
variceal sclerotherapy. Gastrointest Endosc :;.9821 131:
AZ8.
sclerotherapy for bleeding esophageal varices.
Gynecol Obstet 198~; 155: 523-528.
Burg
of the sclerosinq aqents sooium tetradeeyl sulfate and
sodium morrnuats in endoscopic injection sclerosis of
esophageal varices. Gastrointest Endosc 1982: 22: A147-
148.
GILBERT A, VILLARET M. Contribution a l'etude du syndrome
d'hypertension portale: cytologie des liquides d'asite dans
leljl,cirrhoses. Comptes Rand Soc BioI 1906; 60: 820-823
GrNSBDG !m, LOFTES JC, PI.oW EF. Cytoadhesins, inteqrins
and platelets. Thromb Haemost 1988; 59: 1-6.
GOLDE DW. Prod.uction, d.istribtftion, and fate of
neutrophils. In: Raematology; williams WJ at al., 4th
edition, 1990.. McGraw Hill, New York. p799-800.
GOGSTAD 00, mROSSTAD F, KRUTNEB MB, HAGEN I, $OLUM NO.
Fibrinogen binding properties 0: the human platelet
glycoprotein lIb-IlIa complex. Blood 19821 60: 661-671.
GOODALE RL, SILVIS SE, O'LEA..-q_yJF. Early survival after
,
I
GOTTFRIEND EB I GOLDBERG HJ Mucosal bridge of the distal
esophagus after esophageal variceal sclerotherapy.
Gastrointest Endosc 1985; 31: 261-269.
't,;RABOWS1CI EF I JAFFE EA I WEKSLER BB. trostacyclin
production by cultured endothelial cell mono layers exposed
to step increases in shear stress. J Lab Clin Ked 1985;
105: 36-43.
GREENQUIST AC I WEINBERG RWI roo AL, COLMAN RW.
Immunochemical studies of factor V. Eur J Biochem 1975;
58: 213-222.
GROBE JL I KOZERAK RA, SANOWSKI RA, LE GRAND J, KOVAR A.
Venography during endoscopic injection sclerotherapy of
esolihageal varices. Endosc 1984; 30: 6-8.
HAMMONDB, FAIRMAN RR, MONROE P, GLAUSER FL, SUG~ H,
DAVIS D. The pulmonary hyperte~sion of sclerosing agents
is prevented by cyclooxygenase inhibitors.
1985; 290: 93-101.
Am J Med 5ci
HARRIS 00, DICKEY JO, STEPHENSON PM. Simple endoscopic
injection sclerotherapy of oesophageal varices. Aust NZ J
Med 1982; 12: 131-135.
HARTERT H. Blutgerinnungstudien mit der
Thrombelastographie, einem neuen Unterauchungsverfahren.
Klin Wochenschr 1948; 16:(37) 257
I
:
cirrhosis and portal hypartension. In: Textbook of
HAWIGER J. Adhesive interaction of blood cells and the
vesse2 wall. In: Hemostasis and Thrombosis, Colman at a1;
2nd edition, 1987. J.B. Lippincott, Philadelphia;
ple2-203.
HAYl!~S WC I S1WOWSKI RA I FOUTCH PG, BELLAPRAVALU S.
Esophageal strictllreS following endoscopic varj~@al
sclerotherapy: Clinical course and response to dilation
therapy. Gastrointest Endose 1986; 32: 202-205.
HENDERSON JM f WARREN WD. Surgical complications of
Surgery, The biological basis of modern surgioal practipe,
Sabistonl 13th edition, 1986.. WE Saunders Co,
Philadelphia; p1095-1114.
human blood platelets.
1473-1482
Tbrombos Haemostas 1979; 42:
HEYNS A du P, BADENHORST PN I PIETERS H I LOTTER MG, MINNAAR
PC 1 DtTYEl-lEDE WIT LJ, VAN REENEN OR, RETIEF FP.
Preparation of a viable population of l11-Indium-Iabelled
HEYNS A du P, LOTTER MG I BADENHORST PN, VAN REENEN OR I
PIETERS H, MINNAAR PC I RETIEF FP. Kinetics, distribution
and sites of d(:!structionof 111-Im~ium-labelled human blood
platelets. Br J Haematc:1 1980: 44: 269-280.
HIRSH J. Heparin. New Eng1 J Mad 1991: 324: 1565-1574~
HOBas UF. Portal hypertension an~ the non-alcoholic
liver. In: Surgery of the Liver and Biliary Tract.
Blumgart Vol 2, 1986.
p1.411-1412.
Churchil~ Livingstone, Edirmurgh,
HOEFS JL, JCMAS GM, SARFEH IJ. Diagnosis end hemodynamic
assessment of portal hypertension. Burg Clin North Am
1990; 70: 267-289.
HOLMSEN H, WEISS HJ. Seoretable storage p~~';"t= in
platelets. Ann Rev Med 1979; 30: 119-'134.
HOSKING SW, ROBINSON P, JOHNSON AG. USEsfulness of
manometric assessment of varices in maintenance
sclerotherapy: A controlled trial. Gastroenterology 1987;
93: 846-851.
HOWARD MA, FIRKIN BG. Ristooe'tin - 1:1. new tool in the I
investigati.on of platelet aggregation.
\
Throm Diath
Haemorrh 1971~ 26: 362-369.
HULTIN ME, NENERSON Y. Activation of Factor X by Factor5
IXa and VIII: A spe "'i:fie assay fo~ Factor IXa in the
presence of throm'bin--activated Factor VIII. Blood 1978;
52: 928-940.
HUNTER GC, STEINKIRC'fINERT, BURBIGE EJ, GUERNSEY JM I PUTMAN
\
,I
I
( I
cwo Venous complica~~ons of sclerotherapy for ::>phageal
varices. Am J Burg 1988; 157: 497-501.
I
\
I
------------------------------------------------------------,~
HUR:LE'l'-JENSENA, CUMMINSHZ, NOSSELHL, LIU CY. Fibrin
pol:V'lllerisation and release of fibrinopeptide 13 by
Thromb Res 1982; 27: 419-427.
INC1SMAN S I CABNJ I BERNARD J. Aqqregation, adhesion and
vi8c:ous metamorphosis of platelets in congenital fibrinogen
defi.c7,encies. J Lab Clin MEld1966; 68: 21-32.
INFANTE-RIVARDC, ESNADAS, VIIJ~ENEtJVEJ-P. Role of
endoscopic variceal sclerotherapy in ~l. lonq term
management of variceal bl.edinq~ a meta analysis.
Gastroenterology 19891 96: 1087-1092.
"CSAACSONC. The changing patterl1 of liver dis.astil in 5.A.
Blacks. S A Mad J 1978; 33: 365-368
ISHII 1<, KARUBEH, Jro..TITA Y, SHIBATAH, OKUDAI'RAM,
TSUCHIYAM. Is macronodt!lar liver oi:r:rhosis an
irrEtv'qrsible lesion? Cha.nges in the intrahepatic
microv~Bculatur~ treated with estradiol benzoate in rats.
Anqiology 1990; 41(7): 5:~2-517.
ITTYERAHTR, RAWALARI COLMANRW. Immunochemical studies
of factor V of bovine platelats. Eur J Biocham 19ts11 120:
235-~!41.
II- ••
JACOBSON BF, LAAGE NJ, CILLIERS K, LOP~S RMC, FRANZ Re.
Effect of sclerosing agents on blood cOdqulation. S A
Journal of Surg 1984; 22: 182-183.
JAFFE EA. Cell Biology of Endothelial Cells. Hllman
Pathology 1987: 18: 234-239.
JAFFE EA, NACHMAN RL, BECKER CG, MINICK CR. CUlture of
human endc)thelial cells der1ved from umbilical veins:
Identific2ltion by morphologic and immunologic criteria. J
Clin Invest 1973: f'2:2745-2756.
JEFFERSON JR, HARMON JT, JAMIESON GA. IdentificatiQn of
high-affinity and low-affinity platelet binding sites for
ADP and competition by ADP analogues.
110-116.
Blood 19887 71:
JENKING SA, SHIELDS R, JASER N, EI,'LENEOGEN S, MAKIN C,
NAYLOR E, NOWSTEAD H, BAXTER IN. Thd management of
gastrointestinal haemorrhage by s~,~ato~tatin after
apparently successful endosco~ic injedtion sclerotherapy
~or bleeding oesophageal varices. J ,Hepatol 1991; 12:
296-301 •
•
JENSEN DM, SILPA ML, TAPIA JI; BEILIN DB, MACHICADO GA.
comparison of different methods fer endoscopic hemostasis
of bleeding canine esophageal varices. Gastroenterology(.
1983; 84: 1455-14b1~
JOHNSEN ULl[, LYGERGT, G.ALllAL KS, Parol H. Platelets
stimulate thromtx)plastin synthesis in h'~ln endothelial
cells. Thromb}i1t.DlO~t 1983; 49: 69-72.
JOHNS'.L'ONGW, RODGfltms HW. A review of 15 YEtarSexperie.nce in
the use of scleroi~erapy Ln the control ot' acute
haemorrhaqe from c>esophageal varicel!:. Br J Surg 1973; 60:
797.
JOIST JH. Hemos'll:.aticabnormalities in liver disease.
In: HemostasiA attl1Thro.m.bosis, Colman at aI, 2nd edition,
1987. J.B. Lipp;lncott company, Philadelphia.
..:-I.CONOJV. Thrombosed .Prima~y Cervicu!lI.lEIJophageal VariCEUlJ
cau,sing acute respiratory distretlus.
1987; 82: 72-73.
Am J Gastroenterol
KALEBIC T, GARBISA S, GLASER B, L:rOTTA, LA. Basement
membranecollagen: degradat.i.on by migratirlg endothelial
cells. Science 19831 221: 281-283.
KANG JH, KAMBAYASHI J, SARON M, SHIOZAKI H, OGAWA Y, OSHIRO
T, MORl T. Mechan.i..mof the haamostatic effect of
ethanolamine oleate in the injection sclerotherapy .Lor
oesophageal varices. Br J Surg 1987; 74: 50-53.
" ;: \ . ""- . ." .-
J. .. I
•KANT JA, FO:i<NACB AJ Jr I SAXB D, SIMON HI I MCBRI10E OWf
CRABTREE GR. Evolution and organisation of the! fibrinogen
locus on chromosome 4: Gleneduplication accompunied by
transposi tion and inversic)n.
82: 2344-2348.
Proc Natl Acad 3(:iUSA 1985;
KATAYAMA K, ERICSSON LH I :ENFIELD DL, WALSH KA, NEURATH H,
DAVIE BW, TITANI K. compa,rison of amino acid seq-.lenceof
bovine coagulation Factor IX (Christmas Factor) with that
of other vitamin K-dependent plasma proteins.
Acad Sci USA 1979; 76: 4990-4994.
Proc Natl
KEANB RM, BRI1.t'TONDC. Massive bleeding from rectal
varices following repeated i~jection sclerotherapy of
()Gsoph&qeal varices. Br ,J Surg 1986; 73 (2): 120.
KEPPEL G, SAAFLEY WH. In't:roductionto Design and
Analysis: A Student I s Hanlibook. K H Freeman and Co, San
Francisco 1980. p174
KEW MC I SONG E I DUSHEIKO GJ.!~. Hepatocellular carcinoma in
White South Africans - aetiological considerations. S A
Med J 1984; 66: 835-837
KIM MHt NBUBIG RR. Memb~an$ reconstitution of high
affinity alpha2 adrenergic agonist binding with guanine
nucleotide requlatory proteins. Biochem 19871 26:
3664-3672.
KINLOUGH-RA.THBONE RL j' PACKHA._JIMA, MUSTARD JF. V~ssal
injury, platelet adherence and platelet survival.
Arteriosclerosis 1983: 3: 529-546.
KITANO S, KOYANAGI Nt ISO Y, ISANAGA T, HIGASHI H,
SUGlMACHI K. Prospective randomiz~d trial comparing two
lnje::::tiontechniques for sclerosing oesophageal varices:
over-tube and free-hand. Br a surg 1987; 74: 603-606.
KITANO S, TERBLANCHE J, KAHN D, BOFNMAN rc, Venous
Anatomy of the Lower Oesophagus in Portal Hypertension:
Practical Implications. Br J Surg 19P~~ ,3: 525-G31.
KITANO S, KOYANAGI !if, ISO Y, HIGASHI' H, SUGIMJl.<;:S!K.
Prevention of rec:::urrenceof esoph,a.gealvar:t("'.l(~$1$.fter
endoscopic injection sclerotherapy with ethanolamine
oleate. Hepatology 1987: 7: 8110-815.
KITANO S, ISO Y I YAMAGA H, HASHIZtlME M, HIGASRE H,
SUGlMACHI K. Trial of Sclerosingr 8.gents in ,Patients with
oesophageal varices.. Br J surg 1988; 75: 75l-753.
KJAERGAARD J r FISHER A, MISKOWIAK J'. Sclero'f,nerapy of
bleeding esophageal va ...-ices. Long-term results. Scand J
Gastroenterol 1982; 17: 363-367.
KNAWER CM, FOGEL MR. Pericarditis: complication of
esophageal sclerotherapy. Gastroenterology 1987; 93:
287·"290.
KOCHLAR R, GOElUA MK, MEHTA S, MEHTA SX. A oomparative
evaluation of solerosants for oesophageal varioes: a
prospective randomized oontrol study. Gastrointest Endoso
1990~ 36: 127-130.
KORNEc:KI B f NIEWIAROWSKI S, MORINELLI TA, n.,oCZEWIAK M.
Effects of chymotrypsin and adenosine diphosphate on the
exposure of fibrinoqen reoepto~s on normal and Glanzmann's
thrombasthenio platelets. J BioI Cham 1981; 256:
5696-5701.
KORULA J. Pseudotumour of the esophagus: an unusue I
oomplioation of esophageal variceal sclQrotherapy.
Gastroenterol 19S5; 80: 954-956.
AmJ
KORUL.A J t BALART LA ( RADVAN G, ZWEIBAN BE, LARSON AW, no
A prospective randomized controlled trial
of chronic esophageal ,(aricea.lsclerotherapy. Hepatology
1985; 5: 584-587.
KORULA J, BAYDUR A, SASSOON C, KARIMURA Iw Acute and
chronic assessment of lung function in\patientr.undergoing
'l)
variceal sclerotherapy: a controlled ~~respective study.
Gastroint:estEndosc 1989: 30: A134-135.
KONICKI TJ I NUGENT DJ, STAATS SJ, ORCHlttOWSKI RP, WAYN'ER
EA, CARTER WG. The human fibroblast class II 6fxtra-
cellular matrix reoeptor (ECMRzII) mediates platelet
adhesion to collagen and is identical to the platelet
glycoprotein Ia-IIa complex. J Biol Cham 1988; 263:
4516-4519.
LANDERMAN' NS, WEBSTER.M, BECKER IL, RATCLIFFE HE.
HerCitditaryangioneurotic edema. J Allergy Clin Immunol
1962, 33: 330.
LANGE S, LAUGHLIN 13,HUGHES RW. Septic complications of
variceal hemorrhage and ethanolamine sclerotherapy of
varices. Gastrointest Endosc 1983; 29: A191.
LARSON GM. Injection sclerotherapy for esophageal
varices; An update. Surg Annu 19861 LS: 356-373.
LE13REC D, PE FLEURY P, RUEFF F, NAHUM H, BENHAMOU JP.
Portal hypertension, sizt!)of esopl}ag<:4. varices, and risk
of gastrointest.inal bleeding in alooholic cirrhosin.
!Gastroent&rology 1980; 79: \;\1139-;;:144.
LECHNER K, NIESSESNER H, THALER E~ Coagulation
abnormalities in liver disease. Semin Thromb Hemost 1977;
4: 478-485.
LIEBOWITZ HR. Pathogenesis of Esophageal varix rupture.
JAM A 1961; 175: 874-879.
•LINDQUIST PA, FUJIKAWA K, DAVIE EW. Activation of bovine
factor IX (Christmas factor) by factor XIa (activated
plasma thromboplastin antecedent) and a protease from
Russell's Viper Venom. J Biol Chem 1978; 253: 1902""~"09.
LITTLE D, SAID JW, SIEGEL RJ, FEALY H, FISHBEIN MC.
Endothelial Cell Markers in Vascular Neoplasms: An Immuno-
histochemical study comparing Factor VIII-related Antigen,
Blood Group Specific Antigens, 6-Keto-PGF1 alpha and Ulex
Europaeus I Lectin. J Pathol 1986; 149~ 89-95.
LOLLAR P I OWEN WG. Clearance of thrombin from circulation
in rabbits by high-affinity binding sites on endothelium.
J Clin Invest 1980, 66: 1222-1230.
MACBETH R. Treatment cd oesophageal varices Ln portal
hypertension by means of sclerosing injections. Br Med J
19551 2: 877-880.
MACDONALD PS I READ MA, DUSTING GJ. Synergistic inhibition
of platelet aggregation by '-.udot.helium-derivedrelaxing
factor and prostacyclin.
449.
Thromll Haemost 1988; 49: 437-
MACDOUGALL BRn, WESTABY D, THEODOSSI A, DAWSON JL I
WILLIAMS R. Increased Long-Term survival in Variceal
Haemorrhage using Injection Sclerotherapy. Results of a
cortrolled trial. Lancet 1982; 124-127.
M.AC:tDtJ1i' J, DB LACL08 ISI iBORGliAT P. stimulation of
leukotrien$. :biosyntlleed.s in hUlllanblood leukooytaa by
1,\
'\
platelet-der:i.-qed 12-hydroperoxy-icosatetraenoic acid.
Proc Natl Acad Sci USA19821 79:' 6042-6046.
Pathophysiology of Portal
Hypertension and variceal bleeding. Surg Clin North Am
1990, 70 (2): 251-265.
Ethanolamine oleate and renal
failure. NJ MEtd J 19'15~22: 269-270
MAmf KG, JENNY ltJ, KRlSHNASWAMY S. Cofactor proteins in
the assembly and expression of blood clotting enzyme
com.plexes, Ann Rev Bioooem. 1988; 57: 915-956.
MANN NS. Injectiol'lsclerosis of esophageal varices is
withoutr'/ '.''d physiological basis. Gas'trointest :Q'\dosc
MARCHAL G, LE ROUX ME r SA:MAMA. M. Atlas de 1a
Thrombod~lamographic Paris, service de Presse Edition
Information, 1961.
MARGUERIE GA, ARADILLOU N, ClmREL G, PLOW EF. The binding
of fibrinogen to its platelet receptor. J BioI Cham 1982;
257: 11872-11875.
MARUYAMA I, SALEM HH I MAJERUS PW. Coagulation factor Va
binds to human umbilical vein endothelial cells and
acceleratt-s Protein C ,.lbtivation. J Clin Invest 1984; 74:
224-230.
MAISSONNEUVE P, SULTAN Y. Modification of factor VI!I
complex properties in patients w~th liver disease.
J Clin PaThol 1977; 30: 221-227.
MAZER N, HENlF'QUE BARBIERI C, PINTO GONCALVES RP. Effect
of dif.ferent irrigating solutions on the endothelium of
small arteries: experimental stUdy in rats.
1986; 7: 9-28.
Microsurgery
MCCORD JM. Oxygen-derived free radicals in ~ostischemic
tissue injury. N Engl J Med 1985; 312: 159-163.
MCCLA'ifESA, KAISER SC, WRIGHT RA, EDWARDS JL, KRANZ 1m.
Prospective randomized comparison of esophageal variceal
sclerotherapy agents: sodium tetradecyl sulfate versus
sodium morrhuate. Gastrointest Endosc 1990; 36: 567-571.
MCCORMACK T I SMALLWOOD RH I MARTIN T, ROBINSON P, JOHNSON
AG. Doppler ultrasound probe for assessment of blood-flow
in oesophageal varices. Lancet 1983; (ii) 6;7-678.
MCCORMACK T, SMITH PM I ROSE JJ I JOHNSON .AG. perfora'ting
veins and blood flow in oesophageal varices. Lancet 19831
(ii) 1442-1444.
MCINDOE AB. Vascular lesions of portal cirrhosis. Arch
Path 1928; 5: 23.
MCINTYRE TM, ZIMMERMAN GA, SATCH K, PRESCOTT SM. Cultured
endothelial cell~ synthesize both platelet-activating
factor and prostacyclin in response to histamine,
bradykinin and adenosine triphosphate. J Clin Invest
1985; 76: 271-280.
MEYERS WC. Anatomy and physiology of.the liver.
In: Textbook of Surgery, The biologioal basis of modern
surgical practice, Sabist.on1 13th edition, 1986. WB
Saunders Co, Philadelphia.; p1053-1065.
MIYOSHI H, OHSHIBA S, MATSUMOTO A, TAKADA K, UMEYAK E,
HIRATA I. Haptoglobin prevents renal dysfunction
associated with intravariceal infusion of ethanolamine
oleate. Am J Gastroanterol 1991; 86: 1638-41
MOERSCH HJ. The treatmeltltof esophageal varices by
injection of a sclerosing solution.
10: 300-309.
J Thorac surg 1940;
MONCADA S, PALMER RMJ, lfIQGS EA. Prostaglandin and
endothelium derived relaxing factor~ biological
interactions and significance. In: Thrombosis and
Haemostasis; verstraete et aI, 1987. Leuven University
Press, Belgium. p597-613.
, ,
MONROE P, MORROW ell' Jr, KILLEN JE, FAIRMAN RP, GLAUSIR
FL.. Acute rel.6piratory failure after Sodium Morrhuate
esophageal sclerotherapy. Gastroenterology 1983: 85:
693-699.
MOORE MAS. Clinical implication of positive and neqative
hematopoeitic stem cell regulators. Blood 1991; 78:
1-19
MUSSO R, LONGO A, TRIOLO '!':.", Polidocanol may directly
activate the contact phase of blood coagulation during
scl.l.llrotherapy. Gastrointest Endosc 1987; 33: 400-401.
NESHEIM ME, TASWELL JB, MANN KG. The contribution of
bovine factor V and factor Va to the activity of
prothrombinase. J BioI Chem 1979; 254: 10952-10962.
NEWMAN KD, WILLIAMS LT, BISHOPRIC Nat LEFKOWITZ RJ.
Identification of alpha adrenergic receptors on human
platelets by dihydroergocryptin~ Dinding.
1978; 61: 395-40~4
J Clin Invest
NG wn, CHAN YT. Digital gangrene aOJltplicating
intraoperative injection sclerotherapy.
Endosc 1988; 34: 151-153.
Gastrointest
NIEWIAROWSKI S, BUDZYNSKI AZ, LIPINSKI B. Significance of
1;he intact polypeptide chait;lsof hUll\anfibrinogen in
~DP-induced platelet aggregations.
635-644.
Blood 19771 49:
O'BRIEN JR, SCHOOBR!DGE SK, F!1'(\\~ W.1. compa~ison of the
effect of heparin and cf.erat.eon platelet 8ggrega'tion. J
Clin Pathol 19691 22: 28-31.
OLSS01'1'R. ThEl natural hist.)ry of esophageal var Lces ,
Digest.i:m 1972; 6: 65-74.
ORDONEZ NG, BATSAKIS JG. Comparison of Ulex eu~opaeus ~
Lectin and Factor VIII-related Antigen in Vascular
Lesi'=lns. Arch Pathol Lab Med 1984; 108: 129-132.
ORLOF~' MJ, THOMAS HS. Pathogenesis of esophageal varix
rupture. A study based on gross and microscopic
examinatio:n of the esophagus at the time of bleeding.
Arch Surg 1963; 87: 301-307.
OWEN WG. Protein C. In: Haemostasis and Thrombosis,
Colman et ali 2nd edition, 1987. J.B. Lippincott,
Philadelphia; p235-240.
PACQUET KJ, FEUSSNER H. Endoscopic sclerosis and
esophageal balloon temponade in acute hemorrhage from
esophagastric varices: A prospective controlled ra:1domized
trial. Hepatology 1985; 5: 580-583.
243
PACQUET KJ < Endoscopic paravf!ric1l:lalinjection
scls't'otherapY'4l!·tbe esophagus - ind.ications, technique,
compI:icatid !:>ttultso;f a period. of 14 years.
Gestl"~)intest End.osc 1983~ 29: 310.
PALMER HD, BRICK lB. Correlation between the severity of
esophageal varices in portal cirrhosis and their propen$ity
toward h~morrhage. Gastroenterology 1956; 3n: 85-90.
P.AL.Joh...~RM, FERRIGE AG, MONCADA S. Nitric oxide release
accounts for the biological activity of endothelium-deri~ed
relaxing factor. Natwre 19[;17;327: 524-526.
PATTY L. Evolution of blood ooagulation and fibrinolysis.
Blood Coagulation and Fibrinolysis ~990; 1: 153.
PEARSON JD. GORDON JL. VdRcular endothelial and smooth
muscle cells in culture selectively relea~e adenine
nucleotides. Nature 1979; 281: 384-386.
PERAKAS PG. CIRBUS JJ, CAMARA DS. Persistant
bradyarrythmia after sclerotherapy for esophageal
varices. south Med J 1984; 77:\ 531-532.
PERINO LE, GHOLSON CF, GOFF JS. Esophageal perforation
after fiberoptic variceal sclerotherapy. J Clin
Gastroenterol 1987; 9: 286-289.
PFTHlCA SA. structure and physical chemistry of
membranem. Protoplasma 1967; 63: 147-156
PIERSCHBACHlm ,K;., RUOSLAHTI E.
ifC~ll attachment activity
of fibronectin can be duplicated by small synthetic
fragments ~f the molecule. Nature .1904; 309: 30-33,
PIPFR P, VANE Jo The release of prostaglandins from lung
and other tissues. .~n NY Acad Sci 19711 160: 363-385.
POLIO J I GR')SZMAN RJ. Haemadynamic factors involv~d in
the development and rupture of esophage~1 varices: A
phyaiological app.:oachto treatmEm't.
1986; 6: 318-331.
Semin Liver Dis
POWER w. contributions to P~tholo9Y. Md Med Surq J 18401
306-318.
PREBLE Ra. Conclue.Ions based on sixty callEUSof fa'·!al
gastrointestinal hemorrhage due to cir~hosis of the
liver. Am J Med sci 1900: 119: 263-280.
PROCHOWNIK EV, Al'l"l'ONARKISS, BAUER KA, ROS:=:NBERGRD, FEARON
• ER, ORKIN SH. Molecular heteroqeneity of inheriteu
antithrombin III deficiency.
1549-1552 •
N Enql J !oted 3.983; 308:
•
RAi~or' aD, BUSIE rJ, SHEON RP. The demise of John
Hageman N Engl J Mad 1968; 279: 760-761.
REILLY JJI SCHADE RR, VAN THIEL OS. E.sophageal Function
after Injection Sclerotherapy: pathogenesis of Esophageal
Stricture. Am J Burg 19841 147: 85-88.
ROARK G. Treatment of postBele~~therapy esophageal ulcers
with sueraltate. Gastrointest Endesc 1984: 30: 9-10.
ROTH GJ. Developing relationships: Arterial Platelet
adhesion, Glycoprotein Ib and Leucine-rich Glycoprotein.
Blood 1991; 71': 5-19.
ROSE JO, CRANE MD, SMITH PM. Factors affecting sucoessful
Emdoscot.-;,csclerotherapy fOl' oesophageal varices. Aust NZ
J Med 1982: 12: 131-135.
ROSENBERG lIDI OAMUS PS. The purification and mechanism ot
action of human antithrombin-heparin cofactor.
Cham 19731 248: 6490-6505.
J aiol
ROSS R, RAINES !W, BOWEN-POPE Dr. The biology of
platelet-derived growth factor. Cell 1986; 46: 155-169.
RUGGERI SM. Cl.assificatio::1of von willebrand Dis6IaIB8.
In: Thrombosis and Haemostasisl verstraete et ~l¥ 1987.
Leuven university Press, Belgium. p421.
SAGE H, PRITZL P, VORNSTEIN P. Endothelial cells secrete
a novel collagen type in vitro independently of prolyl
hydroxylation. ColI Rolat Res 1982, 2: 465-4794
SANOWSKI RA, KOZAREK RA, BRAYKO C, SARLES H. Esophageal
variceal sclerotherapy (EVS): cotrrse and complication.
Gastroint$st Endosc 1983; 29: A193.
SARIN SK, NANDA R, VIS JC. Oesophageal ulceration after
sclerothertlPY = A complication or an accOlnpaniment?
Endoscopy 1986; 18: 44-48.
SARIN SK, HANDA R, SACHDEV G I CHARI S I ANAND BS, EROOR
SL. !ntravariceal versus paravariceal sclerotherapy: A
prospective, oontrolled, randomised trial. Gut i.ge7~ 28:
657-662.
SARIN S, SACHDEV G, NANDA R. Follow-up of patients after
variceal eradication. Ann Surg 1986; 204: 78-82 •
•
SARLES HE, SANOWSKI RAt BELLAPRALU S. MoniU.a esophagitis
associated with esophageal variceal sclerotherapy.
Gastrointest Endosc 1984~ 30: A152 ••
varices. Endoscopy 198$, 171 170-172.
SAmmBRUCH ~f WEINZIERL H, KOPCKE W, PAUMGARTNER G.
term sclerotherapy of bleedinq esophageal varices in
patients with liver cirrhosis: An evaluation of mortality
Long-
and rebleedinq risk factors. Scand J Gastroenterol 1985,
j
20: 51-58.
SCHERL' EJ, FABRY TL. Pseudadivertioula secondary to
injection sclerotherapy.
401-403.
J Clin Gastroenteral 1983; 5:
SHIELDS R. Bleedinq oesophageal varices and the
Br J Surg 1991; 78:513-515.sur<Jeon.
SCHWARTZ ML, PIZ!O SV, HILL RL. ;The effect of fibrin-
b~abilisinq factor on the subunit structure of human
fibrin. J Clin Invest 19711 50: 1506-1513.
.. 248
SCO'l'TCF, COLMAN RW. Function and immunochemistry of
prekalllkrein high molecular. kininogen complex in pla.sma.
//
J Clir.tInvest 19801 65: 413"'421.
SEIDMAN E, WEBER AM, MORIN ~L.. ETHEIR R, LAMARCHE JF,
GUERGUIERIAN AJ, GEOFFREY G, ROY CC. Spinal corn
paralysis following sclerotherapy for esophageal varices.
Hepatology 1984J 4: 950-954.
SHERLOCK S. Disease of the liver and biliary systemo
8th edition, 1989. Blackwell Scientific Publications,
Oxford. p174
SHERLOCK S~ Disease of the liver and biliary system.
8th edition, 1989. Bl~ckwell Scient.ific Punlications,
Oxford. p176
SIRDLER E, GROSZMANN RJ. Interaction of flow and
res~stance in maintenance of portal hypertension in the rat
model. Am J Physiol 1986, 250: G205-G212.
SIGURDSSON GH, Vlt..LLGRENS I CHRISTENSON JT. Influence of
aspirin and steroids on acute lung injury after i.v.
injection of a sclerosing agent.
155: 1'53-170.
Acta Chir Scand 1989;••
• SILPA ML, JENSEN DM, MA~HlCADC GA, TAPIA JI, BEILIN DB •Efficacy and safety of agents for ~;ariceal soleroths:tclpy.
Gastrointest Endosc 1982; 28: A152-153.
SIVPll{ MV, BLUE MG.
Oesophag$sl Vario@s. In: TherapQutiC! Gastroinbastinal
I~ndosoopy, silvis; lnd editiofl, 1990. Iejaku-Shoin, New
York. p42-97.
SIVAK MJ I STOUT OJ 1 SKIPP!P_ G. EndOScopio inj.otion
sclerosis of esophageal varices. Gastrointest Endosc
1981, J7: 52-57.
SIXMA JJ, WESTER J.
19771 14: 265-299.
The Hemostatic Plug. Samin Hematol
SIXMA JJ. Platelet adhesion in health and disease.
Thrombosis and Haemostasis; Verstraete et al, 1987. Leuven
University PrQss, Belgium. p127-146.
SMITH-LAING G, CA:MILO ME, DICK R, SHERLOCK s,
Percutane~ls transhepatic portography in the assessment of
portal hypettension. clinica~ correlations and comparison
of radiographio techniques. Gastroenterology 1980, 78:
197-205.
SODERLUND C I IHRE T. Endoscnpic sclerotherapy 'lIB
conservative management of bleeding oesophageal varices.
A 5 year prospective corttroll~d trial of emergency and
long-term treatment. Acta Chir Scan 1985; 151: 449-456.
In:
aggretip'1tion o£ wasited b'Ul1liU1platelets indll.:l:o&dby .dena.ins
d.ipho~phate, thrombin, oollaqen Dna adr6naline.
Clin Lab Invest (suppl) 19651 17: 170-122.
&candJ
SORENSON TIA, BURCHARTH F, PEDERSEN ML I FINDAHL F.
Oesophageal stricture and dysphagia after endoscopic
sclerotherapy for bleeding varices. Gut 19841 25:
473-477.
SORIA, J I BOlUA C, RYCDWARRT JJ I SAMA.kA H, THOMSON JM,
POLLIa L. study of acquired dysfibrinogenaemia in liver
di••a8&. Thromb ReB 19801 19: 29-41.
SPRING~ WR, COOPER ON, BAROHDES SR. Discoidin I is
implioaud in cell-substratum attachment and ordered cell
miqration of Oictyostelium discoideulll.and resembl ••
fibronectin. Cell 19841 J9: !5!57-5~4.
STEIN .}3F,H.ARlOm LA. ,Kinet.ic and functional studies of
platelets, fibrinogctn, and plasminoq&n in patients 'With
hepatic cirrhosis. J t.,abclin Med 1982; 99: 21'/-229.
STEMERMAN'MB, ROSS R. EYperimental arteriosclerosis.
Fibrous plaque formation in prilnatesI an electron
microscope stUdy. J Exp Med 19727 136: 769-789.
Sodium morrhuate stimulates
granulocytes and damages erythrocytes and e.ndothelial
cells: Probable mechanism of an adverse reaction dus::h'g
sclerotherapy. J Lab Clin Med 19851 106: 498-504.
SUBRAMANYAM K, PATTERSON M. Chronic esophageal ulceration
after endoscopic sclerother~py. J Clin Gastroenterol
19861 8: 58-60.
TERBLANCHB J, NORTHOVER JMA, BORNMAN P, KAHN D I BARBEZAT
GO, SELLARS SL, S~ONDERS SJ. A prospective evaluation of
injection sclerCltherapy in the treatment of acut~bleeding
from oesophageal varices. Surgery 1979; 85: 23~"-245.
TERBLANCHE J I YAl{OOB m , uO:RNMAN PC. Acute blfiHBding
varices. A five yea~ prospective evaluation of tamponade
and sclerotherapy. Ann Burg 1981; 194: 521-530.
TERBLANCHE J, BORNMAN PC, KAHN D, CAMPBELL JA, JONKER MAT I
WRIGHT J, KIRSCH Rw Failure of repeated injection
sclerotherapy to improve long-term survival after
oesophageal variceal bleeding: A five year prospective
controlled clinical trial. Lancet 1983; 2: 1328-133~.
TERBLA:'f~HEJ. The long term management of pati~nts after
an oesophageal variceal bleed: The role of
sclerotherapv- B'!': ;,' Surg 1985~ 72: 88-90.
TERBLMlCME J f K.A:l!IN D, BORNM.Ur PC. LGn(J-term In jeotioll
Sclerotherapy Treatment for Esophageal Varioes~ Ann Burg
1989, 210 (6): 72~-731.
Tm<BLAN'CHE J, BmmOOGEI AK, HOBBS KEF. ControvC!;":'siesin
the Management of Bleeding Esophageal Varices (2 parts).
N Engl J Mad 19891 320: 1393-1398 & 1469~1475.
TERBLANCH~ J. Has sclerotherapy altered the management of
patients with variceal bleeding. Am J Surg 1990; 160:
37-42.
TERBLANCHE J, ~IGE JEJ, BORNMAN PC. Endoscopic
sclerotherapy. Burg Clin North Am 19901 70: 341-359.
THOMAS DP, REAM VJ, STUART R.K. Platelet aggregation in
patients with Laennec's cirrhosis of the liver.
J Mad 1967, 24: 1344-1348.
New Engl
TRANZER JP, DA PRADA H, PLETSCHER A. Ultrastructural
localization of S-hydroxy'tryptamine in platelets. Nature
1966; 212: 1574-1575.
TRANZE'.RJ~, BAUMGARTlUm. HR. p'illing gaps in the vascular
en~Qthelium with blood platelets.
1126-1128.
Nature 19671 216:
TRUDEAU W, BRIHOIVILLE T, GIBBERT V, YOUNG W, SIEPLER J.
An update on the safety of sclerosing agents u$ed :i.n
endoscopys Gastrointest Endosc 1983; 29: A168-169.
TSCHOPP TB, BAUMGARTNER HR. Pl&telet adhesion and mural
thrombus fonnation on aortic subendotheliwn of rats,
rabbits and guinea pigs correlate negatively with the
vascular PGI2 production. J Lab Clin Mad 1981, 98:
402-411.
TURITTO VT, WEISS HJ, ZIMMERMAN TS, SUSSMAN II c Factor
VIII/von Willebrand Factor in the subendothelium mediates
platelet adhesion. Blood 1985; 65: 823-831.
VALLA D, BERCOFF a, MENU Y, BATAILLE C, LEBREC D.
Di$crepancy between wedged hepatic venous pressure and
portal venous pressure after acute propranolol
administration in patients with alcoholic cirrhosis.
Gastroenterology 1984; 86: 1400-1403.
VALLGREN S, SIGURDSSON < t$H , MOBERGER G, CHRISTENSON JT.
Influence of intravenous injection of sclerosing agents on
the respiratory funct.ion. Acta Chir Scand 19881 154:
271-276.
VAN DER GRAAF F, KOEDAM JA, GRIFFIN Ja, BO~~ BN.
Interaction of human plasma kallikrein and its light chain
with Cl-inhibitor. Biochemistry 1983~ 22: 4860-4866.
VAN ORR GRAAF li', ltOm>AM JA, :B'OUHA BR.. tnaC'tivatinn af
kallikrein in bu1aen plal!\lDa... J Clin Invest 19.$3, 11:
149-158.
VAN HINSBURGH VWM, BER'l!tNA RM, VAN WIJNGAARDEN A, VAN
Activ~ted protein C
decreasu plasminogen activator-inhibitor aotivity in
endothelial c.ll-conditioned mediUl'll.
444-451.
Blood 1985; 65:
VE~ GA, KEYT 5, BATON D, RODRIGUEZ H; O'BRIEN DP,
OPPERMAN NH, DC!{ R, WOOD WI, HARKINS RN I TUDDElffiAM EGO,
LAWN RM, CAPON OJ. Structure of huaan faotor VIII.
Nature 1984, 312: 337-342.
Intravascular
coagulation in liver disedse.
447-455.
AnnU Rev Med 19741 251
VlUEL JP, CASSIGlfEUL J, LEVADE H, VOIGT JJ, PASCAl, JP.
Assessment of short-term prognosis after variceal bleeding
in patients with alcoholic cirrhosis by early measurement
of portohepatic gradient. Hepatology 1986, 6: 116-117.
VON RYLL GRYSKA P t HEDBERG SE. Injection thrombosclerosis
of esophageal varices. Surg Gynecol Obstet 1985; 161:
438-444.
ciroulatian in port.al"'h~"y;>ert6nsiverat. :model: A parimary
\:,1,
,\
factor for maintenanoe 01:\ ohronic portal hypertension.. Am
J Physiol 1ge3; 244: 52-57.
Ulcer problem. canad MGldAss J 19451
53: 3()~-331.
WEBB IJ, SHERLOCK S. The aetiolO9YI presentation and
natural history of extrahepatio portal venous
\\
obstruoti'6n. Q .1 Med 19791 4S: 627-639.
Platelet adhesion
Ml,d thrombus formation on subendothelium in platelets
deficient in i',IJlycoprotel..nslIb-IlIa, Ib and storage
granules. Blood 19861 67: 322-330.
WENCEL-DRAKIl JP, PAINTER Kef 2;J:MMlm.:MAN TS, GINSBURG MR"
Ultrastructural localisation of human platelet
thrombospontiin, fibrinogen, fibronraotin and von Willebrand
factor in frozen thin section. Blolpd 1985; 65: 929-938.
WESTABY ~'I" MACDOUGALL BRP, MELIA W. A prospective
randomised study of two sclerotherapy technique~ fo~'
esopbageal varices. He~tolo9Y 1983; 3: 681-684.
WRS'rABY 1), WII.,LIAMSa, If.jection sclerothet"apy f,or the
long term. manaqe'l'llGnt sf variO$al bl66dinq. world J Surg
1984; 8: 667.
WESTABY D,'MELIA WB, MACDOUGALL ,BRI), HEGBRTY Ji!: 1 WILLIAMS
R. Injection sclerotherapy for oesophageal varices; a
prospective randomised trial of different treatment
schedules. Gut 1984; 25: 129-132.
WRIGHT JR. 'J7llQ origin and nature of' blood platelets.
Boston Med Surg J 1906; 1f"4; 643.
Plasma prekallikrsin:
Isolation, chal'acterisation and :mechanism of activation.
J Exp Med 1972: 135: 1-20"
YAMAGA H, HASHIZmm H, KITANO S, HIGASHI H, SUGIMACBI K.
Platelet aqgreqability after endoscopic intravariceal
injection of 5% ethanolamine oleate into oesophageal
varices. Br J Burg 1989; 76(9): 939-942.
YANAGISAWA MI KURIHARA H, KIMURA S I TOMOBE Y, h.( ~ASHI M,
MITSUI Y, YAZAKI Y, GOTO K, MASAKI T. A novel potent
vasoconstrictor peptide produced by vascular endothelial
cells. Nature 1988; 332: 411-415.
ZUCKER HD. Platelet thrombosis in hUlaanhemost~sis : A
histoloqio study of skin wound in normal and purpurio
individuals.
',\
"ii
ZUCKER-FRAHila..IN D. The submembranous fibril$ of hn:man
blood platelets. J Cell BioI 1970; 47: 293-299.
ZU'CKER-l"RAKKLIN D. Platelet morphology and funotion. In:
IIe:ma.toloqy, Williams at ala 4th edit.ion, 1990. McGraw
)Hill" NeW York. p1173
APPENDIX ....
---,-~-----..._.
FACTOR XII (% OF CONT'ROt.)
STD 1 2 3 4 5 6 '"NEAT 100 100 100 100 100 100 100
10,u1 102 65 106 100 89 88 106
25",1 100 106 98 85 iOO 87 112
351'1 110 120 - 98 102 88 102~-
50",1 98 103 95 109 1(,,3 89 99_.
100J,£1 101 104 81 96 90 87 104-
150J,£1 103 82 72 80 93 68 92
200~1,1 83 68 63 86 69 60 75
1-:----
350",1 - - 48 68 49 48 53
DATA FROM FIGroRE4.4
25 ~1 9S.2857
35 ~1 103.3333
FACTOR Xl! <% OF CONTROL)...--- .......,~,...,...------...._-------.=------- ..
".
X VALUE 'I. J"""'..AN
!mAT --_ ......-- ! 1('~· ,'-------1-------+---------11
10 ~l --- ';-;3.7143
y TOTAL Y MlliDIUM
700 100
" 65~ 66
68S 85
620 SS
696 89
663 81
590 68
504 60
266 48
50 ~l 99.4286
100 ~1 94.7143
150 ~l 84.2857u--...;.---·;r---+-------il-------+--------tl
200 ~1 72
;
350 ~1 53.2--,----------------------------------------~----~
DATA FROM FIGURE 4.4
X VALttm y MAX SD (n-1j &:~ (n) SD N :','
nAT 100 0 0 0 7,
10 ~1 106 14.6596 13.5722 5.5408 .,
25 pl 112 9.6387 8.923'7 3.6431 7
35 ~l 120 10.8566 9.910'1 4.4322 6
50 1J1 109 6.4254 5~,9488 2.4286 7
lCO p.1 104 8.9762 fH3103 3.3927 7
1--'----"
150 #-£1 103 12.4193 1/1..4980", 4~6940 7
200 ",1 86 9.7980 9.0711 3.7033 7
350 ",1 68 8.5264 7.6263 3.8131 5
o
N = 9 TOTAL
X-DATA 102.2222 920
53.2Y-DATA 11.7735 198.9619
N .. 9 MAXIMUM so _(N-I) SD (N) SEM
X-DATA 350 114.7854 108.2207 38.2611
Y-DA'l'A 103.3333 16.4648 15.5231 5.4883
LINEAR REGRESSION OF Y ON X
Slope of line
Y-Interoept
X-Interoapt
XY Corrillation
(Corre.lation)2
.. -0.138086
102.8890
745.1098
-0.962676
0.926745
..
Trapezoidal
start-Rectangular
End-Rectangular
27563.09
29660
25466.19
DATA FROM FIGURE 4.4
---------- --·- =m "'I;I ~:.
FAC!'fOa XI ('OF ~)
STD 1 :I 3 4 5 6 "i
NEAT 100 100 100 100 100 100 100
~10~.l 100 94 105 ~4 92 93 105
25p1 99 IS 97 94 102 '6 94
3!S",1 107 ,. 94- 97 94- 94
5010'1 103 97 94 109 101 '1 96
10~1.1 114 93 81 93 104 91 102
3.501-'1 115 ,. 68 87 108 73 87
200)'l 108 59 67 79 94 70 82
3501'1 .. 46 44 70 49 S3
100~1 81
10~1 97.5714 683 9211--------+-----,-- ..1'--------1------- ....
25~1 97.1429 ~680 940--..;..:...-----+----..-. ..,,-_.~t--------+------"'...._ ...
35l"1 97.3333 •584 94..._..-:.. -+-....._. ----_ ..,'1-- -+- ....
50~1 91
NEAT 100 700 100
-150,.,.1 68
350~1 44
x V~ l' MAX SD (n-l) SD (n) SEM NO
NEAT 100 0 0 0 7
10p.1 105 5.6821 5.2606 2.1476 7
25~1 102 2.8536 2.6419 1.0785 7
35,.,.1 l.07 5.0465 4.6068 2.0602 0
501-'1 109 6.0749 5.6243 2.2961 7
100JJ.l 114 1046994 9.9057 4.0440 7
150JJ.1 115 17.5879 16.2832 6.6476 7
200JJ.1 108 16.8070 15.5603 6.3525 7
350JJ.l 70 10.4067 9.3081 4.6540 5
DATA FROM FIGURE 4.5
• == 9 Mt.\N TOTAL MINIMUM
X-~TA 102.2222 920 0
Y-])A'I'A 89.7540 807.87tS2 !S2.4
FACTOR XI (% OF ~L)
N lIIII 9 MAXIMOM SD (N-1) SD (N) SEM
X-DATA 350 114.7854 108.2207 38.2618
'i-DATA 100 15.4322 14.5496 5.1441
LINEAR REGRESSION OF ~ ON X
Slope of line
Y-Interoept
X-Interoept
XY .Correlation
(Correlation) 2
.AREA UNDER THE CURVE
= -0.129396
102.9912
795.9361
-0~962456
0.926322
-...
=
Trapezoidal ==Start.·Rectangular :or:
F.nJ-Rectangular -
28517.38
31052.14
25982.61
DATA FROM FIGtJRE 4.5
P'ACTOlit X (t Gl' CO~L)
STl) 1 a :3 4 5 6
NJU.L"t' 1.00 100 100 100 100 100
J.0l-'1 92 95 I 100 9€ 103 107
25p1 92 91 100 96 101 100
35",,1 88 94 .1 91 89 lOO~~-
501'1 88 s 84 103 89 90 98--100#1 08 71 94 89 84 100
1501'1 82 71 94 82 86 83
200",1 74 68 79 72 75 SO
350#1 - 17 14 32 20 13
DATA FROM FIGt1l?E 4. 6
580 91
FAC'l'OR X (% OF COlfl'ROL)
X VALUE T MEAN
NEAT 100
lOlll 91.8323
25p.l 96.6667
35l!_1 92.4000
50p.l 92
1001'1 8806667
1501>'1 83
200p.1 74.6667
350p.l 19.2000
Y 'i'O'l'AL Y JI:DiDlOM ,_
600 100'-~----------+-------------~--------------r--------------593 92
462 88---------4------,------~~----------~552 84
532 77
498 71
96 13
MAX
'I
X VALUl!I ''T SO (n-l) so (n) 8EM n-,
-, -.
NEAT 100 0 0 0 6- ......"10p.1 107 5.5648 5.0799 2.2718 6
25p.l 101 4.3665 3.9861 1.7826 6
35p.l 100 4.8270 4.3174 2.1587 5
50p.l 103 "7.0711 6.4550 2.8868 6
100p.l 100 7.9415 7.2495 3.2421 6
150111 94 7.4297 6.78~3 3.0332 6
200p.l 80 4.4572 4.0689 1.8196 6
350p.1 32 7.6616 6.8527 3.4264 5
DATA FROM lI'IGUR4 <4. 6
FACTOR X (% OF COl!fTROL)
It == 9 MEAN TOTAL KlND1Ul(
X-DATA 102.2222 920 0 i\
Y-OATA 92.8259 745.43:33 19.2 \1
N == 9 MAXIMUM SD (n-I) SO (n) SEM
X-DATA 350 114.7854 '.OS. ~207 38.261a-Y-DATA 100 25.1683 23.7289 8.3:'94
( I
I~NEAR REGRESSION OF Y ON X
Slopa of line
Y-Intercept
X-Int.:eroept
XY Correlation
(Correlation) 2
= -0.208631
104.1526
499.2197
-0.951505
0.905362
==
==
==
=
AREA UNDER THE CURVE
Trapezoidal
start-Rectangular
End-Rectangular
= 24578.75
29218.50
19939
=
==
DATA FROM FIGURE 4.6
•
FACTOR IX (% OF ~L)
ST!) 1 2 ":l 4 5 6..
,"
OAT 100 100 100 100 100 100
10#1 95 9 III 94 92 88 101-.-
25",1 ],08 91 94 llO 95 110...
351'1 92 94 100 91 101
50#1 113 90 108 108 ~6 104-
100Jj1 103 79 93 99 88 104
:.1.501-'186 71 87 102 80 91
2.00#1 58 66 79 01 70 66
350#1 39 .,,4 53 44 32
DATA FROM FIGURE 4.7
X VALt]E Y JmAN Y TOTAL Y mxIHDM~------------~------------~-NEAT 100 600 100
FACl'OR IX (% OJ' ~L)
101-'1 94.6667 568 88
251-'u1 101..3333 608 91
351-'1 9.!'$.. 600 418 91
1----. .........~--_f_------__1r__------_t_---------_tI
501-'1 103..1667 619 I' 90~~-----------f-~------------1r-----------,----~-------------t100Jjl 94.3333 566 79~--._-------.~~-~----------+--------------+------------~.
1501-'1 86.1667 517 71
~2_0_04p_1 -f-_7_0_ ~I,.~' +-4_2_0 -+_5_8_' ~
350p1 42.~00 212 32
X VAWE Y MAX SO (n-a) SD (n) SEM n
i,
NEAT 100 0 0 0 6
-:
101-'1 1:01 4.!'461 4.1500 1.8559 6
251-'1 ,I 110 8.8919 8.1172 3.6301 Ei-
351-'1 lQl, 'i 4.6152 4.1280 2.0640 5
50#'1 U3 .x: 8.5888 7.8404 3.5063 6-100.u1 104 9.6678 8.8255 3.9469 6
150#1 102 10.419r: 9.5117 4.2538 6
2001-'1 81 8.6948 7.9373 3.5496 6
3501-'1
,I,
53 7.7006 6.8877 3.4438 5
:-
DATA FROM FIGURE 4.7
. .' ~'. . ....' " . .
H - 9 1mAN TOTAL MIlf.tlWM~---+-------------+-----------~~-----------1102.2222 920.000 0.0000
87.5185 1<)7.6661 .2.4000
X-J».TA
~-DATA
k == 9 ..... MA.Xn1tJM SO {H-1) SO (N') / --....-I-S_EM_•._.-----I
~~,..DATA 350 '114.7854 108..2207 U.261~i;:-M-T-A-•..•--+-1-0-3-.-1-6-67----+-1-9-.-6-S-11.-.·- -+-1 ....S-.-S-5-5S--...........;f)·:56:;4
LINEAR~~SS!OM OF Y ON X
Slope of linflc
~/.Y-IntE£roept -
X-Intercept
XY Correlation
(Correlation) 2
= -0.164404
104.3294
634.3983
-0.959141
0.919952
=
==
==
Trapezoidal =
start-Rectangular ==
End-Reotangular ==
26702.91
295'50.66
23855.16
DATA FROM FIGURE 4.7
FACTOR VIlli (% OF COJl'rROL)
STD 1. :a 3 4 5 6 7
NEAT 100 100 100 100 100 100 100-
101'1 108 106 98 101 95 89 9".-~
25/.'1 90 100 92 104 101 95 93-
351'1 121 103 .~ 94 100 81 88
50J,£1 104 97 86 92 104 90 91
1001'1 107 89 78 88 95 80 93
1501'1 72 !, i 76 66 72 98 62 71
200p.l 50 46 59 62 ,76 58 65
U 3501'1 - I' - 38 38 49 42 49
DATA FROM FIGURE 4.8
99.1429 6~4
46 ------I,
38
. X VALUB
100 700 100
l0J.'L
675 90
98~8333 593 87
664 86
90 630 78
511'150 1 7) .8571 62
416
3501-'1 21643.100
x VAI.tl:B Y MAX SO (n-l n) srm n
NlU-!.' 100 0 0 0 7..
101'1 lOS 6.5174 6.0339 2.4.633 7
25J.'1 104 5.2554 4.8655 1.9863 7
."=':IIit£
35/.£1 121 12.5764 11.4807 5.1343 6
501'1 104 7.0339 6.5122 2.6586 7
100 1 107 9.7639 9.0396 3.6904 7
150",1 98 11.5820 10.7229 4.3776 7
200/.£1 76 9.1634 9~1317 3.7280 7
350JIl 49 5.5408 4.9558 2.4779 5
DATA FROM FIGURE 4.8
FACTOR VIII (ft OF COWROL)
X VAWE Y !mAN y TOTAL y MXlO:MOM
NEAT 100 700 100
10J.'L 99.1429 694 89-
251'1 96.4286 675 90 );
351'1 98.8333 593 87 ,I
50~1 94.8571 664 86
100~1 90 630 78,.
1501'1 73.8571 517 62
200~l 59.4286 416 4G
, --
3BOJ.'l 43.200 216 38
X VALUE Y MAX SD (n-i) SD Crt) SEM n
NEAT 100 0 0 0 7
101'1 108 6.5114 6.033~ 2.4633 1 ,-
2S",l 104 5.2554 4.8655 1.9863 1
351-'1 .1.21 12.5764 11.4801 5.1343 6
501-'1 104 7.0339 6.5122 2.6586 7
100/-,l 107 9.7639 9.0396 3.6904 7
1501'1 :98 11.5820 10.7229 4.3776 7
200/-,l 16 9.8634 9.1317 3.7280 7
350/-,1 49 5.5408 4.9558 2.4779 5
DATA FROM FIGURE 4.8
---~-- ---------_ ..__.-_----
N ... 9 M.EAN TOTAL MINIMUM
X-DA'l'A 102.2222 920 0
Y-DATA 83.9720 755.7476 43.20
Ltl .. 9 MAXIMUM SO {N-l} SD (N) SO1Ir:,
IF!X-DATA 350 114.7854 108.2207 38.2618
Y-DATA 100 20.5698 19.3934 6.8566
LINEAR REGRESSION OF y. ON X
Slope of line
Y-In'cerc.pt
X-Intercept
XY Correlation
(Corre'l.ation)2
=
-0.176136
101.9770
578.9663
-0.982890
0.966072
..-
Trapezoidal ..
start-Rectangular ..
End-Rectangular -
24638.63
26783.92
22493.33
DATA FRON F1GUP~ 4.8
FACTOR VII (% or C05TllOL)
STl:) 1 2 3 4 5 6
NEAT 100 100 100 100 too 100
101'1 91 93 100 89 100 if 98
25#,1 90 sa 102 91 98 97
35#1 93 93 87 88 97
-!--
50'1#1 94 83 96 83 90 92
1001"1 91 72 96 80 79 92
1501-'1 82 6'7 94 72 83 85
2001J.J. 71 64 '11 60 72 62
350",1 31 35 2S 38 18
'"
DATA FROM FIGt1RE 4. 9
FACTOR VII (% OF ~L)
~NBA_~T ~_1_0~0 +-6_0_0 ~'~'__,D_O_, ~
10",1 95.1667 571 89
25",1 94(.3333 566 ~8
g-..-..:..-----+--: ..------f----.----t- - .---- ...u91~6000 4Sa 87
\i
50",1 89 ..6667 538 83
72
67
60 .,
18350",1 29.4 147
,
X VALI11i! Y MAX SD (n-l) SD (n) BEM .n""~~'i
MEAT 100 0 0 0 6
10J,61 100 4.7924 4.3·/48 1.9565 6
25JJl 102 ~.4650 4.9889 2 ..231.1 6
351"1 97 4..0988 3.6661 t~~330 !.
, '-
50!!1 96 5.5377 5.0553 2.2608
I!
6
1001-'1 96 9.3381 8.5245 3.8123 £)
150#-'1 94 9.6488 8.8081 3.9391 6
:>'00#-'1 72 5.2789 4.S1SC) 2.1551 6
35\)",1 3a- 8.0187 7.1722 3.5861 5
DATA FROM FIGURE 4.9
102.2222
,
o
FACTORVII (If; OF COftROL)
N == 9
X-DATA 920
,
Y-DA'.t'A 81.3704 732.l3~3 29.400
MAXIXUM SO (N-l) SD (N) SEM
X-DATA 350 114.7854 108.2207 38.:618
Y-DATA 100 21.8230 f 20.5750 7.2743
LINEAR REGRESSION OF Y ON X
Slope tJf line
Y-Intercept
X-I'nt$roept
XY correlation
(Correlation) :2
- -0.18654·'100.4396538.4149-0.981204
0.962761
=:
Trapezoidal ...
start-Rectangular "'"
End-Reotan9Ula~) ==
24074.58
27503.16
20646.00
DATA FROM FIGURE 4.9
------,-------~---
FAC,OO:R v (t OF OO~L)
STD 1 2 3 4 5 Be ~ '.c_ 7-
NEAT 100 100 lOO 10'0 100 1·00 100
101-'1 98 89 98 114 98 1.07 104
25#'1 92 91 83 114 98 98 99
351'1 109 91 le6 95 87 99
50#'1 106 91 88 111 88 91 100
100~1 118 95 80 118 91 sa 109
15°tcl 118 83 12 97 81 87 98
2'00#1 69 44 51 54 53 48 53
3501'1 21 26 21 17 24
DATA FROM FIGURE 4.10
X VALUE Y MEAN y 'rOTAL
:nAT 100 100
10J.'1 UJl.14~9 108
25J.'1 96.4286 615
35J.'1 97.8333 587
50#1 97.2857 681
100#1 99 693
150141 90.8571 636
2001-'1 53.1429 372
350J.'1 21.8000 109
100
FACTOR V (% OF COWIaOL)
83
87
88
80
72
44
17
X VALUE y: MAX SN (n-l) SO (n) SEM NO
NEAT 100 0 0 0 7
1.0",1 114 8.0039 7.4148 3.0271 1-
25141 114 9.5718 8.8617 3.6178 7
3510'1 109 ~.5421 7.7978 3.4873 \ 6
5010'1 117 10.9805 10.1660 4.1502 7
1-"
~OOpl 118 16.0831 14.8901 6.0788 7
150#-'1 118 15.0270 13.9123 5.6797 7
20010'1 69 7.8194 7.2393 2 9555 7
.;
3501-'1 26 \ 3.4205 3.0594 1.5297 5...... '":..
DATA FROM FIGURE 4.10
MAXnmM SD (N-1J SD (N) SRM
FAC'.l'02R V (% 01' ~)
Y-DATA '84.1656 157.4905
X-DATA ~!iO 114.1854 108.2:;:01 38.2618~~~----~~-------~,.~---------+----------~--------~
Y-DAT~ .~Ol •.1429. \ 21.7601 26.1725 9.2534
Slope o·f lineY-Xnteroept
X"'Il~terceptXY cc:rrelat.ion
(corralation)2
'""
-Oo2~7072
107.3774
472.8767
-0.9~,8920
0.881.570
'""
'""
Trapezoidal '""
start-Rectangular '""End-Re.otangular ==
23796.48
27277.50
20315.47
==
DATA FROMFIGURE 4.10
OATA FROM FIGURE 4.11
NEA«J.' 100 700 100
10#'1 100.5714 704 98
25p.1 99..8571 699 90
351'1 96.8333 581 87
501'1 93 ..5714 655 84~~------~.~~------------+-------------~------------~100tJi1 91.4286 640 79
150p.l aa 616 73
2001'1 74.1429 519 45
350",1 38.2000 191 20
x VAWl£ y 1QX SD (n-l) 5D (n) SEM n
..
NEAT 100 0 0 0 7
101'1 105 2.2991 2.1285 0.868966 7
25tJi1 107 5..9841 5.5402 2.2618 7
35#-'1 102 5.5648 5s0799 2.2718 6
501-'1 102 6.3994 5.9247 2.4187 7
100",1 98 6.6045 6.1146 2.4963 7
150",1 102 10.0167 9.2736 3.7859 7
200",1 83 1.3.3220 12.3338 5.0352 7
350#-'1 44 10.2557 9.1739 4.5869 5
DATA FROM FIGURE 4.11
FAC1'OR II (% OF CC):m'R.OL)
..~.----------~!~.~--------~------------~------------~.',I~1WlN '1= 9
¥-DATA 8$.9561 782.6048 38.2000
:X-OATA _ _'_ 102.3222
TO'1'~'L MDllMtlK~--------~------------~920 0
N "" 9 MAXIMUM SO (n-l) SO (n) SEM
X-DATA 350 114.7854 108.2207 38.2618
¥-DATA 100..5714 20.0802 18.9318 6.6934
LINEAR REGRESSION OF Y ON X
Slope of line'
Y-Interoept
X-Intercept
XY Correlation
(Correlation) 2
= -0.169709104.3041
614.6052
-0.9701J.8
0.941128
=
=
==
=
Trapezoidal =
start-Rectangular =
End-Rectangular =
26507.55
29731.07
23284.04
AREA UNDER THE CURVE
DATA FROM FIGURE 4.11
•
BTl) 1 2 3 " 5 $OAT 100 i' 100 100 100 100 100\
10#,1 96 93 104 86 102 73
25#1 94 95 98 90 100 76
35#1 98 - 93 82 101 70
50#,1 89 92 106 ~O 99 69
100#'1 91 81 97 76 91 68!
150}i1 85 77 96 67 86 60
200#1 0 70 89 66 90 68
3501-'1 - 0 0 51 76 65
DATA FROM FIGURE 4.12
:ND,tfi 100 GO$) 100~, ~'--------~------------_r------------~~~--------~10,/( ~~..3333 554 of-J_3 -I
25#'1 92,,1667 553 76~..;;..:;.;..;;;.-----+_--- -.+-', ~------_+-----......,_---tI
351-'1 88.8 444 70
f50#1 89.1667 I • 535 69~~----------+-------------+-------------~----------~~,
1001A]. u 84 504 6e I".......-~---,'-__f------,---f--------f---,.....--------I
1501'1 'r,.l!. 5 471 60
"
200#,1 63.8333 383 0
350#1 3&.4 192 0
x VA.LtTB y ~ SD '(n-l.} SO (n)_.:.,...,. SEM n
NEAT 100 0 0 0
.,\_
" 6......,'
10#-'1 104 3,1.4659 10.4669 4.6809 6
'"
~5p.1 100 ., 8.6352 7.8a2tS 3,,5253 6
35#-'1 101 12.7554 11.4088,., 5.7044 5
50p.1 106 1.3..3577 :ta.l02~\; 5.4124 6:
100#-'7 97 10.9179 9.9666 4.4572 6
l.50#~ 96 13.2778 1~.1209 !'i.4206, 6
200#1 90 33.0237 30~1464 13..4819 6
300#1 76 36Q1566 32.3394 16.1697 5
DATA FROM FIGURE 4&12
l\,...JL /'~ ___;
N == 9
80.8000
X"'DATA
YO-DATA
TOTAL
920 o
38.4127.2000
N == 9 MAXlMOM SO N) SEM-
X-OA'rA 350 114.7~54 J...OS.2207 38.2618
Y-DATA :.O() 18.9276 17.8451 6.30!n
Slope of line
':I.-Intorcept
X-Intercept
XY Correlation
(Correla.tion)2
Trapezoidal ~
Start-Rectangular ~
End-Reotanqular -
== -0.162805
97.4422
598.5230
-0..987322
0.9"/4804
-..-..
24202.50
26797
21608
DATA FROM FIGURE 4.12
•
PROTEIN C (% OF CO:NTROL)
"
ST1J 1 2 3 4 5 EI 7
NEAT - lQ~ 100 100 100 i. :i~OC 1001_---'
10#'1 - 1.16 88 84 I 72 S'8 84I-
25#'1 - 82 95 60 66 73 63
35#'1 - 103 - 67 63 68 69
50#,ul - 87 98 50 72 60 66-
100#,1 - 86 78 70 71 64 63-
150#'1 - 79 98 64 60 66 57
200#'1 - 50 79 60 75 61 43
350#,1 - - 28 127 45 33 19
DATA FROM FIGURE 4.13
NEAT 100 600 100
10",ul 90.333 542 72
2!5t£ul 7~.,1,7 439 60
35#,ul 74 370 63~~----------+-------------~---'----------~------------150#'\\1 7~.3.667 433 50
lOO/J.ul 72 432 63,-----------r-------------I
3.50/J.1 10.6667 424 57
200/J.ul 61.333 3613 43
35010'1 30.400 152 19
X VAWB y ·MAX GD (n-l) SO (n) GEM NO
NEA'l' 100 0 0 0 6
10~1 lUi 15.0953 13.7800 6.1626 6
25/J.l "5 13.2878 12.1301 5.4247 6~
351'1 103 16.3701 14.6424 7.3212 5
501-'1 99 1'.690~ 16.1495 7.2223 6
100",1 86 8.7407 7.9791 3.5684 6
150",1 98 15.3840 14.0436 6.2805 6
200",1 79 13.8948 12.6842 15.6125 6
350~£1 45 9.5812 8.5691 4.2849 .$
DATA FROM FIGURE 4.13
PROTEIN C (% OF CONTRO:r~)
N ... 9
X-DATA
TOTAL
102.2222 920 o
Y-DATA 71.5630 644.0667 30.4
N ;0: 9 MAXIMUM SO eN-l) SO (N) SEM
X-DATA 350 114.7854 108.2207 38~2618
Y-DATA 100 19.2675 18.1656 6.4225
LINEAR REGlRESSION or Y ON X
Slope of Line
Y-Intercspt
X-Int.rcept
XY Correlation
(Correlation) 2
... -0.153696
87.2741
567.8355
-0.9156'38
0.838394
==
==
Tra.pezoidal
Start-Rectangular
End-Rectangular
- 21360.8324138.33
18583.33
=
==
DATA FROM FIGURE 4.13
o
,.
PTT
'1
8TD 2 " 5 6 71 3 4
NEAT 36.5 33.1 34 33.5 37.4 33 35.6
10 ",1 37.5 30.4 36.7 40 34.3 32.6 34,5-25 p.l 39.1 30.'1 36.1 ~5 ..5 33.5 34 32~g
35 p.1 43 31.9 - 36.8 37.6 34.9 :33.2
50 ,.,1 42- 33.S 36 37.5 I 34.2 34.3 34.9
,
100p.l 32.5 39.2 37.5 46 37.2 3sL.s 36
150",1 42 46 46 57 41.2 45 45.9
200Jjl 61.1 92.9 73 91.5 58.1 63.4 70.5
350p.1 - - 120 120 120 120 120
DATA FROM PIGURE 4.14
X V.ALtJlIl i BAli ! roTAL l' MllO:MOM
DAi' 34..7286 243.1 33
10 ~1 35.1429 246 30.4
25 ~1 34.3286 241.7 30.7
35 #1 36..2333 217.4 31..9
50 ",1 36.1 252.7 33.1
100 1&1 38.3143 268.2 ~~._5
150 1'1 46.1571 323.1 41.2
200 ~1 72.9286 51t;).5 58.1
350 #1 120 600 120
X VALUE Y MAX SO en-l) SO (n) SEM n
NEAT :37.4 1.7661 1.6351 0.667516 7
10 ~l 40 3.2056 2.,9679 1.2116 7
25 JJ1 39.1 2.6862 2.4869 1.0153 7
35 ~l 43 "...~.9429 3.5994 1.6097 6
50 ~l 42 2. 'EQ71 2.6822 1.0950 7~---
100 #,1 46 4.1459 3.8323 1.5670 7
150 #,1 57 5.1781 4.7940 1.9~71 7
200 #,1 92.9 14.1436 ],3.0945 5.3458 7
350 ~1 120 0 CI 0 5
DATA FROM FIGUP~ 4.14
. - . .
. . ,.' .~ '. ,." ..... -..':~ ..... ~.. . -',.,..... ~ .
!-OATA. 50..4593 454.1333 34.5286
N .. 9
102.2222 920
.---------~~-------~~----------.. ---------~--------..~N-==-9 __ _+__MA.......?..;..XIM..;..·....OJ_._~SD (If-1) SO (N) SD
X-n\TA 350 114.7854 108.2207 38.3618g...;;;,;_.;.:.;.;;,;:.;,;.;.;;;;;.......,.._-+.....;;...;...._----+-.;;:..;;...;;..;;...;..;;..;;;...;;...- •.•+-....-..;...;;..;;...;;..;...._~_;...;;...;;...;._._-- ....
Y-DATA 120 2$ ..8340 •.'27.1849 9.6113
Slope of line
Y-Interoept
X-InterceptXY correlation
(Con'e1ation)2
== 0.239134
26.01.45
-108.7865
0.951.968
0.906244
...
-
Trapesoidal
Start-Reotangular
End-Rectangular
.. 23187.1318731.07
27643.1.9..
DATA FROM FIGURE 4.14
,$0.4593
X-OATA 102.2222 o
454.1333 34.5286
_so (N-1) SElf
21.8340
SO (N)
X-DATA 114~7854 3802618350 lOS .2207
120
LINEAR REGRuSlcnr OF t' ON X
Slope Qf line
Y-Intaroept
x....Intercept
Xi Correlation
(c!:\rrelation)2
==..
==
TrapeRoidal
~tart-R&etangular
End-Reotangular
....
0.239134
26.0145
-108.7865
0.951968
0.906244
21187.13
18731.01
21643.19
DATA FROM FIGURE 4.1.4
9.611·3
:om It
STD 1 2 3 4: 5 6 ?
NEAT 1.05 1..25 1.06 1..09 1.02 1.04 1.1
10 p1 1.07 1..53 1.07 1..14 1 1.05 l.08
25 ",1 1.21 1..46 1.16 1.0'9 1..05 1.06 1.1l
35 pI 1.08 1.31 1..U 1.09 1..08 1.11
50 p1 1..115 1.56 1.19 1.15 ]. 1.16 1.1
,II
100p.l 1.l2 1.47 1.11 1~12 1.06 1.19 1..12
150jJ1 1.23 1..41 1..23 1.18 1.31 1.18 1..17
200#1 1.:37 2.63 1.52 1..39 1.49 1.53 1.5
350J,£1 4.64 4..52 Hi lO 3.68
IHR
1.1314 7.92 1
NEAT 1.0871 1.61 1.02
25 p1
35 p1
1.1629 8.14 1.05-------r-------------+------------~1.1317 6.7g 1.08
50 ,.,.1 1.1886 8.32 1
100 p1 1.17 8.19 1.06
150 /-'1 1.2529 8.77 1.17
200 pI 1.6329 11.43 1.37
"3S\) p1 6.5680 32.84 3.68
x VALt'J'm ! MAX SO (n-1) SO (!l) Slnl n
NEAT 1.25 0.0"16966 0.071257 0.029091 7
1(1,.,.1 1.53 0.179391 0.166083 0.067803 7
::---
25 1-'1 1.46 0.142562 0.131986 0.0~3883 7
35 p1 1.31 0.088863 0.081121 0.036278 6
50 p.1 1.56 0.,175350 0.162343 0.066276 7
100 1-'1 1.47 0.137598 9·127391 0.052007 7
150 1-'1 1.47 0.107194 0.099242 0.040515 7
200 1-'1 2.63 0.444174 0.411225 0.161882 7
350 1-'1 10 3.1547 2.8217 lQ4108 5
DATA FROM FIGURE 4.15
1NR
N '"" 9
920 o102.2222
16..3254 1.0871Y-DATA 1.8139
If '"" 9 MAXDlOK SD (n-l) SD (n) SEM
X"'1lATA 350 114.7854 108.2207 38.2618
Y-DA'fA 6.5680 1..7902 1.6878 0.596726
LINEAR REGlUWS10N OF Y ON X
Slope of line
Y-Intercept
X-Interoept
XY COrrelation
(Correlation)2
,.,. 0.013291
0.455334
-34.2598
0.85218.9
O.72622~
=
=
AREA mmBR '1'B.E ctmVE
Trapezoidal
start-Rectangular
End-Rectangular
= 863.9173
481.9464
1245.888
=
=
DATA FROM FIGtn1E4.15
1 3
...
i 11 i i1 1 11 (. )
,
11. :L2 ~Oo5 12NEAT 13 r
25 ",1 10 :tel 9 9.5 8.5 10.5
30 ",1 8 7 7.5 8.5 7 8
35 ",1 12.5 12 10 11.5 9.5 8
, '
40 ",1 13 12 1:,': 12.5 11 10.5
45 ",1 21.5 20.5 23 21.5 19.5 .l
k VAlui
1 2 3
i i1 i 1i 1 i1
NEAT 6 5 4.5 5.5 6 5
25 ",1 :3 3 3.5 ~ 4 3
,
30 #1 3 3 3.5 3 4 "...
1
Y4teinlal ARml itude
2 3
'"
i ii i ii i ii
NEAT 45 48 52 51 44 40
25 ?£l 23 26 35 38 28. 24
, ,
30 #.£1 21 25 30 29 25 20
,
35 ",1 10 12 14 11 10.5 12
11/
40 ",1 11 12 14 10 9 10
45 1-'1 6 8 9 6 5 / 6f·
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o
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o
c
o
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